var title_f29_34_30240="Tumor bleeding 14a";
var content_f29_34_30240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Frontal chest radiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A frontal chest radiograph on a 45-year-old woman with recurrent left hemothorax secondary to metastatic leiomyosarcoma of the uterus. There is a large collection of blood (verified by pleural tap) in the left hemithorax with displacement of mediastinal structures to the right. After embolization, she improved clinically with less accumulation of blood in the left hemithorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30240=[""].join("\n");
var outline_f29_34_30240=null;
var title_f29_34_30241="Calculator: Sokal score for chronic myeloid leukemia";
var content_f29_34_30241=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Sokal_form\" name=\"Sokal_form\" onkeydown=\"clrResults();\" onkeyup=\"Sokal_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Sokal score for chronic myeloid leukemia",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         SokalScore = e",
"         <sup>",
"          (0.0116*(Age-43.4)+0.0345*(SpleenBelowCoastalMargin-7.51)+0.188*(sq(Platelets/700)-0.563)+0.0887*(BlastPercent-2.1))",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"Sokal_fx(); minMaxCheck();\" onchange=\"Sokal_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <span style=\"white-space: nowrap;\">",
"             <span class=\"medCalcFontOneBold\">",
"              years old",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Spleen Below Coastal Margin",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Spleen_Below_Coastal_Margin_param\" onblur=\"Sokal_fx(); minMaxCheck();\" onchange=\"Sokal_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Spleen_Below_Coastal_Margin_unit\" onchange=\"Sokal_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Platelets",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Platelets_param\" onblur=\"Sokal_fx(); minMaxCheck();\" onchange=\"Sokal_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Platelets_unit\" onchange=\"Sokal_fx();\" style=\"width:105px;\">",
"             <option value=\"0.001|0|/microL\">",
"              /microL",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|10^3/microL\">",
"              10^3/microL",
"             </option>",
"             <option value=\"1|0|10^9/L\">",
"              10^9/L",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Blast Percent",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Blast_Percent_param\" onblur=\"Sokal_fx(); minMaxCheck();\" onchange=\"Sokal_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <span style=\"white-space: nowrap;\">",
"             <span class=\"medCalcFontOneBold\">",
"              percent",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sokal Score",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Sokal_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Sokal Score Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Sokal Score &lt; 0.8:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Low Risk",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Sokal Score &gt;= 0.8 and &lt; 1.2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Intermediate Risk",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Sokal Score &gt;= 1.2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         High Risk",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      The Sokal score is primarily used to stratify patients enrolled on clinical trials by disease aggressiveness.",
"     </li>",
"     <li>",
"      In the original Sokal study of 813 patients with newly diagnosed chronic myeloid leukemia (CML) treated with chemotherapy (eg, busulfan), patients with low-risk disease had overall survival rates at two and five years of 90 and 81 percent, respectively.",
"     </li>",
"     <li>",
"      In comparison, patients with high-risk disease had a 65 percent survival rate at two years. Survival rates have improved dramatically since the incorporation of tyrosine kinase inhibitors into the first-line treatment of patients with CML.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Sokal JE, Cox EB, Baccarani M, et. al. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia.",
"       <i>",
"        Blood",
"       </i>",
"       . 1984 Apr;63(4):789-99.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30241=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Sokal_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Sokal_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Age = param_value;",
"if (Spleen_Below_Coastal_Margin_param.value.indexOf(',') >= 0){ Spleen_Below_Coastal_Margin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Spleen_Below_Coastal_Margin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Spleen_Below_Coastal_Margin_unit.options[Spleen_Below_Coastal_Margin_unit.selectedIndex].value.split('|');",
"Spleen_Below_Coastal_Margin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Platelets_param.value.indexOf(',') >= 0){ Platelets_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Platelets_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Platelets_unit.options[Platelets_unit.selectedIndex].value.split('|');",
"Platelets = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Blast_Percent_param.value.indexOf(',') >= 0){ Blast_Percent_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Blast_Percent_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Blast_Percent = param_value;",
"dp = 2;",
"Sokal_Score =  eTo(0.0116 * (Age - 43.4)+ 0.0345* (Spleen_Below_Coastal_Margin - 7.51) + 0.188 * (sq(Platelets / 700) - 0.563) + 0.0887 *(Blast_Percent - 2.1));",
"",
"if (doCalc) Sokal_Score_param.value = fixDP(Sokal_Score, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Sokal_Score < 0.8){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Sokal_Score >= 0.8) && (Sokal_Score < 1.2)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Sokal_Score >= 1.2){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Sokal_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Sokal_form){",
"",
"Sokal_Score_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f29_34_30241=null;
var title_f29_34_30242="Patient information: Doppler ultrasound (The Basics)";
var content_f29_34_30242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83954\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/15/27891\">",
"         Atherosclerosis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44533\">",
"          Carotid artery disease",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"           Peripheral artery disease",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"            Deep veins of the leg",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/5/23635\">",
"         Patient information: Atherosclerosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/14/12512\">",
"         Patient information: Carotid artery disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/49/34578\">",
"         Patient information: Peripheral artery disease and claudication (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/47/41714\">",
"         Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/17/35091\">",
"         Patient information: Chronic venous disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/35/14900\">",
"         Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Doppler ultrasound (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/doppler-ultrasound-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H193551611\">",
"      <span class=\"h1\">",
"       What is a Doppler ultrasound?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Doppler ultrasound is a test that uses sound waves to create pictures of the inside of the body. Doctors use this imaging test to check for problems in the heart or blood vessels. A Doppler ultrasound can also show how blood flows through the blood vessels.",
"     </p>",
"     <p>",
"      There are different ways doctors can do a Doppler ultrasound. One type of Doppler ultrasound is used specifically to check blood flow through blood vessels. It uses color images to show blood flow. Doctors sometimes call this test a &ldquo;duplex&rdquo; ultrasound.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193551626\">",
"      <span class=\"h1\">",
"       Why might my doctor order a Doppler ultrasound?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might order a Doppler ultrasound to check for:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Atherosclerosis &ndash; In this condition, fatty clumps called &ldquo;plaques&rdquo; build up in the arteries and make them narrow or blocked (",
"        <a class=\"graphic graphic_figure graphicRef83222 \" href=\"UTD.htm?27/15/27891\">",
"         figure 1",
"        </a>",
"        ). Atherosclerosis can happen in different parts of the body, including the carotid arteries (",
"        <a class=\"graphic graphic_figure graphicRef72617 \" href=\"UTD.htm?43/31/44533\">",
"         figure 2",
"        </a>",
"        ) or arteries in the legs (",
"        <a class=\"graphic graphic_figure graphicRef60105 \" href=\"UTD.htm?6/23/6514\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A deep vein thrombosis (also called a &ldquo;DVT&rdquo;) &ndash; This is when a blood clot forms in a deep vein in the leg (",
"        <a class=\"graphic graphic_figure graphicRef70603 \" href=\"UTD.htm?24/47/25343\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Problems with how the leg veins are working &ndash; If the veins in the legs don&rsquo;t work well, blood can collect in the legs.",
"       </li>",
"       <li>",
"        An injury to an artery",
"       </li>",
"       <li>",
"        Problems with the heart valves &ndash; To check how well the heart valves are working, doctors can do a Doppler ultrasound as part of another test called an echocardiogram. An echocardiogram (also called an &ldquo;echo&rdquo;) uses sound waves to create a picture of the heart as it beats.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors can also use a Doppler ultrasound to check a baby&rsquo;s heartbeat when it is inside the mother&rsquo;s uterus (womb).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193551641\">",
"      <span class=\"h1\">",
"       How do I prepare for a Doppler ultrasound?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You do not need to do anything special to prepare for this test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193551656\">",
"      <span class=\"h1\">",
"       What happens during a Doppler ultrasound?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor, nurse, or technician will put a small amount of gel on the part of your body being checked. Then he or she will press a thick wand, called a &ldquo;transducer,&rdquo; against your skin. He or she will move the transducer around on your skin. Images will appear on a computer screen.",
"     </p>",
"     <p>",
"      This test does not usually hurt, but people can feel pressure when the transducer presses against their skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193551671\">",
"      <span class=\"h1\">",
"       What are the downsides of a Doppler ultrasound?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Doppler ultrasound does not have any downsides.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H193551686\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"       Patient information: Atherosclerosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       Patient information: Carotid artery disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=see_link\">",
"       Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=see_link\">",
"       Patient information: Chronic venous disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/34/30242?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83954 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30242=[""].join("\n");
var outline_f29_34_30242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551611\">",
"      What is a Doppler ultrasound?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551626\">",
"      Why might my doctor order a Doppler ultrasound?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551641\">",
"      How do I prepare for a Doppler ultrasound?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551656\">",
"      What happens during a Doppler ultrasound?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551671\">",
"      What are the downsides of a Doppler ultrasound?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193551686\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/15/27891\">",
"      Atherosclerosis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44533\">",
"       Carotid artery disease",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"        Peripheral artery disease",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"         Deep veins of the leg",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=related_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=related_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30243="Patient information: Fractures (The Basics)";
var content_f29_34_30243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16990\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"         Foods and drinks with calcium and vitamin D",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\">",
"          Foods and drinks with calcium",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/25/40338\">",
"         Patient information: Ankle fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/6/5219\">",
"         Patient information: Boxer&rsquo;s fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/26/39330\">",
"         Patient information: Clavicle fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/20/7491\">",
"         Patient information: Common wrist injuries (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/5/3155\">",
"         Patient information: Finger fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/33/14867\">",
"         Patient information: Hip fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/0/15363\">",
"         Patient information: Neck fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/59/12211\">",
"         Patient information: Paget disease of bone (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/21/5459\">",
"         Patient information: Pelvic fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/53/41810\">",
"         Patient information: Rib fractures in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/33/12819\">",
"         Patient information: Shinbone fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/22/355\">",
"         Patient information: Toe fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/63/27635\">",
"         Patient information: Vertebral compression fracture (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Fractures (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/fractures-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7956796\">",
"      <span class=\"h1\">",
"       What is a fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. There are different kinds of fractures, depending on how the bone breaks. When a bone breaks, it might crack, break all the way through, or shatter. If a broken bone sticks out of the skin, doctors call it an &ldquo;open&rdquo; fracture. If the bone does not stick out of the skin, doctors call it a &ldquo;closed&rdquo; fracture.",
"     </p>",
"     <p>",
"      People with a condition called osteoporosis have a higher chance of getting a fracture. That&rsquo;s because osteoporosis makes a person&rsquo;s bones weak. This condition is especially common in older women.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956811\">",
"      <span class=\"h1\">",
"       What are the symptoms of a fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on which bone breaks and the kind of break it is. Common symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, swelling, or bruising over the area",
"       </li>",
"       <li>",
"        The area looking abnormal, bent, or not the usual shape",
"       </li>",
"       <li>",
"        Not being able to move or put weight on that part of the body",
"       </li>",
"       <li>",
"        Numbness in the area of the broken bone",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956826\">",
"      <span class=\"h1\">",
"       Is there a test for a fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and take an X-ray. He or she might do other imaging tests, such as a CT or bone scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956841\">",
"      <span class=\"h1\">",
"       How are fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends, in part, on the type of fracture you have and how serious it is. The goal of treatment is to have the ends of the broken bone line up with each other so that the bone can heal.",
"     </p>",
"     <p>",
"      If the ends of your broken bone are already in line with each other, your doctor will put a cast, splint, or brace on that part of the body. The cast, splint, or brace will keep your bone in the correct position so that it can heal.",
"     </p>",
"     <p>",
"      If the ends of your broken bone are not in line with each other, your doctor will need to line them up. To do this, he or she can move your bone to the correct position without doing surgery, and then put a cast, splint, or brace on.",
"     </p>",
"     <p>",
"      He or she can also do surgery to put your bone back in the correct position. This can involve:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using screws, pins, rods, or plates to fix a bone inside the body",
"       </li>",
"       <li>",
"        Putting pins or screws through the skin and into the bone, and then attaching the pins or screws to a bar that is outside the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also treat your pain. If you have a severe fracture, he or she can prescribe a strong pain medicine. If you have a mild fracture, he or she might recommend that you take an over-the-counter medicine for your pain. Over-the counter medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      After your bone heals, your doctor might recommend that you work with a physical therapist (exercise expert). The physical therapist can show you exercises and stretches to strengthen your muscles and help your joints move more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956856\">",
"      <span class=\"h1\">",
"       How long do fractures take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the body part involved and the type of fracture. Most fractures take weeks to months to heal. Fractures in children usually heal faster than fractures in adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956871\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your fracture is healing. For example, he or she will probably recommend that you eat a healthy diet that includes getting enough calcium, protein, and vitamin D (",
"      <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"       table 1",
"      </a>",
"      ). He or she will also probably recommend that you avoid:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Playing certain sports",
"       </li>",
"       <li>",
"        Smoking &ndash; If you smoke, it can take longer for your fracture to heal.",
"       </li>",
"       <li>",
"        Getting your cast wet, if you have a cast that shouldn&rsquo;t get wet",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956886\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your pain, swelling, or other symptoms get worse",
"       </li>",
"       <li>",
"        You get a fever",
"       </li>",
"       <li>",
"        You can&rsquo;t move part of your body",
"       </li>",
"       <li>",
"        You get your cast wet, and it&rsquo;s not supposed to get wet",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956901\">",
"      <span class=\"h1\">",
"       What can I do to prevent getting another fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To protect your body from getting hurt, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear safety gear when you bike, ski, rollerblade, or do activities where you could get hurt. Safety gear can include helmets, elbow pads, knee pads, and shin pads.",
"       </li>",
"       <li>",
"        Keep walkways clear of clutter, and remove or tack down loose rugs.",
"       </li>",
"       <li>",
"        Wear a seatbelt every time you ride or drive in a car.",
"       </li>",
"       <li>",
"        Put a non-slip mat in the bathtub and handrails on the stairs (especially for older people).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To help your bones stay strong so that they don&rsquo;t break easily, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat and drink foods with a lot of calcium, vitamin D, and protein. Calcium and vitamin D are nutrients that help keep bones strong.",
"       </li>",
"       <li>",
"        Get regular exercise, even if it&rsquo;s just taking a daily walk.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956916\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       Patient information: Common wrist injuries (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"       Patient information: Finger fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=see_link\">",
"       Patient information: Clavicle fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"       Patient information: Hip fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"       Patient information: Rib fractures in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=see_link\">",
"       Patient information: Ankle fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"       Patient information: Shinbone fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"       Patient information: Vertebral compression fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"       Patient information: Boxer&rsquo;s fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"       Patient information: Neck fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=see_link\">",
"       Patient information: Pelvic fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"       Patient information: Toe fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"       Patient information: Paget disease of bone (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/34/30243?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16990 Version 10.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-BF0A88A09A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30243=[""].join("\n");
var outline_f29_34_30243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956796\">",
"      What is a fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956811\">",
"      What are the symptoms of a fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956826\">",
"      Is there a test for a fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956841\">",
"      How are fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956856\">",
"      How long do fractures take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956871\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956886\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956901\">",
"      What can I do to prevent getting another fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956916\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"      Foods and drinks with calcium and vitamin D",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\">",
"       Foods and drinks with calcium",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=related_link\">",
"      Patient information: Ankle fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=related_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=related_link\">",
"      Patient information: Clavicle fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=related_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=related_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=related_link\">",
"      Patient information: Pelvic fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=related_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=related_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=related_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=related_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30244="Kocher maneuver";
var content_f29_34_30244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Kocher maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 659px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKTAhUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poorlPiuqv8ADbxIrqGVrGQEEZBGKAOrorzbxz4U8G+H/DdxeWfgfwxcag7x21nA+mQ7ZbiVxHGpwucbmBOOwNYf/CN+EtY+Eesao/gzw3ZatBY3kVwkOmwqYLqFXR9p25GHQkHrjBoA9loqrpP/ACCrP/rin/oIq1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8Vf+SceI/wDryk/lXVVV1XT7XVtNudP1CITWlzGYpYySNynqMggj8KAOZ8a+G7zxNrugRNcTWukWLy3s0tvLsla4ChIQvHQB5GJ9Qtc/e+G7zwz4e+IkS3E11pF9p8t7DLcS75VuDA6TBuOhCRsD6lq6b/hAdA/556l/4Nrv/wCO0yb4eeHJ4Xing1CSKRSjo+qXRVgeCCDJyKAOj0n/AJBVn/1xT/0EVapsUaxRpHGNqIAqj0Ap1ABRRTJZY4Y2kmdY41GWZjgAe5oAfRXFa18SdB04skEsl9KO1uMr/wB9HA/LNcnefFy9fIsdKgj9DNIX/QYrGVenHdnTDB1p6qJ7DRXgl18RfE9xnZdw24PaKBf/AGbNZc3irxJOT5ms3g/3H2fyxWTxkOiOhZbUe7R9H0V8ySatrUp/eaxqbfW7k/xqP7bqf/QT1D/wJf8AxpfXI9iv7Ml/Mj6for5iTUNVT7mq6iv0upB/Wp01/Xovua1qf43Tn+ZpfXY9g/syf8yPpaivnOHxn4lhxs1e5OP74V/5g1fg+I/ieIjfdwzf9dIFH8gKpY2HZkvLavRo99orxW2+LGsp/wAfNjYyj/YDIf5mtO2+LjE4udFOPWO4/oV/rVrFUn1MngK66fier0V5/a/FXRJMC4t763PcmNWH6HP6VrW/xA8MzDjU1Q+kkTr/ADFaKtB7Mylhqsd4s6qiudPjfw2Bk6vbfmf8KU+K7GeISaaTeKedynao/Ej+lP2ke5Hsan8rOhoriF+Jnh9VYTyyrKrFSiRs449DjBqvN8VtBT/VwahJ/uxKB+rVPtqfctYWs/ss7+ivM5fi3Yj/AFOl3b/7zqv+NVX+Ljf8stCY/wC9dY/9kqfrFPuWsFXf2fyPVqK8lPxZuyfl0OMD3uD/APE0n/C2rsddEj/8CD/8TR9Zp9x/Ua/b8Uet0V5VF8XP+e+iMvutzn/2WtSy+KuizEC5tr23PclAyj8jn9KaxFN9SXg6y+yeg0Vg6d4v0DUSBbapbbj0WRvLJ/BsVuqwZQVIIPII71qpKWzMJQlHSSsLRRRTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmuyohZ2CqoySTgCqOuavZaJYPealMIoV4HcsfQDua8L8ZeM9Q8TymEZttMBysCnlvdz3Pt0H61jVrRprXc6cPhZ13pou53vi34nWlizW2hIl7cDgzE/ulPt/e/Dj3NeW61req65Jv1S9lmGchM4Rfoo4qhHFjoKnSImvOnWnU3PapYenRXurXuQLGPSpki9qtRw1YSMVnY1cymsPtTxB7VdCAU7aKHEjnKPke1IYa0Aoo2A0rBzGf5NBg9q0dgpNntRYfMzO+zj0pTbD0q/t54FL5ZP8JpcocxnfZx6UogA7Ve8lz0Wk+yyHtimoBzlBoh6VC0Q9BWqbQ/xGqsyJGfncAU+Ww1O5Xs7ZZbqNCmdzAY6V32v3B0Pw7stgqTS4hjGc7SRyfwGa4zSpom1S3WPkhs5NWfHV+TPZwbyZVVpCPQHgfyNaQfLFmVSLnOKZkR2yog3ED60oNun3mH4VkvMzdSTURc1Gh08je5vi6tE/hzTl1O2TpCPzrnNxoyaOYPZo6ddYtv4oBT11ex/ihrlOfWmsGI4NPmYvZROw/tHS5OseKcP7MmHyOAfrXEMHHem+ZIvc0cwex7M7SbTY35hcGnWV9q+iNnT724t1/uo52n6r0NcdFqE0RyHYVqWuvPgLL8w96L9VoJ03az1R6d4f8Aild27JDr1sLmLoZ4Rtce5XofwxXqWkatY6xaC4025jniPXaeVPoR1B+tfNyXNrcrwQrGp9Nvb3RL5LzTJmimX05DD0I7it6eJlHSWqOCtgYT1ho/wPpiiuV8EeMLXxNblGAg1GMZlgz1H95fUfy/U9VXoRkpK6PInCVOXLJahRRRVEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWb4h1qz0DS5b+/fbGnCqPvO3ZQO5NXbmeK1t5Z7iRY4YlLu7HAUDqa+ePG/iSbxVrBl+ZLCElbeI9h/ePuf8A61Y1qyprzOrC4Z15a7Lcr+JNdvfE+ptd3pKxDiGAHKxL6D1Pqe9U0i9qWGPAHFWkSvLbcndnupKK5Y7EccNWFjxUiKBSsyr1OKTairtmVSrGC5puyBU9KcFxUX2hB61Ik0Z6kj8KyVam3bmOSOY4aTspokC5PrU0ds7fwmqU+r2lmccFx61nXHi2YkrAAoroSR2KMpfCdRFp7N1wPrU/2CJfvyoD9a4KXxBeydZCKgOqXLfekb86d4roP2M31PRPs9mv3p0H40xm06PrMprzz7dKerk/jQblz/EaOfyH9XfVnfNfaYn8WfoKjbWdOTopNcGZXPc0xnY96XOx/V13O0l8RWi58uDP1NZ9z4kZv9XGq1zOSfWm7SaXMy1QijUuNYnkz82PpVCS4eQ8sTURWgVNzVRS2N3wo2dUjBPXtS+NQy+Ist91rdCv0y39c1D4ZwNUQ55xWp4+X99pz5HKyDHfjb/jV/ZMHpWRyxptLSgVB0CYpwWngUtArjNtG2n8UZoAj2ZpjR+1T5pDigCo8INQPCR0rQIqNgKB3KSSPGeprWsdTIwr/Mvoaz5EBFVW3IcimDSZ2VpcS21zDfabM0U8R3K69Qa968D+JofEuliX5Y72LC3EQ/hPqPY//Wr5l0y+aNgM8dxXXeGdZk0PW7bUbdiIshZl7MhPzA/z+orWjVdOXkcOLwyqx81sfR9FNR1kRXQhlYAgjoRTq9U+eCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKzvEOqR6Lol5qE2NsEZYA/xN0UfiSBSbsrsaTk7I82+MviQSMugWb5AIkuiPzVP6n8K81t4wKa80t3dTXVy5eeZzI7HuScmrUS8V5NSbqS5mfR0qSowUESxgZxVlRUManNTbti5qCmJPIIU/2j+lY1xdMWIBq3fyE5J6mk0Kw+3XyIe5xXnOTrTu9uh8Hj8VPFVnrotjNaSQcnIqWK7ZevNdr4g0CGzjAwCcZziuKnt9rHFOpCMXys45wcHZk00VvqEW2UDd2YdRWBdWctnPsl5U/dfs1aSM0bccVoFI7+1aKX8D6H1qYVHQf909XK81nhJKE3eD/DzRz6KT2p/l+tTwxMGkgf/WxnH1HrSMMHBr0U76o+6jNSV1sRhBTgKcBS4oGJijFKaDQAmKQ0E01jQAjGoyaVjUbHmgo2vDCltUiOeKv+Pyw1WyH/ACz8g4+u45/TbVfwdCzX/m8YUcetaHxEYD+zRtG794d3p93irXwnNJ/vkcmTTlYVAXpu+oOmxb3ikMlVC9NMlAWLfmCjzBVIyUnmUDsXfNFHmVR833pPPxQFi/5lRs9UzcUwz0WCxc31DMQRVUzGkDljTSEyeIkNxW9p826Joz3HFYEQJI4rb0a3lub63t4FLSSuFAHvQTLY+mPAszT+ENJeTlvs6rz7DA/lW9WXoUC2Ol21qn3YYwg/AVobq9aD91HytTWbaJKKarZp1aGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV/HHVCkGn6TG2PNJnlHsOF/Xd+VeqV89fE28a+8dagSfkg2wJ7BQM/qTXNipctO3c7svp89a76amBCBxV+JOBVGH7wrYtIjIQBXmntSdh8EORuP3RWXq13hJFjPOD0rT1e7W2g8pD81co829z3qnoKmubVmpKfNtkcfxKDV7wlOIdQUkgHPFZWmuGje3Y8ryv+7/9amhmtbkOOOa8qC9nNx7H5/i6LwuIlB9H+HQ9S8TKZ7beGDllByK8+ni+Ygiug03XFmtvKlI/EVnaiIzLlOhpYmSk+dGdVqfvI564iwaZbSGN60p4tymsqRSslKElNWZzsfq58mW3vFHGdj/TtTL5AJQ6/dcZFW5IvtenywHqy8fXtVGwY3OnGJ+J4Dgg9a7MJO8XB9D7XIcT7Sh7NvWP5PYhzS0xjg0geuk94kppNIWppNAwY03NBNMLUDBjUZoZqtaZZPf3Swxg89SOwoBuyuzsPBNmUtjM2DvOQR6CsLxrqgvtVMMePJtcxg+rfxH8wB+Fd7aQrYabkYVYo+M+wrx8knJYkknJPrVy0Vjloe/NzF3U1mpjNioneosdhKZKY0lQF6acmqsK5I0tN8wnpSLEzdq0dO0i7vX22tvLKf8AZXIH1NMVzOyxpQjH1rsbXwVqJGZ1ihH+02T+la9t4LiGPOllc/7AC/40m7bmc60Ibs87WJqeICa9asfBloxwtpuPq7mt+z8I2EIy8UIb/YjH8zTjGU9jL61HojwlLNnPyqT9BV220e7kI8u1mb3CGvd10K2UYR3X2wMU4aOo+6Qw/KnKnNdCHin0ieRad4U1K4YYgEan+KRgMf1r1DwX4YtdFAnP769YYMpH3R6KO1acVoIzt24NadrHjArKLbZyV8RKasbdq52iratmqdsvAq9GlenTu0eXIemd1TCmqtOroSM2FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8u6hdfb9Vvbw9Z53l/Nia+ldcnNromoXAODFbySZ+ik18vwDCrXDjHsj1ssj8T9C7brlxXR2yra2TTPwSOKxNLiMtwo7Zq14qvPJiS3Q4wOa5Y6K53z96SijndVuzPcMc96pKeajLFnJqQVB0pWViwm4lWjbbKpyp/pWlGy3kJONsi8Ov901kqcVPGzbxJG2yYDGexHoawrUfaK63R5WaZbHGwutJLZ/oy2m+B++PWr0Uu8cmqkN0kzeXMvlS+h6H6GpthQ8V5tRPaSsz4ivh6mHlyVVZlrqKqXMAIJArc07T/tVsXU/MO1UbiFo3KOMEVHLKnaRm4tK5kwsY2xUV7H9mmF/CPl+7Mo7j1qxdx7TkUWzh1Mb8qwwRW8JuLVSJvg8VLCVVUj8/NGXdKA+5futyKrHipVDIskDnJhcqPp2qNhXqXvqj9IhJSipLZiBqCaaTTc0yxWamE5oPJrX0rQbu/IIQomerDrQlcHJRV2ZtrbyXMqxwqWY9hXoOj6fa6Bpz3N5IqnGXc/yHqap3Fxp/heFESIXF84+6DggepPYVzOq6jc6vc+bcnCr9yJfup/8AX96tWic8uatotInaaNqJ13Trm5dNirK8aRf3VABGffBrzvUoDbXUiFdoB4FaGk6tc6NOzwANE+PNibo2PT0PvWr4wtobqzg1GyBMUqhvz9vWhvmQQXsp26M4eRuaYFzUpTLVvaD4en1ArJJmK2z98jlvp/jU3OiUlFXkYMNs8sipGjO7HAVRkmuq0nwXeXAD3ZW2Q9iNzfl2/GvQfD2hWtlbv9lt1Vzj94eWI+tdDZ6ap+Z+TW9OmpK7Od4hNXRxmk+D7C3KkwG4f+9LyPy6V2Nlp3lqoCBVHQAYArZt7ZEAGBVgxjHArojBLY5Z12zINmhPIpVtQD0UD1q88ZB9qbs9qidGM3qZv3tWRqAowowKKfsNGw1olbRFJoZSg07ZTSMUDHg561atipIB4NUgcGpUPNS4qW5nUpqSN63wMVfj6Vj2E287G+92PrWvF0ranoeXVi4uzJaKKK2MgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAw/HTlPButkf8+co/NSK+b4Ogr6Q8coX8G62B1+xyn8lJr5utuQtefjPiR7OWfBL1Oj0NAitK3RRXL67dme7ds9+K6VpPs+kSMOpGK4a6cvMa53tY76SvJsfDzzU4FRQjgVOtQbsAKcDiiigRMJAV2uAy+hqeGYwLuBZ4O6nkp9Pb2qjmponxkHoetTOEZq0jnxGGp4iDhUV0dPo+rHT7iN1O6M8g9jV/V7u2uwZYsKTziuLt5hbnyJj+4Y/I/9w+h9qtuXjOGJxXnzTgvZyPhMbhqmDm6U9uj7li6YFSKoIdsmamMgxyark5aohGyseeyG6H/Ezlx0kiV/xHH9KquOtaF5GVlt5v4SDGx9O4/rVaaIg5r0KEr00foWU1faYSD7K33FJs1e03Sri+BdQEgX70rkBVqzY2MKQG91F/LtFOFA5aQ+gFVbzWrjVL6G1s4TFYpx5Kf+hMfX2reMXJ2irvsdOKrypU5TgrtI01utG0sskAa+vVPIIKqPfJH8s1T1PWbzUMKz+TABgQxEhfx9fxp2p6ebvR2vrdcXdl8sqgfeT1/CsfSo7nVbgQWwCj+OQ9EHrWSqpxu9DkwWOpV6H1ibs1v5CljvWK3jMk78KijJNbNnoUNvCbvV5y02DthQ5G7sPetGxsbbT5Gg0tGu7o8SXD9Pp9KumyWNJJ7mRXdRlnY4SMV0YbD1sX7tGOnWT2X9f13PEx+cTxD9lh9I9+rOHnmAmliyT5Zxz29q2vDWqCWM6PcgGCXd5Td1Y84+h/nXL3MiS3lxJFny3f5c9x611ngrQJrieO/uFZIkO6JccufX6VMoqEmk7pde59LTXJhoqpukt97lnw14a82T7RfJlM/u4z/F7n2r0Ww0wnBcAKO1RxW7W6xykZAPIroICs0IeLkY5HtWLfY5KtWU3djEURrhRgVatJPmIqBlx05B6UQnY49K6MLLeLCm7po1kGcVYVcjFQwfMAauqoC13pGE5WKrxelM8v1q8w4qF1ptCUyvtFJtFSFaTFItMjKD0qGRPSreMio2FJoqMigwINKrY4qaZKrMMGpZutUXYHIYEHBHNdLZyiaFXHXuPQ1ycLc1saTP5c2w/df9DWkHqcWKp3V10NuiiitjzgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFXVbf7Xpd5bYz50Lx/mpH9a+XbXsD2NfVlfMuvWv2DxPqlrjCx3LhfpuOP0xXFjFsz1csl8UQ1mYJpyIO9cg3zSmug1x/3Ua+1YMYy1cbZ69NWRZjHy1KBTUGBUlSWGKQ0uaQ0CGmkBxSmmGgZMGDKVcZU9QacjzQKAn7+D/nmx5H0NVwaekuKmUVNWkYV8PTrx5KkbospPBMcI+x/wC5J8p/+vUqR4I3ZA+lVWaKUYkUH6io1hjT/VSyxD0RyBXO8N/Kz56vw5Bu9KdvJ6/idDC9k8RjuW+UjnIp40i3uOLO7Q5/hZv8f8a5xkY9by4/77NSWtveSyFbaZZdqltsgwTj0I5qYYecPhZNPKcZhVzUai9NV/wDR8S2V2kqC5hMUMabIVHKgdz9SaTwNDEiRu6g72IY+4NX9E1r7bY/YL3LwSZVd/JRvSsXTHfTdeuLCQ4EnzIT/eHQ/iMj6ivZyXFqGJUZ7vQieJqYyhKhU0nDX1tv9252a2gg12dUQGG6jyV7ehrmbmJbW6XTdPQRIW+fb3rsLGfzZYJTjKRtn9K5exXz9cvrk9EJFYY3CKeYyox2bX42/K7PAldLkT0bNGW4tdJ0+R3by7eIDcwHzOfQepNcHq2rXmtSFWBhtAcpAp4+rHua2vEAa/vorReUg5I7Fz3/AAHH51cstBCKHl5PpX1NbCTrWowfLTXRdT18JiKWEjzKN5+eyOd07SXndc8D17V7f4fsI4tPtA3zFYlyT7AVwUUAjcDGAK9K0dc6bbj1QflXmZthYUKEFBdf0OnC4qpiKspVHfQdebEgYvjbjpXP6TrdumpS2kc4aSPl0/u5/n70zxlrAs4G28v9yNfVu34DrXn62ssKpcI7CdTvEmeS3fP1rwYx0PpcDl0sVCUm7dvNntalXTenKHqB296Y6lT+orlPCXiBLuPa3ySJgSRn+E+o9Qa65wNgKnKHke3tRFuErnnzhKhPlkrNGhYPlQK00Py1iWL4fFbMJzivWg7q5lWWtx/aonFSsKjaqMkQnrTaV+DSVJqgpG5pTSUDIpFyKpyDmr7dKpzDmpkbU2RRnDVehYjBB5HSs8feq5AaSKqI6uF/MiR/7wBp9VdNbdZx+2RVqulbHiyVpNBRRRTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvAvirafY/Hdy4GFuY0mH5bT+qmvfa8i+OVqFv8ARrsDl0kiY/Qgj/0I1z4pXp37Hdl8uWtbujyvWnztHtWXD1q/rB+cfQVnw9a81n0Edi0p4p+aiBpwakMfRSA0poAaxphNOaombFAAzVEZMUjtUDtQUkWBNR51Uy+KYZTmiw7GksvvWx4WuFj1u33Hh8pz7iuXSUk10Ph/Rrq/kWYFoYVOfM7n/dprQyqWUXcNMtJ57iYQKcoMvjoGXof6VsXVour2aXcIxdRcMO6sO9dfpOmLH8sKBVLbmOOWPcmq3iDSf7KmXU9P+VSQs0Y6H3rBydKoqsNGj5TNqLlP6zT07/5mfpcjw6dPLMu07MYPY96o+H4v+JVNO3WaUmtnXJY5PDck8KhQwJOPpVDS1x4bt9vpmvVyiUsTj/bVNXZv8LfqeDvNGJboD4muQ397P8q7dY08hTgVxcv7rX4pOglQH8Rx/hXa24324z0r7CLtc3Zj3oAlyK7nTJdmgxyD+5iuF1I4k4rqrSfb4ZiDHAyefbNeRnivQT8/0Z35b/Fa8jz7xjfGbUmCkMIcRj3ZsZ/oPwq3exbNMhyMMRkiuZ1J3e2W55DSTGVj6EkmsW3s7u6DyTXyxvk8Eivm4xVj9Lpp0IQpxV7HTRXcumXVtcQDLksGUn7y9x/n0r1nw5qEV/Zp5b7o5F3If6fXtXhOmm6aaOG5k3lHO0g8EY613XgK/a2vp7Uk7RiZB6c4b+lRKNtDjzXDqvTeISs1+R6hCSsordt2yorAjkDTgjowzW1bHCA12YZ3gj5yavFF08009KQNkU05NdJgkRSdeKjBqRhUbMiH5jz6VLdjVDxTXwBknFRmcj7qfnUMjPIctwB2FZuouhSiyUuD05qvMKeh4wOaSXpzQpXNI6MqHrVq3NVmqxb9aEaT2Oj0Y5tWH+2f5Cr9Z2i/6mT/AHv6Vo10x2PFrfGwoooqjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK86+N0O7w7Yz45juwPwKt/gK9Frivi/F5ngi4f/nlLG/8A48B/Ws6yvBnRhXatH1PnzWW+cfSs+FuatauczfhVKKvJPpo7FomlU1EDTt2KRROpoZ6rmTFMaWgLEzyVXkkqKSWq7y0WGTNJzUTvnpUYYmgmnYdxCadDG80qxxKzyMcBVGSTVjTNPuNSuhDax7mPU9lHqTXrXhHwS9rbiaONcsPnupvlH0Xvj6Zo21MK1eNNa7nL+G/CPlss2pAO/aEcgfX1+lehWOmlsbhgDoK27PRLSAjzbwFsZwsbf1xV4QWIGftMigdjGOf1rnliKa05196PNnUnUd2n9xnwxLGoAHFUvEUYk0e6BHRd35HNb6W8ErFYPtDqByyx5x+tVdZ07bps+J42V42XbkBhkelVQcakk1qupz1leLjLqjzm4G/wxdRgdAaTw4n2nw/Eo7Lipo1Emi3SDuv9Kb4FP/EqAPOGNehkbcMTy+TX9fcfJR+NHPa7G0cccuPmgf8AQ/8A18V12jXCzWCN6iqHiOyV5ZYRwsq4+h7VmeE7x1t2hf70Zxg19lF3Oh6GpqMeZPxrTu5PI8LOf7kUj/kpqjcYkcE1Y1xgPDF0qnBFvKf/AB015udL/Z16r9TvyrXEJHI6Yivp8auAQVHBpr6NZMxPkjn0OKpwTuotIUOC5GfoP8it7VALW3QA/ORXy67n6pKK5lEz3tLe1iPkxKp9RT/C5/4qBRzloXH6g/0rMe4c37xyOdkcSjGerHn+ord8Jafeya/DItpOsQifMjoVXBGOp96mWmrOfGSgsLONz0nTHMhjz2WulthmMVz+mQNAdrAE+3at62Vmxk8eldVD3YI+QmrRLBkSP7zVC93zhEyPU027AXGMbs8VGucdBVynK9kZxirXYTTuygbdi9yDTVVdpOQacU34yfl9BTJ0UDI4PtWTb3Za7IWKMbMsSfalbAHFNdnVB8vamI2cM3T0pqy0Gl1JM44xUch4o3Fm9qSTpWsSorUgPWp7cVCBzVqEYFUi5vQ3tGB+zuf9r+laFVdMTZZp/tZNWq6Y7Hi1XebCiiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct8T1D+BdVU/3Fb8nU/wBK6mua+JIH/CD6wT2gJ/UVFT4Wa0P4kfVHzDqL5mqqDiluXy+ahLjFeQfVInEmKQy1UL00yUWKLLSe9RPJUJYmkJp2AVmJptHWnqjMQFBJPYUCGitnw/oNzq82QDHbA/PKRx9B6mtrw54OkmKT6oCkfUQ/xN9fQfr9K9b8LaZFFm5mhX7NbjEceOGfsMeg61Lkkrt6HLWxKirQ1ZW8L+F7LRLFJJ7bJcbkhbJLf7b/ANBXQSyS3MiqxDE4AVeij0A6U5fNuJuSHkdsH/a96l8xLcGOA7nxtaQdAPQf414v73MZ8q0h/X3v8jlvyavWQkkNvbf6wmaY/wDLNT8q/U+v0pv2iQEeQiRD/ZGT+ZzTo4gw+6AKtRwgdK97D5fSo/DH+vXchv8Andym/nzY815HA6bmJxUclpuRgQcEYrWEWB0pRF7V2exj2I549jz+68P3NrHKtt++iYYx0Yf41i+FbK6s7e5jnt5oismRvQjPWvW2hGORTfLjAPGfpTw1OOGrquvPT1T/AMzyqmW0Zy5oNr8TyvXJM7WIwwNcwP8AQdeJHEVwA4+p6/r/ADr2XU9PivVKzW0bA9yOfzrnbnwjp9y8XnLIHizs2vjOf/1V7CzajFe9FoznltTeLTRzMrfdIq9e2dzf6Jcw2sTPI8DqoHGSRwMmuvsfC9pDhnTee285rWAhtgA8W30OOK4cxzKOJp+zhGyve7NsFhpYep7RvU8j0PwPqEt1FJqMkdoUTCoPnY889OO3qa7dfBljLhroSTsOheQj9FwK6j7O9ztZEEag5DHipnDxpiRVweCQa8Xkk99j262Z16rvzW9NDA0jR9MtHJhtYY5s4Z1T5jjj73WtmS3jSMuAAR0NXmligi4CqgFZM05uphtGIx0961jQS31ORSnVd2JaISxbHJNakUYCc/lUdrEcDjip5DjgV1xVgqT5nYrPGokGB1pk3yoamZCxyTjHSoXyJBv6dqiQJkCCUJ2HsaI+pMh5FPeRQODVWSVRnJrFtI1WpNLKMEA5JqumWfC81GpaVgEFaEMIiTJ+9TgnNlP3UIE2LjvVeU81ZkPFU3OWroemg4LqCDmrsKkkKOp4qtCuWrX0qHzLkH+FOT/SnFXIrT5Vc2okEcaoOijFOoorpPHCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkvixL5Pw91lvWNV/N1H9a62uM+MKF/hzq4XqBE34CVCaip8D9DbD/xY+q/M+XZmyahLU+So8GvJPqwJpKcFp4SgCMAmlCc1o6bpd3qMwjs4HlbuQOB9T0Fd9ofga3gVZNTb7RN18teEX+ppOVjOpVjT3OF0XQ7zVZcW0ZEY+9K3Cj8a9F8P+GLbTMOB59z/wA9GHT/AHR2rpraxVUVIkVI14CqMAD6VpQWqxjJHNQ5nBVxEp6LRFSysCzKCOScCuilAQxWcGdkeU+X+Jj1P58fSotPTErS4+WFd349B+pFWbI+Sv2pjyMrGDxlsYz+ArhxPNVcaEftb+i/r8DCLteb6fmLORArW0fLAYlkz/46PaoYo97DAAHtQWBO0jcx5JNXLdQF6CvboUY0oqMVYpXgrvdjo0wKmUce9KFAFNY4NdOxg3clDU2SUIMscCovNCgkngVmy3HnS7s/KOgqZT5So0nJlmSdpZD821R0FTJJ2HNUlKOwLdqtIVxxWab3KlG2hfWFZF+9zVC7swMnJz2NLDcOrlR82Ks+cJRgjB96p8skYrmgynDeGMBZV3gfxDr+VE17BIVAJ656Vae0RhwoJ9ahFrtzhQDWbg9iv3b1HnUIf4Wz7YqndXxkBSJCSeOasNZ7+dvPrTo7bb2waTg5aMaVOJmpDcyKvmnIHQVoWlr3IxjiraRqoyaGmCDjoa1jFRCVRy0iOJEa4AqLJJyaazhwaRWGwU3IlKw/cMdaqzsD+FMnkCvwaiQNMeOlZOV9EaRjbUid2kbavSp4rAFQZWOT2FTxwJFz1NTpyacKPWRTn2I4oEiHyKB70SmpnIAqpK2K2skrImN5O5DM3aq9PdsmkRdxqGdKVkT268ZrotKh8u23Hq/P4VkWMHmzJH26n6V0YAAAA4FbU11POxVS/ui0UUVqcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ/iHTl1fQr/T2x/pMDxAnsSOD+Bwa0KKTV9BptO6PjPUbC50++mtLyJoriFijow5BFVxGT2r648QeF9F10q+q6dDcSKMCTlXx6blIOKyIPCmiaQd2nabbxOOjkb2H0ZsmvOqYdw1voe5DNItax1PnrTvCurXqK8dm8cR6PL8g+ozyfwrrdH8C28JV75muXH8C/Kn+J/SvUbpAWORVcIo6CuOUmtAlipzWmhkWeniGNY4YkijXoqjAH4VoRWqjGetWgoxnNGBjrUNs573FEaovYfjQu05LE59hSHbjjJoGR0OKBF63XNnIqgkyyKgB+h/rilu8Nc4Q/uYV2rnv6n8TmpdOybKSQuMQvvP/fJx+uKqRbPLJySSa2oUv3nO+v5L/gv8Bw1duw+FcnOa0Yl4FUoCo6CtGMfLnFenFFVmITiopHCjNSPVS4YA85/CmyIK7KWp3kNvAXuZVjT1P+eaxP8AhIbLgLDdFO8nl8f41a8i1vtUa4u9zRxHZFGeh9T+dbEUMDyhJI0CEY247VxTqXlZGsqnLoVreSK5tkntZA8TDhhT1ZxyWwKy3iGgapsU/wDEuvG69o37fnWvNGQOOlWncqMlIlgkHK55qVj8pwcGsoIXlHzFcDqKtKuRzIx+tK7FKFi5Hduo6E/Splundxldo7k1XhK+UNv40rMR059qtSa6mLgn0LX2lUHPSla6GOKznk3/ACBeT60zasajc7MfrQ6jD2SLQuN83sKSZwepqm8gH+rGD60g8yXrWfPLoUo2LEbgrnfz6U12IBCMee1JDa7SSTjParAQA1cYSktRleKBmOXq2oCDApM0VrCCjsIcOTT1IFR5xTHfFWK1x8snFULiYDvRcT4BrPZi7VLZvCFixGxZq0IEwKq2kPAJrd0u182QOw+RD+ZpxVyK1RRRe0228iPc4/eN+gq7RRXQlY8iUnJ3YUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEf7tZl8Mqa02+6azr0cGsquxcNzm7oYY1V71eux8xqketeLU3PQjsKVO3JoGMc5zSY96OKkY4DCkkUKPUA/jTRjPNKRn7gNAHM3fiS+i+JFh4YtFg+x3GnSXt0SCXAVwqYOePmz2NdaowgFc+vhq3Xxm3iVppReNYDT/LJGwRiTfkDGc5966LG5VCjtXbQs3p2Ko7u5NAOlaMR+UVn2/GM1fiYkcV2RCtqEp4rMvnCxsdwDH5R9TWjKOOaxNTPMf/XVc/nSm7K46SL9pDDFaDn6cVLJaCeJXD7HxxxVGdpWSNVQ+VnlvWrZuAsIwCMCvPUk9zFp7mbdabJfpNbSSBkXGeODVbTbua3lGm35/fKMRSE/6xf8RW7YyL5DydC55qlf21tqkMkMx2yI2UccEHsRTj7uzKjNp6hJEUBbr61AZQox3qKx1CSOYWOp4Fz0SQfdlH9D7VJdruJ28Ad61bVro6YSvox0cgXq5yew6VKtw2cKKzonG7hSfrxVyN8EZx+FEU2VKBMS7nJpRET1qRZFNO31qqa6mdmEcIGM1MAqjgVDv96N4rRJLYTiyfNJkVCZB600yCncXIyYtSb8VXaWoXmA70rlqBaaWoJZveqktxnpUSh5G70rlqKQ6Ri7cVZtbfJyRT7e1PBatixsHmwQNqf3j/SmotkVKqihthaNO+Bwo6mugijWKMIgwopIYkhjCIMAVJXRGNjyatV1H5BRRRVGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjfdNULsfKa0G6GqVyMis6mxUdznbwfMaz261q3q8msyQYNeNVWp3wegyl3cYwKQUvLVkWeXfEy8vrXX40gu7iKFoFYIkjKOrA8A+1dJ8MLmS68Pym4naSRLhly7Fjjap/qawfi5blbvTpyOGjZM/Qg/1q18IrgGHUbbIBDJIM+4IP8AIV6s4qWETS/rYCa9vbq3+N+m2bXc39m3WiSbYN58szLLkttzjdtwM9cV6NvHlgIMDHWsa80PTrnWLDVZ4FfULJXWCbJBjDjDDAODketbEKhohjseSa56Ek5WXYqlo3ckiPIq/AelUUAHC5Pv0FWoj05rtRdTUsSdKw9WBWNmxnaQ35GtzqtVbxSYyB0IxRJXRFKVnYgilC2nParySoYVAC9KwdOJKiO5d32MUbJ9On6Yq/PaEYMEpKkgEY5Arzk3G6RnOKTsyVYY5GYqxUZqR7e3QKAmT3almgEcO1Ccrzms+e6fbghgR7UO0d0JXlsLqOlwXkMkM6/K2CrDqpHpWMk82mTpb6oxlticJcY59g3+NdI77rXg/NjrXO+JpFuNIcEfMrKc/jW2HUZVoQeza/EmdSVOEpLoajWyuoeIhlIyCO9U5UdWrm7DU7zTAPLO+HqUbp/9aug0/wAQafqGEkPkTf3X6fga9XEZdUou6V0LDZjTq6S0Y9ZWU1KLg96sPaq3MZBHtURtT6Vw2Z6HMmN+00faaDbUn2Y0ajA3NMNyTUgtqUWo9KNQ0K5lZqZtdjWhHaDPSpWWGBcyMqgepp2E5IpQ2pbrV5I44ELSMFUdSeKozaooBW1jLH+83AqstrcXjhriU7fSi9thO73O1sNPBRJZSCpGQorUAAGAABVfTONPtwTnCAZqzXTFJI8arJyk7hRRRVGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABqrOMirVRSrkVMldDRhXqdax5hg10F4nWsW5XBNeViI6nbSZTpRQetHQ8VyGxynxMsTdeG3lVcvbSCTj+70P88/hXBeAdRGneJIDIcRTgwMfr0/UCvZJ41nhkimUNHIpVlPQg8EV4PrdhJpOrXFo5OYn+VvVeoP5Yr1cDJVKcqLA9X+Jelzax4E1i00+SVL7yfNgZCQfMQh1HHqVx+NafgnX18S+F9M1VflF5brIy4xtfGGX8CCPwrDg8Z2sPhW3vrgiS7YeWYVPzNIOv0HQ5966e11Kz/tJdOWaH+0xALg25cb1jzt3beuM8ZrkSnSsmuv/DiXuy5jRyyjB4xVqFsqKgbBOQN7GhGIfBOa70dD1RpRtxQ2GGCMioY2qUGquc7VmZl0qwTGVIAwbh+e3rTIr59wf/ln2IFakkQcc1ny2awlmTcynkp2P+Fc9ai5ax3L92XqPmvBJGQOSanWdBarGxX7vNZokQAgRGM+rfNVW4nhQYM4DHgcVyNTj0J9k+xbuN0S5Q7lJx9Kj12SNdDuIUxjZk+5zmkfb185cY9ap35hexuEV2djGwGFOM4q8M5Rqxkl1X5k1ablBq3Qw1USWucdqwrZQbtlPFdDpi+ZYtjqBWGE26h+NfoDdz5VGBa6hqFldzzWNzLFl2JCtwee46Gum0Hx7qE91FbXdtDOzuEDL8h5OPcVy8I+a4B6h2/nT/Cig+J7IMOPPT/0IV+fqUoysmfs1bD0a1JynFNpfoeu/wBqAfftXB9jml/tW37xSj8B/jWq1rGeqiq8ttEvIUV22Z8WpRZRbVYsfLBKfqAKjOpzN/qbbHuxzU8JU3UqkDaFBAp9oWkLy9Izwi+3rS1Lsikw1C5+85RfReKfDpQB3SNuatZEJp7IBT5ROVtCh9njhHyrz606I8064NNh60FdDr9M/wCPCH/dqzVfThixg/3asV0rY8Sp8TCiiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTWp1IaTAz7pODWJeJya6OdcrWReR8GuKvC50UpGE4wabk1NOuDUPf1rzGrM7EQ3kskNtJJDC08ijIjUgFvYE8V45421ZdX1NJDYSWc8SeW4kb5m54yMDGOa9orM1vQrHW4fLvIQXAwsq8Ov0P9OldOFrxoyvJDPEtMi87UrSLGfMmRcfVgK9M8f6Jf/wBtaF4n0G3afV9PmWCeFSqm4tHOHTJIGRncM9Oax7fwRf6Z4ksJVxcWKzq5kHBUA55H4dq9OLDGAoFdGMrxlKLg7kyXNoWBKqrsTjPfrTASprgbzxVc+HPGbWXiho49E1JlXTL5EwkUmMGGU9iTyG6dfw9Aj2MMEkt2461FGo1aMvkaU5rYtwSAjFTqazSWTHYelTRT11XKcbmgpqQgEVWjlGOtSCSqMXFg8CN/CM1CbSM/wirIfNODCiyBSkin9ij/ALg/Kj7LGVZSgwRjpV3dTC+OlFkh88medaNuVZIj1GQaybkFNQ/Gt+yQLq95H/dlcD8zWTq0e2+/Gvroy5lc+VkrOxzPlYur4DnEr/zqt4fbyvElq/8AdmQ/+PCta3QDUL9SOSxP5isbTvk16IngCQfzr4SvHlqteb/M/YcJP2mH16xX4o95klyOOlVpZMCmvJULHIJYgAdSa62z46MTPuzItwCn/LUbK2o0CIqKPlUYFV4wjzRqRnBzn3q2v3qiMlK9inK+xPCKJRwakhHy0kw+WtOhhf3jMn+9RB3ouPvUWxqTo6HX6d/x4wf7oqxUNkMWcI/2B/Kpq6VseJP4mFFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkPWlpG6UARyDis67Tg1pnkVUuUyKxqK6NIOzOau15NUyK2byHk8VlypgmvJqwszthK6Ihk9KOV5pOho5NYlikk9TTg/H3VP4UgbA6CgbiOOlMCO6s4b+IR3NvDNGGVwjoGAZSCDg9wQCDXIeLPGV14Q1uI63pzJ4amCoNSgYuYJD2lTHyqexGf1wO2SZ4zgYP4VDexx3sUkN1FHLFIpR43UMrA9QQeoq04rclp9B9rdRXUEc0UqSwyqHSVGDK6kZBBHUH1qXYc/LzXM+KhrtnpcEnhGGxlmtnBeznG0TxAEeWjDhD0wSMcVN4L8XReILS4/4lt7pt/auI7m1u4yrRsRng9GB7EdvSumlWaV5bGiq20Z0gLRgFvyp4uM1CJDKfmU59ulTJCMZDA46n0rphUjLZl3iyVJGzT/ADsHBNVG3AkKCB6+tMG7PeruPkuXjcGo2n5qAA4y1G0saLiUUc3EwHiC6x3cmsvXjt1EfWtR18vXpuOdw/lWV4iB+2g+9fWUfgi/JHylb+JJebMlFxrN6PUKR/3yK55j5erE+hro2+XXGH9+JT/T+lc3fjZq2P8Aar43HLlrzX95/mfq2Ty58NT/AMEfyPWdZ8Qado8W+7mBkIysScufw/xrhrjxXca1dIqqILVXBEQOS2D/ABHvXn0TOxmEjszh2BYnJOCa2dAGJV+ornnVk3y9DXC5bRpUfavWR7na/wDHwlX161Qtf9en1/pV9eta4T4H6nx0di1HwtLL92mI2FpXbIrrM7amZdcMaWzUs1SzxF24FX9Msj1YUkrs1lUUY6m7bf8AHvF/uj+VSUiDCKPQYpa6Dx3qwooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKAGd8VHKuRUrjvSEZFS10GmZlxFkHisi6hwTxXRyJVG4h3A8Vx1qVzeE7HNuuDTMkVoXMBU9KouuDXnTi4s64u4ztS8460KQDyM0hOagYDmlK4GeaAxHQ4p2CQCWXH1pgII2IyMUyRdysuSuRjI6j6U7JPGaQCkB57YeHfGnhzU7dNF8Rx6roZlUSW2rqWmijJ+YpKvLEDoGwOK3PFfj/AEXwxfwWevSXVqkqB1uTbO0GSSNpdQRnjp7iupEbHpyfaorm3SaJ4bmJJInGGR1DKw9wa057/EieW2xy+ta5DqnhpL/w3rEUkImUefbTggcHKnHfkcGsGPxZq9tGUTUPPk9WjUgfjit3xFoGm2Xg/UbHTLOGwt5jvZLRBENzEAsMdDjv7V5JpHhGe01CCePXdXaFHBMVxN5iMPQ8V9HlUI1KHw3V3+h5mMqThU0lbQ9ATxV4iZdxuIT/ANslqC78W+Iwh23qx4/uwp/UVha14Y1LUb1Z9O8RXWnxhAvkxwqyk888n/OKl07RbzTLKaK/1ObUpGbcJJUVSox0GK9VYenf4PyOR4mpb4397Ow8L31xfwx3N5KZbhmO9yAM4OB09sVb8RDNyprA8O6hZ6bpJkvZfLVZWUdyT1qxceKtFvZAv2iRT/eZDiuxOKSRyu7bZHqLGPXLduxhX+ZrA1w41TcB3q94t1aCymtLhP3ytF8pU8Hn/wCvXL3fiOKeZWls5oiT95un8q+PzGD+sTt3P1HI68I4Si5P7NvxK3S7uh/01c/rmtnQf9Yp96ww4kvbhgMBmzj8BW1ov3685/Ee9T/3ex7pb8Tp9a0O9ZkJ+eMj1BrVVSWxXRg/haPz2Og9OatRQM5HFSWloW6ir00lvYWzT3UqRRIMs7nAFdqj3OapWs7RGQWSjlhVtUVB6CvOfEXxOgt2aHRLf7Q2P9dLlVB9l6n9K861nxHq+ssft17K0Z/5ZKdqf98jj86zniYQ0WpUMHVq6z0R7nqXivQtNJW81S1V16orb2H4Lk1hXPxQ8ORLmJ7qf2jhI/8AQsV4csAzUqwj0rB4yb2R1Ry6kvibZ6vcfF2wB/0fS7uT/fdU/lmqMvxfl/5ZaCpHq13/APYV50IKXyKzeKqdzRYKh2/FnfH4u32eNEt//Ak//E0q/F29z82iQEe1yR/7LXAeT7UeV7UvrNXuP6nQ/l/Fno8fxfb/AJa6Fj/du8/+yVbi+Ltif9dpd0n+46t/hXlhhz2pv2ej61V7h9RodvxPY4PiroEn+siv4f8AfiU/yY1fg+I/hiVsHUGjJ/vwOP6V4Z9lpPstUsZURDy+i+59FWvirQbrAh1ixJPZplU/kcVrQzRTpuhlSRfVGBFfMAtB3FOSAxNvid429VODWkcc+qMpZbH7Mj6hor5tg1zWrYYg1jUFUdF89iPyzVkeK/EjEKNZuvzFaLGR7GTy2fSSPoeSRI0LyOqKOpY4FNhmimXdDIki+qMCK8s0ee7/ALMNzrWoSXKopkLSvuCDH5VwFxq2oXV3cTQXl1BDK5KxpKygL24Bx0qpYrl1sRDAuba5tj6W6VXlvrSH/XXUEf8AvSAV8ztHPcH99PLJ/vOTTk01T95gPqaj62+kTZZaus/w/wCCfRUniHRouJNX09PrcoP61A3izw+vXWtP/CdT/WvAk063H3pUqVdOtD/y1T86X1qXYf8AZ9P+Znu48XeHieNZsP8Av8Kni8R6JKcR6xp7H0Fymf514GNJtm6SpStoUZGUlWj6zPsL6hS/mZ9GQTwzrugljlX1RgR+lSV82JpE9u4kglKOOjIxB/StK18ReJtKI8nU7l1H8Mx80f8Aj2apYv8AmiRLL/5JH0DRXj+nfFXUIQq6lp8FwOheJjG2Pocgn8q7nw9440TXHWKC4MF03SC4GxifY9D+BraFeE9EzmqYSrT1a0OnooorY5gooooAKKKKACiiigAooooAKKKKAA0zpT6RhkUmAxwDULx5qUilHpUtXKvYz7iBWU8VjXVttJwK6V0zVSeDcOlc1WjzGsKljlnQim4GOhzWvc2hBOBVCSEivOnTcTqjNMq4xRUjIRTCDWVixRn0FITz2H0oI460cUASLNJjAakO9uWOabxjr+lOVUP8RP6VWrEU9biQ6RdeY3RC3HtzXmsc0bz/AHWZQeMnFem6nGslhcpkAGJh+hrze2iRZDsUvz94jAr6bI2nTkuzPJzFe8n5GzZBWTiMCmX0GQeKt2DHaAuB9KkuiWHJNe9F62PNexwN/E0LMhRJYi2/y5BkZ9fWoDeLtCrp1sD6kEj8s1u6tbFiWrFEeJRUtWY0ZGqG5nnUl0UR/KkewBVAOeBUEpv50CyzKV+n/wBetK4XzL2Rf9o/zq6tgPLzXxFapKVSV9dT9jw2FowoU7aaLb0MO3t/KBJJJPUnvW1oq5biqdzAy8KK6bwdo811KPlOKxinKR115wo0W9kerWsDsEAHIArqLSzGdzCk06xWKNcjnFcn488bx6aJNN0hw1/92SUciH2H+1/L6120aaoRcpH5nzTrS5KZseKvFth4diMQxPfEfLCp+77sew/WvHNd1/UNbuDJfzswBysY4VPoKoSu8rs8jF3Y5LE5JNNWMk1hVrynp0PSoYaFFX3fciwSaekRNWEi9qnSP2rE3ciusHtUqwip9uKcB6CjQhsiEQpREKlCk1IsLGiwrlYwikENaK2crdFNPGnzH+Gq5X2FzruZnkik8oCtcaZKevFL/ZTdyKPZsPaIyPLFNKAVtjTUH3nUfjTHtraP780Y/Gj2bD2iMQj2puxm6Ka057iwi/5ahj7Cs641i2TPlgmjlSKTb2RA8TA9KWKHEse/Ayw4qhc6u7k7AF+lJpMzT6lDuJPzA0rI05Xa7O48Y3/leHUt4xtjeRY2xxkcn+lcM9/gYjUAVqePJm+12EOTtCO+PUkgf0rmSaqbuyaFNKFy097Kf4zUbXUh6sarE0VFzo5UTG4f1pPPk9TUeKXFAWQ43Ug6Mab/AGhOp4dh+NG2mmP2phZFmLXLpP8Alq1XYPEb9JQGHvWI8INQvCR0ouxOEX0OuXULO7GGARj3pstorLmNgw9q5Ab0PGat2uoyxMPmNG5Ps2tj0zwr491PQpEgv2e908cbXOXQf7LH+R/SvadI1O01ewjvLCZZYJBwR1B9COx9q+Y7a/juRiXAb1rd8M67eeGNTW5tCXtnIE0OflkX/H0NdFHEOGktjz8TglU96KtL8z6Loqjo+p2msadFe2EokgkHB6EHuCOxFXq9FO+qPFaadmFFFFMQUUUUAFFFFABRRRQAUUUUAIRTcU+kIpWAQc01kBFOwRS0DK0kAYdKoXFlnkCtgimlQazlSUiozaOalsyO1VpLYjtXVPCp7VXe0U9q5Z4XsbRrHKvCR2qPYQa6aSwz/DVV7D2rnlhpI1VZMwmBPWgL7VrtYH0qM2R9KydGRftEZcwJicAdQRXlwdzLhiSK9kNofSvM7vTCl1Jnj5jgfjXv5H7nOpeX6nm5h73K15lrTGAAyM1bnkXB/dqafY6e6qAQasSWDsMAGvejKPMea07HJ6qA2cKB9KwnTEo4r0CXQpJv4TUH/CIyO4O00p1oJ7jjCTPPBFnUZeP4q3bazlmUKqnmu207wJunMsg6nNdnpfhi1tVBKAkV8jLDuVST6XZ+jSzulToQitWkvyPM9L8HTXThpFIX6V6R4d8OxadGOBmuiitoogAigVneKdbg8PaJPf3GDsGI488yOei/57ZreNGNNXZ4WKzSvi3yLZnPfEbxeNBthYWDA6lMvX/nip/i+vp+f18aiBZiWJLE5JPc0XV3PqV/Ne3r77iZt7t/ntU0a4Argq1HUlfodVCiqEeVb9RVSp40pY1GKlAwCTwBWe2rLlJJXYKlSoAOtZtze7OFOKpG+YniuZ4n+RXPBr57ThLlpxv57G+w3fdFPSMYy7BV96wY7w9W4pL1ZbuH9xOUcdB2NKOLinaasOhnlKpJRqrl890dBJqGnWw+d9x9BVV/E9pET5UWfrXBz+fHMY7gMsg7HvTlwRXZz31R9BGjCSUk7pnaP4vc/cRR+FQt4ruSflYCuUCnsKcFalzMtUILodHJ4iu3/wCWhqtJrNy/WVvzrJApwFK7ZSpxXQuPqU7dXb86rvdyN1Y/nUe2k20rjSSEaVz3NMJY1JtFIaCiMCtDRcjUoCOzVnk1c0hiNRgx3ahClszpPHkStBp9xg7wzJnsQRn+n865I11vjyYpYadB2kkZ/wDvkY/9nrkSaqe5lQ+AUCnhaapp4IqTYULS4ppakL0XEPxRio94o30AOIprLRvpN9AyN0BqvJFgcVZZqjLZoGVUlaJq29N1DcBHJyp/SsaZRio4HKPxTE1c9W+H3iNvDutLHM5/sy6YLKM8Iez/AId/b6Cvea+UbOfzoCjdQMivoz4fX76l4P02eVt0gj8tiepKkrn9K7cJN6wZ4uY0UrVF6HRUUUV2nlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRiiigAxSYpaKAExSFfUA06iiwDDEp7U026GpaKXKh3ZAbZMVnXGg2sjFvLG4nOa2KKcfcd4ifvbmP/ZEYxhRTv7Kj9BWtRWntZdyeRFCHT40/hFWBboOiip6Klyb3GkkMVAvQU6loqRiV4T8VtdGseIvscD5tLDMfB4aT+I/h0/A+teueM9X/ALD8NX18pHmom2L/AH24X9Tn8K+cIQW+ZiSxOST3NceLqWSgj1MupXbqvpsWoF4qygyQKZCvAq1HHyMVwHptk8acVHeMNmF6Cn3Mwgj+brWcZzPbbwOuf51z4uVoW7s8XO6jhhtOrt+pTMZnmCjqTWy/h6WO1WUgjI71n6Ng6im/pmvTdW2S6XDsUgKlRTiuVvsfK0oKSbPJLmF43KntTIZmibg8Vr3sWZX471lTxFTXOqinozB7li5t49St8H5ZV5VvQ1jxQkM8bjEqHDCtG0l8t6TVkEbxXqdMhZPp61rQm6cvZvZ7H0WRZg6c/q83o9vJ/wDB/MpEYoAqzeRBCjr91xmq4ruPsL3ACloooADSUGmk0ABNMY0E01qBjGNaPh8F9UhUdzzWYx5rovBkJkvWbHCj09aa3JqO0WzX8fRI2lWcxOHSbao9QVOf/QRXElq7P4hXEa2tpbZ/el/Nx6KAR/X9DXClqc9yMOnyE+/FJ5lQFqaXqTexYMtMMtV2emNLQFi15tHm1SM1MMx7U7BoaAl96DMPWs7zGNALGiwF5px61GZxVfDGk8pjRYCVpt1KnJpkcDGrkNscjNMRcsH2OCa+lfhzatY+ErGGQYYqXI/3iT/WvHvAvg2a+u4rvUo2iskIYIww0p9Mdh717tZMFjAUYA7V0YbSVzx8xqqSUImlmlBqurZqRTmu9M8hokoooqhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXiLXrPQLa3mvluX+0TC3ijtoHmd3Ks2AqgnorH8Kyv+E3s/8AoEeJP/BNcf8AxFHjj/kI+EP+wyv/AKTz1xOuQ3WofEfxTENG1nWUt7azMKWermzWFmSQn/lqnLEDkA4xQB2yeOdO+020M9jrdr9omS3jkudMnij3uwVQWZQBkkDmuqryuzvpr/4Z+EmvLqa6v4dWsba7edcSLPHdKkiP6srKVJ74z3r1SgDy/wCOeoGPTtN05DzPK0zgeijA/Vv0rymLjFdf8YLv7V41aEHi1gSPHuct/wCzCuRiHIrya8uaoz6HCQ5KMV8zStlyorSRFt4TLJ6cVBpcBkIJ+6OTVLxHfAExIeB1qErK5fxPlRnajdmWU88UmmSZWSA9R86+4P8A9esouWbJqxEzKySRn94hyPf2rCtT9pBxM8fg/rOHdJb9PUuK7W92rjsa9B0nV47uwEMr8AcD3rg28u8g8yL8QeoPoaZazSWz4BINcVOo46dT4BOVGTjJWZ0WrW4SYsvQ1jTxblNW/tbTLhjTSMiuSUrSuiJNN6GHICj1cRRc2UsLfxKQKdd2+eRUVuxjODW7lzxutxQk4SUluilp8hudOaJgfNgOCD1qE8VbuovsV8L6MfuZPlmHpnvUF6gWQlTlTyK9OnUVSKkj9HweKhiqaqQ6/g+qI91LmoM4pQ1WddiRjTCaQmmE0AOJpjNTWam9aChQCzYHJNejeErBraxQyA+a/JHp6Cue8J6G91MtzcKPIXkA/wARrs4r6J57m0snDTW+BMw6ISDx9a0gupx4ipf3EebeKLtrvXr1ycqjmJfYLx/9f8ayCav6zAYdSuATnLlvzNZcjYqHudcLKKsOd6haT3ppJNN2kmmkO4rOajJJq5a2UtzII4I3kc9FUZNdPpvgm+mYG5KW6H1O5vyH+NNJvYTaW5yCRs3arMNm8jbVVmPoBmvWNI8EadDtMyPcP6yHA/If1zXUQ6RFAgS3iSJP7qKAK0VKT3MZVorY8XtPDGozgFbR1Hq/yfzrVt/BN4/MksEY9Mkn+VetrpseRnJq3DaRRYIQZrOEXN2Ry/Wpy2PMLP4ePKMtPIw/2Ywo/MmtOH4eW0eC6TyfWRf6V6Jk0ma39hEHUm/tHFReDNOiABsxn/aZj/WtjTtBsrUgxWsCMP4ggz+dbwenAKTnGKiVB/ZZjPnfUdZx7ABW1bfdFZ9sgJ4rVtlxV0YNbnBUZZQVMgxSRjipa7oo5WwoooqxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8RZ1s28NXssc729tqySTGGB5ii+RMuSqAnGWA6d65m/vtDm8QX+r6f4l8WaXPfJFHcR2mkMyOIwQp/e2jsDhj0Ir1WigDyme90NdI0LQ/DiarM66xa3DNPY3IZz9pWSWWSR0AySWYknvXq1FFAHzb40uDc+M9ZlJz/pLR/98nb/AErPgGWApt/KbjVL2Y9ZJ5H/ADYmrelxeZOoxXjPWTPp0uWCXZG4ZFsNKLn7zDiuDvrhppix7muj8WXm0rAh4UVyIbc1En0Kox05mTLUqEiowKeKk2ZahlaKXzYQCTw6dmH+NXkaG7TdGeR1U9R9aylYg5FTKUZg/KSDo6nBrnrYdVPeWjPHzHKaeM99aS7/AOZoKDGcVoWkL3AOwZxWVHdMu0XABU8CUf1Hat3RLxLS5AkxsauCVJqajPQ+PxGDqYWfJVVvyKssZUlWGDWdcR7TkV2WvWttJ+/tGBUjNcvcgFSDUuLpTsc84crsVoXWVGjkGVYYINZJUxebbOSTCflJ7qelXVJSTiodRP8Ap8Lf89Iyp9yP/wBddeHfLO3Rnt8P4hwrul0kvxX/AALlFhTDUsgwTUDGu4+2Qpamk0AEkAcmtqw8PzzRGe6Zbe2AyXc4wPxoSuKUlHcxo43kbailj6AZrqND8OBo/tWouIoEG47jgY9yelNbUNL0qNRpkS3lyeDI4IVf8fw/OsvVtYvNURVu5EWFTkRxjaufX3/Gq0W5m3Ofw6I6DWfE0dvELTRCpAXBnHRf931PvWP4V1SPR72Zrncbe5AEjAZKkZw3v1OfrWXptre6jMosIAYd2DI/3ffFJdfu5GjfbuHQqeGpOTUlc51Ww/tPqyl7zOh8Z2CbI762ZXilGQynqO31riJAS1dn4avYLnT5NIunw5YtBnpg9Vz9cn8axbTRrm91SS0hTlGIdj0UZ6mm+5003ypxl0My2tpJ5VjiRnkbgKoyTXdeH/AvnDzNTkK458mM/wA2/wAPzrovD/h6309QtvHulIw0rDk/4CuvtLVYIjkZNEWk1c5amLu7R2MnTNFhtohHaQJDH/sjk/U962bXS0HLcmrUBXtU4OOld6SRnOcmC2yoPlFMZcHpVhTkUFfWmZXZW5xSYNWdgo2Ciw1IrYpMGrewGo2TFFilIqNleaaJCDU7rVaVcHipNFqXbeYggg4NbdlMJV9GHUVy0Um01p2dwUdWXqKaOavR5kdREeKlqG3YPErr0IzU1dMdjyXuFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfKZytzMp6iRh+tb2hgLuc9hVDXrf7J4k1WDtHdSqPpuOKt2z+Tp0rZ7YrxkrSPp5O8VY5vXbky3cjZ6mqEA70Xrbpj9afAvFJnQlZEy08CkApwFIAoziikzQInhkxkHlTwRUtpMVb7LKcDrE/9KpBsGnttlTa/TsfSs6lNVI2Zx43BwxdJ05/J9mbKXs0a7Cx+lRtKX61ni7MYCXgLIOBMoz/AN9D+tTHlA0bB0PRl5FcE4STtI+ExeCrYSXLVWnfoxJMBqivRxaSHoshX8x/9angEmtK3shdWzQvjDfhg+tCn7NpiwNf6viI1XsmYc6cmmW9rLdXCwwqWkboK2bjSbuIYaPzFHRl60y4f+z9PWC0Yi7nGZZBwUX+6Pc16MJxnsz76jjaNdfupJv+ug2e6svDahB5d1qDnDN1WD3Pv7f5NTVoLq/tDqQnlmeA/voi2QF9QOg/CqegadFfX7m55RG2qp6Zrto7JdN1pIsbrW6i2kHp6EV1V8HVhh1iul9jwMyx7o4qMqbfu79mefC7i2Zzz6Ctiz0OWSNbrV/9GtDysROGk+vcD/PFSposGg3kk8rfaHVyIUIwB6fjXRafYSagDeajJ8o4A9PpXPhadXGVfZ0F82GPzxz/AHWG+8omSR4fJsl8m2C7cgY49AOwrjtaXydVZQ3IjAI/u+39a7HxNq8WlwJFbIrTuMxp2Uf3j61yGjaZca1qiQq/72Ylmkf6ZJr0cRg6WGi6cW51N2+w8lwrpy+tVXZPTXrcNGtLm/1GGKzBMoYNu7IAepr2Kxso4FZkQLvfe59Se9HhnwvBpNt5cIJduXkbq5/w9q6VrRFiKAcetec3Y9fEV/aOy2JLeBEjDJjB7ipCMVm6deeRMYn5TOATWqQMDB+U9D6VLRyvQrRHbIV96vKMiqU4K8gcirlowcCu+jLmidHNzR5idAafxUoj+XIqJh1rexlzXYdqYetGaWkPYF4pSARTc0ooAhkXmoJFzVxuRUDik0aRkZsmVarFrLyKZcpxUEJ2vUbHQ1zROu0W55MLHhuV+tbFclZyEFWXqDmurjcPGrjowzXTB3R4uKhyyuOoooqzmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD58+J1r9k8e3+BhJgko/FRn9Qaw7qQrpxGeprvfjlZ+XqulXwHEkTQk/7pyP8A0I/lXnN+/wDoaj3ryaq5ajR9Hhpc9KD/AK0MB/mlNWYhgVWHMlW0rI7CQUtNBooEKaaaWkNADTSBsUE00nFAywknGDyKFiUMWgkaFj12ng/UVUL4pVl96TSejJlTU1aSui4Hu0PSGUeuCp/Tinfa7oD5YMH2m/8ArVT8/HelE2e9ZujB9DgnlGEm7umvxX5GjDrl9bFdyzKM9VIcflXQ2WoWWuWpt72ONbhhmOdOMn3rkFmKsDnuKW2LR3bGE48xuno/Y/j0qJ0UleB5uOyiFKDrYW6cdbXf4dbluyVtP1yeymG0yfMh/wBof4j9RXbROl5DYuwy6SBf0/8ArVyWrW51iCG9gLLdwcOB1BHet3wxM1w6MRhR87Y7EZyPzr3cNifaZZUp1On+eh4uJrQxKjV+119e/wAyh4gP2jxKsS8ovOK6HUiIYIbaP5V281iaRH9q8UyyOMjeAPw5rd8RQH7XtHGVKj8RXZw7RUKEqnVv8F/wWcNNXvI8+ezl1S+luNpIduC3Ydh+Vdd4I09LbXrYkZbDc/8AATS+HLZXseeGHBra0OIR69b4/wBr/wBBNeliKMIYeo4rVp/kehCtOpVgpPRNHaxjBJx0rK8T6rHpOmyzSnlATjPJPp/SteIDBJ6DmvHfHWrNquuzQIT9jsyQ3ozjqfw6fnXxcVc+pwWGeJqqHTqZdvqWqrfnVmkLyseYj90p/dxXq/hjXIdRs0eNwytwVPVT3U+9eewxA6UJcdsCs/S9RfRNQF0ATbStslQd/Qj3FW1c9/H5dCrTcqSs4/ie4SDK4PpwfUUlodrbe4qno17HfWcexw4ZQ6MO4NWASs6HseDV0Jcsrdz5qndNxZuw5KUyReaks2ytEw4Neh0ML2kVXXvTakfoahzzUmyFozSGg0FATmmMOKdQaBoqTrlTVBhh60Z+hrPf71Zs6ab0NGyPFdXpj77NPVcg1yNkeRXT6KcwyDsG/pW1Nnn4yOho0UUVseaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn3xstRL4Uhn/iguUOfYgg/zFeI6icWyV9C/FC3Fx4G1MYyUVZB7bXU/yzXzxqX/AB7JXnYpWnc9zLpXpW7MyU+9VlTVSM/NVjPFcp6hMDTs1AGqRTQIfTWpSaYz0ANJxUTtQ71A70FJA71GXprvUDMaCticy+9OWeqmcmtPRNHutVm226YjB+aRvur/AJ9KdiXJJXYQl5XVI1LMxwABkk13Phzw+beRbm7+ac8rGOQh9fc1p6B4ft9PRRCm+bGGlYcn6egrq7GxVOWxu96zlPoefWxF9I7HG634bubc/wBoaS2HHMkR7iqmia1A0xguIhbXB4b0NejXkQNs6AgkqRXnGs6dDcs5K4lHIYcGunC5fLFUpSp7x6f5HyOY4ZUqilS0v0L1rEtjqKy/ws2c/Wt7WLb7dZiaI/OvYV59ZarNZHyr3M9rnbu7pXWabf8Alwh4H861b0OStd+VZj9U/wBnrqyvv28n/WhwQnbQzbGRrC8ZX4imOQfRu4/rXQaPj+3LY5zw3/oJrN1G3jlQuvzRPzkdj607wrNJ/bsEE5+dA2D/AHhtPIr6LFtfV5tbOL/I68O71I+qOr8V6p/Y/hu9u1/1oASMf7R4H88/hXjUieRo8hckySfeJPJzXb/Fe7Zm0zTh91mM7++OB/Nq5iS2W4tth6EV8VHZH6Vk+H5aLqdWYT+J9QlV7aztUMMZ2nA7/jmoE1R7yPyZYPLkjkViD+IrRXTLq3cm3n2g9Tjn9KF02USebcSb269OtW3E9GFKre19H6HXfD3V3gun02Q8R/vYST/Dn5l/XP516bKwMiMOhORXiWhEp4p09hxksp98qa9isS0qQ+wpU1eSPn8zoKniny9dTptPHAqWUcsKZYAhBUjkZJr0lseHJ++ypIODVerM3eq/epZ0R2F7UUtIaQxppKWjOKBorzjis+Thq0Z+RVCQfNUM6KZYsm5FdPoh4mHbj+tczaDmum0PpN+H9a0p7nJjPhZqUUUVueUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGR4ui8/wrq8fUtaS4+u04r5f1Jv9GjFfV+oRibT7mI9HiZfzBr5Lv3/coDXDi1qmexlb0kjPTrVjNVl61IrCuNnsImBp2/FQFwKYZKQ7FlpKheQetV2lqB5c07ATyS1AZMmoixNA4p2C5ITmmE05FaRwqKWYnAAGSa7fw54VEfl3Oorul6rD2X6+p9qNiJ1FBXZl+HfDUt4UuL5WjteoXoz/AOAr1PSdNRbeNIY1jhUYCqMCiwsCxDSdK27UeWNgHArKcux5tWq5skgtUiUcqKlXZu5zS87ecYpBgDg5J7EVkYD2ZB0Cn61wl+ii+cMT17Cu3lBAGUC5rj9QtbqW+k8q2nkAY8pGzD9BX0fD8vfqR8keVma92LOY1Kx+zXIuGQm3k+V8f57VUSOfS5xJZNmNxuCZyrj1FdpJb74DBcxsjEcq6kH9a5cx/ZLg2F0MQs2Yn/uk9vof5162PyyniVd6Po/8+6PGcVP1Rf0/UYrsEwnZKeHibvV/TJI7XU4J2UssTHGeq5GCP1/SuWu7Z4pd2Ski9JB/X/GtPTdUW5YQXgEV0owH7N9a+ep1q2XN4eurwfTy7r+vuJhOVKSZD4/uku/Fi7G3JFAij8ct/wCzCorT7gq3rOlC+cSR4jvEX5fSQelc22oy28saEFdrhXUjkdv51jVoqNpU3eL2f+fmfqGS5jRxOFUYv3o7r+uh0ZA29KqXbKVxkZrbsNF1jUbT9xYmNCch5Tsz+fNKvw41S5vY5rq8t4YtpDCMlm69uAP1rNU5M75Y6jS3lsYXhjTZ7/xFaTQpmG3fdI56Aen1Ney6fb7FUYqpo2hQ6XbJBAAI1/EsfUn1rbjUIOldNOnyo+fx2L+sVHNFuL5E5qCR/mNMeXjGarvIc1s2edGDbuTsc1CetAfimFqm5oo2JBQaYppxNA7CUhHelNI3SgaK0xwKpsctVq4PFVBy1QzohsXbQV0+iri3dj3auctF4FdZYx+VaxqeuMmtaaPPxktLE9FFFbHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyYFonA6kGvj/UX/eEejH+dfYMrBI3Y9FBNfGVzIWYn1Oa4sX0PYyr7fy/UTdxTDJzUW80wtXGeyTGT3phkqKiiwDy2aZmjBpyoSaBCYq3pun3GoXAhtYyzHqewHqTW7ofhS5vNkt2DBbnnn7zfQdvxr0LStLhtYVhtYhGg9O/uT3pN2MKldR0W5j+HfDkGmqrkCW6PWQj7vsv+NddY2BOCwzU9parHgsOa17WzeaRArKu4/pUay0R59So3qx9rZfKHldY4hxnGcn0A7mpbubT7CJZJwioTjdLMF5zwOn9ap+JNXh02ymlkQ+WuEiXHXuB+OMmvGvE2q3msSCSd1BQgxoowqEcjArmhKriJNUtIrrvf7zejhXUXNI91F9II0khWFIiMgKg5+hwTVf8AtYsWM1rFJg4yUXn8sVy3gXV31nTY/NYBokxsz0wcEVrOxV5RglRgnHauGVWrCVnJ/f8A0gdCKdmi8/iGO3QstssQHeNVyT9Tk15p4l8Q6tcanLJDqmoRRs2VRZ2UKPTAOK6i+CtHKB6ZFcNqKk3KnHUCvsuCJOti6ntdfd6+qPA4jgqdCDhpr+hq2fibXFjVbm9N5COsV2glB/E8j8DWoItP8WwNb2qCy1ZRlbZ3ykvr5bHnP+yfzrn7WEuvtVa8jaKQMpKOp3KynBB9RX31bB06l1T91/1uj5eniJws5aonh80TPYXqlLuLIUvwXA6g+4qG5sBcR7osiROw6j6e3tW9K8fjG0jZCF8RW6/vYxwblV6SJ/tjuO/UVSsBNfzpHAv/ABMQwQxjjec4BH+eK8LE4SNaLp1lt+Hmv61O+8ai02ZV0Oe+vblNMEJmnP3H7KP7xPYV6ZpPhqw08pd3UEU18AN9y64GfbPA+vWvPNf8SS6LeTWXh51glT5Lq8QAvM4+9tJ+6oOQMdetclfXl3qM/m391Pcy4wXlcucfU18hGEKDlGDurn1OV5PUox9pOVm1+HY+mEljEa/JkHkMOh/GmSGMj5K+crG7vbEf6Hd3Fuc7v3UhXn14r0Pw/wDEApaJFrcMs0yjAnhA3OP9oHHPvmtVVT3O+eAnDWOp6OKr3EpU4FZ2m+JtH1A7YL+JH/uT/um/Xg/gTWvNEGBWVOD6irvfY5mnF2kjNe8AbBNH2gMar32lSA77R93qjn+RrPM7RsY5VKOOoNLU1XL0NrzQehqRWz1rFS4yeDVqGelcrlvsanSgGoY5gVpd+elMixKTTC1GcioZW2ihjiiGdsmkjXJqFny1W7VdxqdzV+6jQ06EyTRoB1PP0rqhxWVokG0NKR7CtWuiCsjxsTPmnbsFFFFWc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdWJGl3hX7whfH/fJr40lPNfabqroysMqwwR6ivjvxBpsuk6ze6fOCHt5Wj57gHg/iMGuLFrZns5S17y9DJNJUuzNPWPJ4Fcdz2CELTwlbml+HNQv8FITFEf45flH4dzXZaR4SsrXa06m6m9XHyj6L/jmk2ZTrQgcVovh291Vg0Uflwd5XGF/D1/Cu60XwtaacQ+PPuB0kcdPoO1dPDbHAGAAOAKvQWqjtzUORx1MRKXkjPgsycFq0YolQAYFTIhJ2qACKGXb1wfxqHdnPceix5GST7AVqTyw6ZbvuwrCPfM7Z+UYyVz2461X00KzM5T91Hgue7Hso+tcj8Tdf8qy+xqNtxdjLkdkzk/mePoDWNeTfLSpv3pfl1LoUnVnboc14y8QjWrlI7YMLaInBPBc9M49PSsGa1YQhxVKOXaa1YbsNblG5r0KNKNKChHZHscvIkolfw9rR8P6g0jErBI2Sw/gbpk+x716xpl2L2BpwRmQ5OOleL3oVyy4yDwa6r4faySh02eQrLCMKf7ydj+HSvPx9C372Pz/AMzOtTurnY6iojWceozXE6jjz0PsK7TVYV8ksWLZHrXGaoCl0qsMHA4r6LgX/e6n+H9UfKcTf7tD1/Q1NJQOMHpVfXrcIcjtWj4fj3utJ4ljCswx2r9AVS1ax8q43p3PPZZ5YLtZInaOSNtyuhwVI7g9q9B0DxRql+0H2qaF5j+6+0i3jE4DfLw+M9+T19689vx+9auh8LS+W8DHtNH/AOhrVZnThLCzqNapO33CwEpLEQhfRtfmYF/bS2N/PbTfficoffBp9rGGx69q7n4iaJ50Z1W3X50+WUAdR2b8P89K4e1IJHrX5ZGXMrn61QqqrFSLioMY9P0p6rwQB+FAOfvfnThnvyPWqNxVjyPXH51oWGrapp4AsNRuYVH/ACzVzt/FTxUEJVgKn8gNTXkZTSeklc7Xwx45+0zLa6/5URIwt2i7Rn0dR0+o/LvXY3VjFeWwk/dzQt92WNgw/AivFpLfrnqPzp+nalqOjzGTTrmWAn7wU/K31U8GtI1LfEcVTBqTvSdvLp/wD0a806S1y6EvGO/cVBFKfxqTwp4tt9bdbK+jW31AjCEH93N7DPRvbv29Ksatp5gYywj5P4lHb3rXRq6ONqVOXLJCRzEVbilyOtY8b571bgkxUmiaZqB+KrTSc00y4XrVdnJak2XGJKg3NWtYxE4AHJOBWfZpuIOK6jRbbnzWHC8L9auCuznxNXkialvEIYUQdhUlFFdJ4rd3cKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHoa81+Ingqx8R3S3Rka1vVXaZVUMHHbcOM49c16Uelc9q/EprmxXwHRh5yhO8XqeRWnwugSQG81J5E/uxRBSfxJP8q6qy8N6TpMJNnaRrIB/rW+Z/wAz0/Ct0mq14f3WPU15bZ6DrTnpJmStqg7ZqeK3A524FOJHAGaepbnBJ/GoBsTb8xA6Cpf3hU/NgemaZGpbNKFBcjpigQ1VJPTgUqA7vuk0ZzxkgUpzjClj+FCA0oWK2Y3nYC7Nx7AD+teJfEa4mn8S3RyXWFUjQDjA2gkfmTXtl0UighjPJRE7dyNx/nXiuqhdW1W8uIxhZZCy/TtXPh/3mMnLsrf19zPRwKsuZnKRXQZtpyrDsatxTEcZqLU7F4XORh16Gq9rNujyysD06V6p6KTe2poOc80yOSS1u4Lu3/1sTZxn7w7j8qQNke1aOkXFta3Ec8lrJeTI2VhPypnsSep+mBWdSSUWnr5Giw9Sa0iel2tpc3SQNcxNDFtV3MhAwuM4Nchrcqz6xO8bBo2clWByCM8YrI8VeI9X1OExXEvlRSnaLeIkA59e5/GrUKFWVeoQBR+Fe/wNg506lWtPskfF8Y0nQp0YSau23ZeR2HhlhuUe9S+Lo9sje65qn4bY+cAKueKmycnrtr66StiD5OOtI8zvl/fN9avWztFpk7oDuQBxj2IP9KqXo/ft9a1NKA2EMAVYYIPevQxEPa0JU+6aObD1PY141H0af3Hrlmq3LKPvI4zz3FcLrfgW5W4nn0h1dN5PkMNpUZ6A9D+OK7PRAUs7IxnLeUuM9+BWzaS+X5+R85JODX4+4ulNwe6dj9Do4iUPfp7M8Ik3207QXSNFMnDI4wRTwwPIOK9hv9KsNYIa+so2DDAZhyPoRyK5wfDm1lnm8i7uYwGOEyCAPxFWppnpwzCDXv6HCo5B5wau28xUjPT3rqrj4cSxqTDeuDjjcgOfyxXK6np17o9wIr6LarfdkXlGq1JbG8MRSq6RZfULIOKintvlyBkVXtZsEc1sW7CRcGr3CV4nOTRMjBkJBByCOCD/AI17PoOow63otvcxy+bMI1S54wVkxzke/WvMNRtgqlhyppnhrW5vD2rC5QGS3b5J4s8SJ/iOoNVCXK7MyxFL20Lx3R3Gp2xs7nKj905+X29qbG3euh1a3ivLItbuJIpEEsTj+IEZBrlbeTIwa1aPPpyuaKtuFSRRlmFQwcnFa9jbNIygAknoKm1zZ1OVFvS7QyyKoH1PoK6uNFjQKowAMCq9haC1ix1c9TVqumEbI8TEVfaS8goooqzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArA1xcODW/WVrUeUzWGIV4M0pO0jnD1qpfEjZ+NXH61Rvj8y/SvHZ6EdysTz1zT1ZwMDgfSo8c8daeOBg5zUmgoB/GnBmAwMUgxjnNKqZGeg9TTADlRnPNOSRugGTTM/NxT1eRuFOPpxQhFvWHmTTyYkVpfIDfVguQPyxXjGltiVPrXtl3lSrEZXavA68oK8Vtf+PxuNvzng9uelZYGV69Zef+Z6eE/hk3jK2RI4pVGCw5rjYZAZijgBU9O4Ndn4wlDwRKD0Fc5omnxXV47XWfKwMfMRz+FevTw8sVUVGG7OmnjYYCl9Yq3tHtuT295YQLl4BIR6mpm1u4uVMOl2aID3RP/ZjW/aaTpdsQyrGB6gbm/M1oi+0+25gtvMYd5Oa9+jwxLT2s/kl+r/yPCxXGsXf2FL5yf6L/ADORsNEnMour5i8o5VR91ff3NaeAuAKvX+pS3R+bCr2VRgVng5YV9bgcHTwlL2dONl/W58PmOYVsfW9tXld/gvRHReG+LkVa8UnL/hVTw+cTA1Z8UuOCO4rKX+8ImP8ACPPr3/XmrVrN5cYrNvpT57fWpEnSC1e4lBKRjJA7+gr0nKMIOc3ZLVnHGEqk1Tpq7bsvU9d8JXDTaNZyMem5fyJ/pXQrIvnKf4T6+tcB8LtVOraTOkkaxNDOQFB6AgY/HrXcTDyzhm+6RmvyDHThPE1J0/hcm183c/QaVGdCnGlV+JJJmjaFPKkjfB284NRLNIqMwUtxwwrE1LxHoti7LPqcAIGMId7Z9MLmufvPihaWcJj0yze5k/vynYn5dT+lTChUnZJDsbC/EKzsdSksNbgntmjbAlA3ow7Hjnke1aOvtpHibSZItPu7e48xfl2OCyN2OOowa8P1/W7vXLsXF75YIyFWNNoUHt6/mTVbTLK51G/htLGNpLmRsIq+vr7D3r0HhE4auzGlyyUkdA1vdafOba+jMcq/kR6g9xWrYSMSOa1fF/h6TRfDFiZ7mS5uYZB5srsT97ggZ6DO3Fc/p0v3PfiuNb2PcpVfbU+Y6sWontjxnI4rlNQgMMzKRx0rtdHbMRBPasHxNCFmJHpVyWlyKM2puJ23w+uTdeEoFZtzW8skHPUDhgP/AB6s2+hNvq0q/wALHcPxqf4YADQLzByTd8j0+Qf/AF/yrbutGm1TUYfIKqqjEjn+EduO/etUm0jgqSUKk77FCwt3lkVY1LMewFdzpditpEC4BlI5Pp7U/TdPh0+EJCMn+Jz1NXK2hCx5lfEupotgooorQ5QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlqa7ojV2obpd0RqJq8WiouzOQmGHNZ96PmXjtWpdjbKw96zr0MVXB4rxZrU9GDKS4Dckind/WmgHfjrUvK1BqGQBwOfWjnHJNIDgg05iWxk0gFAX1JP0pNrAZ6D60EKBwctRuZuC1MRpSFmsbaRsDYNre4U8f+hV4tdzBNWuzgr++fgjGPmNe02TLLZSQKTvRvMyfT+LH5A/hXmXxSsY7S9guowqvKSkmONxGMH8qwpSVLFu/wBtL8DvwMk7wZx2s3RlOCelaPhW2juLSaSWJ3JYBADtHHUk1z0cUuoXXkW+WbGWI52j1rttL0qdrdIpJfJhUYCL1xX1mVUKcZfWq8+SMdtbNvytr62ODPsS1TWEox5pS37JefQrziO3dkVt5/ug5x7Zpbayv7wj7PbnB7ngfnXXaVolsm0xRBn/ALz8mti4tzDGAwr2MRxPFK2Hhfzf+X/BPmKOSNu9aVvJf5nB3HhrWYIGmkhDKo3EKwJA/OshZD0YYIr2ONvPtE3c7lxx+teP3iBblsdM1pwrn1fN/bQxMUnBra/W/dvsc2cZbTwPI6TbUr7+Vv8AM3fDUv78A1d8UKR19KzfDvFwv1rT8Utnk/3a9uorYhWOGOtI8zvv9e31pbpT/YNx9U/9CFJfH9+31qa5/wCRduT6FP8A0MVrmX+5Vv8AC/yNco/5GFD/ABx/NGl8O3V9YutOee4gF1EHV4JCjBkz0x7E/lXXXXgR71nMmuXLdx56mTP1O4V5vo1yNP1vTbwkgJOoY/7JOD+hNe/QgyMFP93Ar8lhWnTtys/T87o+zxLl31POl+G8hYD+1ECkZyYT/wDFVoad8MIJlZrjVJDj+FIQM/iSa720kj8sxTDBHqOlJFMYJSAMqxyMVqsZV6yPGZyd54I0Wz8L38ttazXOoCEiJncs288DCjA/StL4X+GY9EVri6CtqEgw56+WP7o/qa6G0Be5baCgJ5U1LeRyWM/nID5bdcdjR9YqOFm9CH27mf8AFBUm8PXg4IEZb8Rz/SvItNOVTPrXY/EXxCHi/syIEyyqGY9lTP8AXFchYocoAKIvmbl3PYwFNwo6nZ6E3JzVDxSQZBj0q3pHyISayNdl3zMT2rVv3SoR/e3NT4X3jRa/cWeSYrqBiR6MnzA/luH416tof/H3N/u/1ryH4bIW8V+YoJ8qCRj7ZAX/ANmr2DQVzNcP7AfzrWj0PPzFJOT8kbNFFFdR4gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNk5Q06kflTSYHJaiMTt9azLwfugT2NbGqoROxrLnAMTZGeM14tVWkz0ab0RmY5461JtxjnJ9KbIMtnIoU1kbkvAHINIxBpMjpg/nS57AUgHAqB0OaQbQvU59KVUKjceMdqQKSenFMRLYyeRdRTFgArAkeo7isH4paDBqOiXWWLTWwM8LKew6j3yuK3VODhAv1NaQjW6sHyEeaJNrj1Tsw+nQ+2KwxEJOKnDeLv8A5mlGp7OabPllIpLRt0JZDnOQSK29K8V3to4FwftEXucMPof8a6Lxt4YfS5DKi5gc8cdPauDni2scCu+E41oqcdUz2+SFWOq0PbPCWu299GrRPnPUHqD71114yyW+euBXzx4W1F9P1CNgx2MdrCveNOuPtGmbz1xWkXbQ8TF4f2U9NixpxBtPQgn+deU3wxcsPevVdMz9l6AjeT9e1eU6mSL1x6Gvc4F/3jFrzj/7cfN8SfBS+f6GnoQ/eqelT+JJCcgntVXR3KsDS6yxdWJ9K+5cf31z55O1Oxwt7nzmqxd8eGrv/gH/AKGtQ3f+tapr3I8N3fv5f/oa0Zp/uNb/AAv8joyb/kY0P8cfzRBqduDokEgHU4r2bwhqA1Pw5YXLPmUxAMc5+YcNn8Qa8Vnuml0mOD+6c11Xwj8QxwTz6RdMFEhMsRJxzjkfkM/ga/IL30P2bO8JKdD2yXwv8D1tPnnImHzdM1OoWO82dVUArnvXB6v47sraQraRSXTrxuB2L+fU/lWRP8RL6V0MFlAgXrvcsSP0qlCXY+YWEqy6HsV5GpRZoWCyL29a5/xD4qt9MiWO8kYSuMrGg3Mw/wA+tcM/jzUZ4CsdtDG5GNzOWA/CufIlu7lri7keeZurNWii29dDWjgJX/ebE9/cyanqU17MNocgKv8AdUdBV+xjxg45NVoouRn8q1rdBGm4/e7Ctkj0naKsi4k/kxEZ5ArFvmLHk8mrFzNgbR+NZ1y+ELOcHqT6Cm2TCNtTs/hTbObrVb0jEKwiAMe7swbA+gUfmK9X0SPbaF/77E/0rjPC0A0zwlZJKhjkZDcSgjBy3Iz77dorsvDsvnaPbyYxu3f+hGuqkrWR4OPm53l3f5GjRRRW55YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGHrEXJOKwmXJINdbqMW+MnFcvcKVc15eKhaVzsoyujGlXY5XPSmqcVZvV+YNjr3qvgew/GuM609BQc9ad34zTQMkAU5TtPSkMOo707JQ9qA2DnAoZ8jGAKYhxKkZZsn0AqSzmeC4SRCMjs3QjuDUSmP+LdSkA/cDU79RPsO8TaSNT02ZAwMTrmMtyVI7H3H8q8E1/TZtNvpra5TbIh/Aj1HtX0DazvAGGwSI33kPQ/59a5/x14THiC3hubF9lxEpQBx17hWx+OD9eKxpr6tJtfA9/J/5HfhMVyvkmeAlijnBxXunhS4abQUbPVAf0rxbV7G407UHtbuJo5kPKn+Y9RXtPhVBDooTGCqAEfhXemnZo0zG3LE6TSwPsMRGCxJb+deVX0Zm1Ty1+874+nvXq2mf8eUAb7vJ4/GvKb2cW8t7cnqoMaH3PX9K9jgaTVbFtb3j+cj5HiJXjSv5/oEFyZ9ZFvZsVt4+p9QP8TVzVuEb6VmeFU2RNMw+aU5/DtWhqrbkNff00+a581N6WONvP8AXH60/U2J8NzqByWQf+PCm3g/f4AJJPAAyTVa8vxbQqrld6nKxrzz2LH+lcGeZlh8PhZ0ZS9+Ssl1179j3OGsnxWLxlOvGNqcWm5PRadu/wDVyC8VYktLRPvqoaUj164/lUOnQ/8AEwknBIWMYHPVj/8AWp1jbSzQy3bknmrWnpttd3992J/PH9K/MaavO5+x4ypy4Zru/wDglpE3Hn+VXoIAOpFQ233vvYq/ECe4NdJ4SJIouRyv5VehToAc/SqqHHUVYjlAHWhClcuooTk9aGnxnB/Gqxcv06U0nHuadyeXuPdu7flXV+BNAt9SDanqCebBFJsihP3XcAElvUDI47n6ViaX4b1XV3XybdoLdutxONq49R3b8M16HM9r4c0a3srT5vKXC56ux6sfqf8ACtIR6s48VWVvZwerIPE2pFpRbI2WY7pD/IV23hddug2Y/wBkn8ya8ssle6umkkJZmOSTXrOhqF0m1UcYQV0U97nkY2ygoovUUUVseaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjruUg1zmqW+xyQOK6SqWoQiSI8c1hXp88TSnLlZyE0e9CprOK4JBByOK2p49rHiqN1Duy6/eHX3ryJKx6EJFIfKfrT0U5poAPVqb06GpNCUuTwaFx3zTVODyOaM9aQD8rzgfnUsMiofnQ4+tRIxHSmliTk072E1ctzzq5UxgriltrloHZn+aNhhkzyfcehFUzk85FAVnHyqSad2xWRU8U+FLHxC1jeRMPMtpAS+BkrnOxx2Ge9Ns7SW1guElXHXBHStuzVrb50Yq59PT0qwjwXkbwzrHDI3SQDCk+47fWsYwlRlent2/wAn/n95cqrnHll0MzTXCabFI2FCozMT0wDXjXiKQkw244aQ72Hu3+Ar1zxPBLp2htAsbt5nyhl5AUn5uR7ZH414zfTiTWZJpQcJ91e5PYD8K+q4NpexhiMTUfKpO2vS127/ACZ4Oec1epSoUlzPy632/I6Gx8u2twXZUjQcljgCszWNYjKnYxjj/vsPmb6A9PqfyrIub26vbpbe3AklzkIoysfv7n3P6Vow6AseJb5/Om64J4Fe3LGYvNJuOC9yH8z3fp/X3HVHLsBkkVPMv3lXfkWy/wAT/r0e5hSXc84aO1j8uNvvOerfU9aLnTI4dGmmbLSllGT25FdHZ6Pd6nefZtNtHmcdkXgD1J6Ae5rd1Dwzp9lppi1u+MjZUtb6eQ7jnoZD8q/hmtK+VYPA4SprzVHF6vV7fgY0c/x2Y46imuWkpRtGOi3/ABZwsMyQaXLEWAJINGmqW0+JwOpbn/gRrtYbuysXV9H0axsyPuySp9pl+u6TIB+gFei+CNam1jTbiDUHjnmibB3RLhkPTjGOxr4alCN7XP0PMcTV9lz8ml++v4Jr8TxGN9p7/lVuGUE4OPxFe1X/AIQ0G9LNNpcKO38cBMR/JTt/SsuX4c6I4Jtp9QtZPXesq/kQD+tb+yZ5EcfDqmeYgj0X86UNjpgfSvTbX4faVA4a6vby4UfwALED9Tya1n0Hw3Aql9Ps1RenmyMfzy3NHsn1G8fTvaKbPILZbi6uEt7SKSedzhY0GSfwFeqeHPCVvpaxz34W4vwATnmOI+gHcj1P4etF54r0Hw/C0NksCZ6xWUQG76sMA/nVRddutUt0khHkxvnhTk/nTiop2vdmdd15w5nHlj+Zu6rrCWuUQ+ZOeoz0+tc5eiW8IkkJZjUsVizEFsk1qpahYRkVpvucN0nZFPSbQJjivR9KGNOgH+zXGWaAGu1sBiyhx/dFaU9zlxnwosUUUVqeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2RdykU6igDB1G1IYsBxWRKhBrsJYw4waw9RsypJA4rz8RQ+0jqpVOjOfmtg3zIcHuPWqZDI2DkfWtV1KnmmFVYYYA/UVwNHUpGb0PByaRcE8nFWboQW8Rd2ZBnACjJJPYDufaoISrSrHJDPAz/c8xR83GexP64pWKuKeuEpAQrYIBq4lqcZ8zA+lAt15BJNOwcyKuSwwqdfQVYto3XlhgelTRxBB8oP508Y75oJcgJLHJ61DGzAHCj64qY47ZpInxnMWfxo6iHRzTRwuI5WTIPA6Z+lcvNqtjdgpqumWt7ldvmhRG+Prgj8gK6ghpCSFxXByW2yXHWvoMmoUcRCpCvHmWlvxPMx1arRnCdGVnrt8ia08PeHMP8A2a11prNz+9HnJ+LA7qjuPCGrNc28aJHNbTPtW5ibdGB3JPb8at26lUxx+dSDULuxjmW1maNJUKOnY5GM49fevq6Up0IctF6LZPX/AIP5ni1YqtNyq7vdlDULxUg+waezRaVEcALwZz/ff1J/TisG8cyWshxhQRgfjU0hJYqW4HrSXSBdMkbIJyOn1rkxc7Yeou6f5HoZXD/baL/vR/MzYiWxitTQtTk0bU0ukG5D8sif3lPX/Gs22JZv6CrMkTFeFNfDJtao/WakYyThLZnsen3tvqFqlxaSCSJuhHb2Poaw/FNxPb3toFldYXUgqDgEg/8A1682sNSvNKnMllM8Tdx1DfUHg1uzeKJdYiggu7dFnRsiVCQDxyMfl3r1MvxEfbxUup8lm+U1adCc6Tulr52Rf8QQhow45yM1zOsrusraUdY5Np+hH/1q7CaPz9MzjkCuVv4ydNuEHVMOPwPP6Zr6HHU/aYecfL8tT5jJq3scdSn5pffp+pg6qh2K1eg/DxVu9GIPLRvj8CP/ANdcbqMIfTY5R1xg10vwkuP313bn+JA4/A4/9mr42lpM/Sszj7XBu3RnoEdsFHSluIwEq4RxUFyMrXafIw3Kdvw9djYf8eUP+4K4+H79ddprbrGH/dxVUzHG/CizRRRWx5wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGoZoxIpBFTUEUmrgnY56+sdpJUcVlyxFeorsXQMMGs67sQQSBXDWw3WJ0wq9GcfdxSm5t54VSQxBhsdto5x8wODyMEfQmq1vcrH/pmokLPvEWxeRAD0B+vBJ/pXQT2jITgVn31jHd27Q3CFoz74wfWuFxcTpUkynfak0OowwqA0OD5zgFtnXA46H+dW7S4S7gE0QfyyTtLLjcPXHpVCTTrlIUghdHtxwYziJfxCrz9ARUAvJNMuLgXU6OGKiONhsyxA5X0QdMcnOe5AKKtfY38EgfOBTTkdOlUYNThk4nUwOqF5CT8qY65P4+n65qaC8t7hykMoMi9UYFWH1U89xQTZljGRknmlUY56H2NN9sUvB7YoAc5YYBY151OQLkjB6+tejCMY65rz68RVueVb619HkH/Lz5fqeVmX2fn+hftOV7VHffcp9p93jpSX2RGSK+m6Hk9TnpNvmHB/MU66YDS5PlVuR/OmTMS5BqSYbdKnOf7vI+orgxavQqej/I9LK3bGUf8S/My7Q5bpj6VcYNgkg1TtD8x61cLMRgscfWvi0fq09yjc0li22ZSOoNLdVHa/fojJxkpLoOcFUpuEtmrHpOjHztPdD1xXPyRCSeaBujqy/mMVreG5CeOzLms3UQYtUz2zX3qamvJn441KlPzi/yMO2HnaM6kcr2qX4eXP2bxLbqThXYxn3yMD9cVNbrsvL+3PGWLAex5/rWDZSmy1uOTn5JA3Hsc18LUi6U7Po7fcfrtKSxVCVtpK6+aPoDHFQzD5asp8yAryCMimSRkjpXdY+KTszOjGHrptHbda4/unFYSQNv6cVuaWhjVgehpw3M8U04F+iiitjzgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAMU0jPWnUUAVpbdXHSs2eyGTxW3imsgbrWU6SkXGbRzElmR0qtJbblKuoKkYII4NdU9sp7VE1mp7VyywvY2VY4xdHtY5C0cAQEhiikhCR0JXpUdzpcxRjayhZCG5kBOSTknIIxkDHsOldm1gD2phsPQVn9VZftzl7SCSC0ijlxuVcHDbh+eB/KpdvuK3307I6VUl0x/4RUSw8l0KVVMy9xAIwK8+uyTc16d/Z8gP3a4mfRZWnzg17eRv2fPz+X6nnZgublt5/oVrT7tJf5MR5rYttHkVeaLrSHdCMGvovbQtueXySucO24ucGp7kyDR58n+7/MVsjQWMvINW73QS2nPEgILY/nmuLE1IujNLs/yPQy9cuKpSeylH80cHaklsk5q30PTNao0CSFsYJqUaLIf4TXx6gz9PeJpvW5zt1g/wimW0ZYjahBrqk0EvjKE1p6f4cOOUpqm2ZTx9KC3KWhkxeTnjijxHHtulcdzWvq+nmwTT227Syup98Nn/wBmqlrKGeFWVSSB6V9phHzUIPyt9x+YY+31mpbZtv7znLxhDrMMnaWIZ+oJH+FYGuqIdT3r0zmt3X02R2U7/JsJRieMDr/Q1zes6pp0rrm6XeBg8f418vmlPlxM0vX7z9G4frKWDpTb6NP5Ox9B+C5BqHhjTrgHJMQQn3X5T/KtwWoPWuA+CGrR3uh3lmj7jbShh/uuP8VNek5rSl70Ez5TMIujiZwXf8N0V1tUBqwqhelISe1KBWljicm9xaKKKZIUU07vMGNuzHPrmnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRgUUUAJtHpVRtPiParlFNNrYTVyj/Z6DtSHT0PYVfoqvaS7i5UZbaTHnPFI2lqU+THI71q0UOcmrMcVyu6MMaGnOQOad/YsY7CtqisuRHR9ZqdzITSkXoBVmKzROgq9RRypEutKW7OU8d2F3PoyS6bbme6gZmWMdSCP8QK8Ya28YX0uJnmhOf9Wq5x/OvpKiu2ji3SjyWOSpRU5cx4lbfD/wARa1oM8Wo3KRSZDw+cu0kjsccjqecVhWfwe1zAgey01exuJZt2ffjn9K+iqK5MR+/nzyPSweOq4Sn7KFmvNHH/AA78D2vg6xlSOUz3U4USyYwuBnCqPTk/WuvxS0UoxUVZHPVqzrTc5u7YYooopmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dissection of the lateral peritoneal attachments of the duodenum (A) exposes the first, second and third portion of the duodenum and head and neck of the pancreas (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30244=[""].join("\n");
var outline_f29_34_30244=null;
var title_f29_34_30245="Digoxin: Patient drug information";
var content_f29_34_30245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Digoxin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     see \"Digoxin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     see \"Digoxin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lanoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Digoxin&reg;;",
"     </li>",
"     <li>",
"      Digoxin Injection CSD;",
"     </li>",
"     <li>",
"      Lanoxin&reg;;",
"     </li>",
"     <li>",
"      Pediatric Digoxin CSD;",
"     </li>",
"     <li>",
"      PMS-Digoxin;",
"     </li>",
"     <li>",
"      Toloxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to digoxin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Amyloid disease, constrictive pericarditis, idiopathic hypertropic subaortic stenosis, poor electrical activity in the heart without a working pacemaker, or Wolff-Parkinson-White syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work (digoxin levels) checked. Have blood drawn before the daily dose (take digoxin after blood drawn). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take cholestyramine, colestipol, diet bran fiber, or kaolin-pectin within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A slower, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or the way you see color. Objects may have yellow/green halos.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your pulse is less than 60 bpm, do not take your dose and call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12382 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30245=[""].join("\n");
var outline_f29_34_30245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160142\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027036\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027035\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027040\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027041\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027043\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027038\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027039\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027044\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027045\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=related_link\">",
"      Digoxin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=related_link\">",
"      Digoxin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30246="Candidal intertrigo groin";
var content_f29_34_30246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with satellite pustules is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30246=[""].join("\n");
var outline_f29_34_30246=null;
var title_f29_34_30247="Hypersensitivity reactions to systemic glucocorticoids";
var content_f29_34_30247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypersensitivity reactions to systemic glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30247/contributors\">",
"     Rima Rachid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30247/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30247/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/34/30247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10714189\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are prescribed for their immunosuppressive, antiproliferative, antiinflammatory, and antiallergenic effects, and are integral to the management of numerous conditions, including malignancies, transplantation, autoimmune and allergic diseases, and asthma. They are also administered to prevent late-phase anaphylactic reactions. However, injected, infused, or orally administered systemic glucocorticoids have been associated with immediate hypersensitivity (allergic) reactions, including life-threatening anaphylaxis.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical manifestations, diagnosis, and management of hypersensitivity reactions to systemic glucocorticoids. Topical corticosteroids, usually in the form of skin preparations or inhaled glucocorticoids, can cause contact hypersensitivity, which is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link&amp;anchor=H100383861#H100383861\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Contact hypersensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7948528\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions to systemic glucocorticoids are rare, although the exact incidence is unknown. These reactions appear to occur in &ge;0.1 percent of parenteral administrations, as demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early report in the 1950s described 6700 glucocorticoid injections given to 2256 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/1\">",
"       1",
"      </a>",
"      ]. There were 20 instances of urticaria (including reactions localized to the injection site) or bronchospasm (0.29 percent of injections and 0.89 percent of patients).",
"     </li>",
"     <li>",
"      In a prospective study involving 202 children with rheumatologic diseases, approximately 0.1 percent of 10,000 doses of glucocorticoids administered were thought to cause reactions that were possibly of an allergic nature [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/2\">",
"       2",
"      </a>",
"      ]. Symptoms included pruritus, hives, and anaphylactic-like reactions. There was no statistical difference with respect to the ethnicity or underlying rheumatologic condition.",
"     </li>",
"     <li>",
"      Voluntary reporting of adverse drug reactions to the national Swiss Drug Monitoring Center uncovered 14 cases of suspected hypersensitivity reactions after parenteral glucocorticoid administration in approximately 5 million inhabitants over 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/3\">",
"       3",
"      </a>",
"      ]. However, data based on voluntary reporting generally underestimates the true incidence of an adverse event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7948535\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliable data about whether patients with specific diseases are at greater risk of developing hypersensitivity reactions to parenteral glucocorticoids are lacking. Although some reports suggested that renal transplant or asthmatic patients, especially those who are aspirin-sensitive, may be at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/4-7\">",
"     4-7",
"    </a>",
"    ], this could be attributable to the frequent use of these medications and not to the disease itself [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8\">",
"     8",
"    </a>",
"    ]. In the author&rsquo;s series, five patients received the offending drug for asthma, four for rheumatologic conditions, three for poison ivy, two for orthopedic conditions, and one for the treatment of an allergic reaction on one occasion and asthma on another [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manner in which patients become sensitized to glucocorticoids is not clear. Many of the patients in the author&rsquo;s study had not received extensive systemic (oral, intraarticular or intravenous) glucocorticoid therapy before developing an allergic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]. In other studies, some patients had prior systemic exposure to the same or different glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], while others did not [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/13\">",
"     13",
"    </a>",
"    ]. The role of topical glucocorticoid administration in sensitizing these patients has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7948775\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allergenic moiety in glucocorticoids that is responsible for immediate reactions has not been determined. It could be part of the native molecule or a metabolite that acts as a hapten and binds to serum proteins, creating an allergenic complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714197\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity (or allergic) reactions to drugs are mediated by cells of the immune system. Hypersensitivity reactions may be categorized based upon the time required for the first signs or symptoms to appear after an administered dose. Immediate reactions usually begin within one hour of administration, and delayed reactions begin after one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/14\">",
"     14",
"    </a>",
"    ]. This classification system is intended to distinguish IgE-mediated reactions, which are most often immediate, from other types. A minority of IgE-mediated reactions appear after one hour, particularly after oral administration of a drug or if the drug is taken with food, although this categorization system identifies the majority of IgE-mediated reactions. It is important to distinguish IgE-mediated reactions because they carry the risk of anaphylaxis if the patient is re-exposed. Immediate hypersensitivity reactions to glucocorticoids are the focus of this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19478802\">",
"    <span class=\"h2\">",
"     Immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of immediate hypersensitivity to glucocorticoids include pruritus, rash, hives, angioedema, sneezing,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    dyspnea, throat tightness,",
"    <span class=\"nowrap\">",
"     wheezing/bronchospasm,",
"    </span>",
"    hypotension, and anaphylactic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8-13,15-26\">",
"     8-13,15-26",
"    </a>",
"    ]. Hypersensitivity reactions have been reported following intravenous, intramuscular, intraarticular, and oral administration.",
"   </p>",
"   <p>",
"    The largest available series consisted of 15 patients (with a total of 19 reactions), who were evaluated with allergy testing at the author&rsquo;s center. These individuals presented over a 12-year period, although each patient was studied within a year of the inciting reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]. All reported various combinations of the signs and symptoms listed above, ranging in severity from pruritic rash (three patients) to anaphylaxis (five patients).",
"   </p>",
"   <p>",
"    It is not uncommon for patients to have had more than one reaction before the possibility of allergy to glucocorticoids is considered. Recognition of these reactions is complicated by the fact that patients typically receive these medications for conditions such as status asthmaticus, anaphylaxis, or shock, which have signs and symptoms similar to those of allergic reactions. In such settings, it can be difficult to distinguish a progressively worsening medical condition from a superimposed allergic reaction to a glucocorticoid. In addition, clinicians may not be aware that it is even possible to become allergic to glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19479067\">",
"    <span class=\"h3\">",
"     Causative drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of a specific glucocorticoid causing hypersensitivity appears to be related to the frequency with which it is used. Some papers noted that the incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    and methyl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    allergy seemed higher than allergy to other glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. However, in the series by the author&rsquo;s group, approximately one-half of reactions were caused by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and prednisolone, which are commonly used for outpatient therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]. Reactions to hydrocortisone and methyl-prednisolone accounted for 5 percent and 21 percent respectively. Twenty percent of patients had a clinical reaction to more than one glucocorticoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19478809\">",
"    <span class=\"h2\">",
"     Delayed reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed reactions to systemic glucocorticoids include delayed urticarial reactions and maculopapular exanthema. These reactions are uncommon and have been attributed to a T cell-mediated response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/27\">",
"     27",
"    </a>",
"    ]. Delayed reactions to systemic glucocorticoids are not discussed further in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1363067\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patterns of cross-reactivity among different drugs are not defined, although several patients with allergic reactions to more than one systemically-administered glucocorticoid have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8,9,26,28\">",
"     8,9,26,28",
"    </a>",
"    ]. Therefore, without an allergy evaluation or challenge procedure, it is not possible to choose a &ldquo;safe&rdquo; alternative glucocorticoid empirically for a patient who has had an immediate reaction to a specific agent. Various studies have tried to analyze the literature or small series for patterns of cross-reactivity, without firm conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8,9,15,17,20,22,26,29\">",
"     8,9,15,17,20,22,26,29",
"    </a>",
"    ]. Some papers suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    cross-reacts more with methyl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    than with a halogenated steroid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. In the 15-patient series, no patterns of cross-reactivity were apparent based upon the clinical history of allergic reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the results of the skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of contact hypersensitivity to topical glucocorticoids, at least two theories for predicting cross-reactivity among drugs have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, it is not clear that these theories, which concern T cell cross-sensitivity, have any utility in predicting potentially antibody-mediated reactions when glucocorticoids are given systemically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362890\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs or symptoms of an immediate reaction to a systemic glucocorticoid should be referred to an allergy specialist whenever possible, and advised to avoid systemic use of all glucocorticoids until evaluated. It is impractical to recommend indefinite avoidance of systemic glucocorticoids because of the widespread use of these agents for so many different disorders. If referral is not possible, then the issue can be deferred until systemic glucocorticoids are medically necessary, at which point the patient could receive a different agent from the one that caused the original reaction, using a graded challenge procedure under close medical supervision. (See",
"    <a class=\"local\" href=\"#H10714229\">",
"     'Graded drug challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714213\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an immediate hypersensitivity reaction to a systemic glucocorticoid is based upon clinical history, physical examination (if the patient is evaluated during the reaction), and when possible, skin testing with the culprit drug and possible alternatives. In many cases, a challenge procedure is needed to identify an alternative glucocorticoid that the patient can safely take in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19478944\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate-type skin testing is recommended in patients with reactions that are consistent with immediate hypersensitivity. (See",
"    <a class=\"local\" href=\"#H19478802\">",
"     'Immediate reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Skin testing requires training and knowledge to perform and interpret safely and correctly and should be done by an allergy specialist whenever possible. Skin testing with glucocorticoids is useful, although it is not validated and the sensitivity and specificity are not well defined.",
"   </p>",
"   <p>",
"    Skin testing using the prick-puncture testing (SPT) is suggested initially. In our series, we performed SPT using a full-strength solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]. Testing performed on three healthy volunteers was negative.",
"   </p>",
"   <p>",
"    Positive (histamine) and negative (normal saline) controls should always be included. Preservative-free glucocorticoid solutions are recommended whenever possible.",
"   </p>",
"   <p>",
"    If the results of SPT are negative, and if the glucocorticoid is available in an injectable form (preservative-free if possible), intradermal testing is then performed. For intradermal testing, we used dilutions of 1:1000, followed if negative by 1:100, followed if negative by 1:10, and finally a full-strength solution of the drug. A general discussion of the technique of allergy skin testing is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2815686\">",
"    <span class=\"h3\">",
"     Suggested drug concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We used the following preparations of glucocorticoids for skin testing (concentrations specified are for SPT and full-strength intradermal) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      succinate (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      preservative free)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      containing benzyl alcohol)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      sodium succinate (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      preservative free)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       Betamethasone",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      containing betamethasone",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      and betamethasone acetate, with edentate disodium and benzalkonium chloride)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      acetonide (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      containing benzyl alcohol)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/5",
"      </span>",
"      mL) (no injectable solution available for intradermal testing)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/5",
"      </span>",
"      mL) (no injectable solution available for intradermal testing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19479317\">",
"    <span class=\"h3\">",
"     Preservatives and excipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preservative-free glucocorticoid solutions are preferred for skin testing whenever possible, as mentioned previously. If a preservative-free preparation is not available,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if a patient had an allergic reaction after receiving a glucocorticoid preparation containing a preservative, then a preparation of that preservative should be prepared for skin testing (prick-puncture and if negative, intradermal) as well.",
"   </p>",
"   <p>",
"    Preservative-free glucocorticoid solutions are preferred for skin testing whenever possible, as mentioned previously. If a preservative-free preparation is not available,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if a patient had an allergic reaction after receiving a glucocorticoid preparation containing a preservative, then a positive result to the preservative-containing preparation should be followed by skin testing with a preparation of the preservative (prick-puncture and if negative, intradermal). Skin testing to the relevant preservatives could be done during the same testing session as the glucocorticoid skin testing, or done subsequently if a positive result is obtained with a preservative-containing preparation.",
"   </p>",
"   <p>",
"    Several patients were reported to have an allergic reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    (an excipient) present in some glucocorticoid preparations, rather than the medication itself [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/16,24,32-34\">",
"     16,24,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364519\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive skin test results are useful in confirming reactivity to the culprit drug, and negative results are helpful in identifying an alternative agent that is then administered using a graded challenge.",
"   </p>",
"   <p>",
"    Skin test results are considered positive when the wheal produced by prick or intradermal testing is at least 3 mm larger than that elicited by normal saline control. Because the rate of false-positive reactions has not been clearly determined, it is recommended that if a positive result is obtained, the test should be performed on a healthy individual as a control to exclude an irritant reaction.",
"   </p>",
"   <p>",
"    Information about the sensitivity and specificity of SPT and intradermal skin testing to glucocorticoids is limited. In the 15-patient series, the sensitivity of intradermal testing was 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ]. In a review of the literature from 1966 to 1997, intradermal testing was found to be positive in 76 percent of 25 patients tested, and a negative intradermal test correlated with clinical tolerance of the glucocorticoid in multiple patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19478951\">",
"    <span class=\"h2\">",
"     In vitro testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro immunoassays for glucocorticoid-specific IgE are limited to research settings because they have only been described in few papers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ] and are not commercially available.",
"   </p>",
"   <p>",
"    A positive basophil activation test was reported (ie, 71 percent of basophils expressing CD203c after exposure to in vitro methyl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) in a patient with methyl-prednisolone-induced anaphylaxis, who also had a positive intradermal skin test to methyl-prednisolone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/23\">",
"     23",
"    </a>",
"    ]. Two healthy controls had a negative (2 percent) basophil activation test. This very limited data suggested that basophil activation tests may be useful as a tool for diagnosis of IgE-mediated reactions to glucocorticoids, although we do not use them. Basophil activation assays are considered investigational in the United States, and the technical difficulties of manipulating basophils are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of in vitro allergy tests\", section on 'Basophil tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714229\">",
"    <span class=\"h2\">",
"     Graded drug challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graded drug challenge involves administering a medication to a patient in a graded manner under close observation. This is also called test dosing or drug provocation testing. Challenges are used when the sensitivity of allergy tests for evaluating reactions to certain drugs is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/35\">",
"     35",
"    </a>",
"    ]. In most cases, graded challenges are performed with a drug to which the patient has",
"    <strong>",
"     not",
"    </strong>",
"    reacted and is believed likely to tolerate.",
"   </p>",
"   <p>",
"    We use graded challenges to confirm that a patient tolerates an alternative glucocorticoid (other than the one implicated in the reaction) to which skin testing was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Graded challenge does NOT modify the allergic response to the drug or prevent recurrent reactions. Therefore:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who tolerate a drug upon graded challenge prove that they are not allergic to it.",
"     </li>",
"     <li>",
"      A challenge procedure in a patient with a suspected IgE-mediated drug allergy could potentially induce anaphylaxis and should be performed by an allergy expert when possible, and in a setting equipped to manage possible reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the author&rsquo;s center, we perform challenges starting with one-hundredth of the therapeutic dose, followed if tolerated 30 minutes later by one-tenth of the dose, followed 30 minutes later if tolerated by nine-tenths of the dose. Patients are then observed for two hours. In the 15-patient series, 90 percent of subjects who had a negative SPT and a negative intradermal test (when the formulation is available in injectable form for intradermal testing) tolerated the glucocorticoid when a challenge was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362907\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization is a procedure which",
"    <strong>",
"     temporarily",
"    </strong>",
"    alters the clinical sensitivity to the medication and results in short-term tolerance, allowing the patient with immediate allergy to receive an uninterrupted course of the medication safely. Drug desensitization renders mast cells unresponsive to the drug in question, although the exact immunologic mechanism is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/36\">",
"     36",
"    </a>",
"    ]. Drug desensitization is effective as long as the patient is receiving the drug, although the patient&rsquo;s sensitivity returns shortly after the drug is cleared from the body. Therefore, desensitization must be repeated every time the patient requires a course of the glucocorticoid. Desensitization is reviewed briefly here and in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364784\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization should be considered in patients who are strongly suspected to have an immediate, IgE-mediated reaction to a glucocorticoid, with or without a positive skin test result, AND for whom there are no acceptable alternate medications. At the author&rsquo;s center, it is a common practice to perform drug desensitization rather than a challenge in patients with a positive skin test, even if the patient never received the drug in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364791\">",
"    <span class=\"h3\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization should only be performed by clinicians trained in the technique (usually allergy specialists), in a hospital setting (or outpatient setting under close observation), with intravenous access and necessary medications, personnel, and equipment to treat anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link&amp;anchor=H10#H10\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1363326\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We advise patients to obtain a medical identification bracelet, since clinicians may not be aware that patients can be allergic to glucocorticoids and these drugs are often given in hectic emergency environments. Under such circumstances, the presence of a bracelet corroborates the patient&rsquo;s history.",
"     </li>",
"     <li>",
"      If a patient experienced anaphylaxis to a glucocorticoid in the past, we suggest that they have an epinephrine autoinjector available when receiving an alternative glucocorticoid in the future. At least one report described a patient who tolerated several courses of an alternative glucocorticoid, but subsequently developed an allergic reaction to the tolerated drug [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is also advisable to avoid the specific drug in all forms, including topical or inhaled, although data about this are very limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10714237\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms of immediate hypersensitivity to systemic glucocorticoids include pruritus, rash, hives, angioedema, sneezing,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      dyspnea, throat tightness,",
"      <span class=\"nowrap\">",
"       wheezing/bronchospasm,",
"      </span>",
"      hypotension, and anaphylactic shock. Hypersensitivity reactions have been rarely reported following intravenous, intramuscular, intraarticular, and oral administration. (See",
"      <a class=\"local\" href=\"#H10714197\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may be allergic to more than one systemically-administered glucocorticoid. Patterns of cross-reactivity are not well defined and, in the absence of an allergy evaluation or a challenge procedure, it is not possible to choose a safe alternative agent empirically. (See",
"      <a class=\"local\" href=\"#H1363067\">",
"       'Cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with signs or symptoms of an immediate reaction to a systemic glucocorticoid should be referred to an allergy specialist whenever possible, and advised to avoid systemic use of all glucocorticoids until evaluated. It is impractical to recommend indefinite avoidance of systemic glucocorticoids because of the widespread use of these agents for so many different disorders. If referral is not possible, then the issue can be deferred until systemic glucocorticoids are medically necessary, at which point the patient could receive a different agent from the one that caused the original reaction, using a graded challenge procedure under close medical supervision. (See",
"      <a class=\"local\" href=\"#H1362890\">",
"       'Referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10714229\">",
"       'Graded drug challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an immediate hypersensitivity reaction to a systemic glucocorticoid is based upon clinical history, physical examination (if the patient is evaluated during the reaction), and when possible, skin testing with the culprit drug and possible alternatives. In many cases, a challenge procedure is needed to identify an alternative glucocorticoid that the patient can safely take in the future. (See",
"      <a class=\"local\" href=\"#H10714213\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing with glucocorticoids is not validated and the sensitivity and specificity are not well defined. Despite these limitations, positive results are useful in confirming reactivity to the culprit drug, and in patients with a positive skin test to a specific agent, negative results to other glucocorticoids are helpful in identifying an alternative agent that is then administered using a graded challenge. (See",
"      <a class=\"local\" href=\"#H19478944\">",
"       'Skin testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10714229\">",
"       'Graded drug challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desensitization should be considered in patients who are strongly suspected to have an immediate, IgE-mediated reaction to a glucocorticoid, with or without a positive skin test result, AND for whom there are no acceptable alternate medications. Drug desensitization should only be performed by clinicians trained in the technique (usually allergy specialists), in a hospital setting (or outpatient setting under close observation), with intravenous access and necessary medications, personnel, and equipment to treat anaphylaxis. Desensitization must be repeated each time the patient requires a course of that specific glucocorticoid. (See",
"      <a class=\"local\" href=\"#H1362907\">",
"       'Desensitization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/1\">",
"      KENDALL PH. Untoward effects following local hydrocortisone injection. Ann Phys Med 1958; 4:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/2\">",
"      Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol 1998; 25:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/3\">",
"      Caduff C, Reinhart WH, Hartmann K, Kuhn M. [Immediate hypersensitivity reactions to parenteral glucocorticoids? Analysis of 14 cases]. Schweiz Med Wochenschr 2000; 130:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/4\">",
"      Saito R, Moroi S, Okuno H, Ogawa O. Anaphylaxis following administration of intravenous methylprednisolone sodium succinate in a renal transplant recipient. Int J Urol 2004; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/5\">",
"      Laine-Cessac P, Moshinaly H, Gouello JP, et al. [Severe anaphylactoid reactions after intravenous corticosteroids. Report of a case and review of the literature]. Therapie 1990; 45:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/6\">",
"      Dajani BM, Sliman NA, Shubair KS, Hamzeh YS. Bronchospasm caused by intravenous hydrocortisone sodium succinate (Solu-Cortef) in aspirin-sensitive asthmatics. J Allergy Clin Immunol 1981; 68:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/7\">",
"      Partridge MR, Gibson GJ. Adverse bronchial reactions to intravenous hydrocortisone in two aspirin-sensitive asthmatic patients. Br Med J 1978; 1:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/8\">",
"      Kamm GL, Hagmeyer KO. Allergic-type reactions to corticosteroids. Ann Pharmacother 1999; 33:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/9\">",
"      Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol 2011; 127:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/10\">",
"      Butani L. Corticosteroid-induced hypersensitivity reactions. Ann Allergy Asthma Immunol 2002; 89:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/11\">",
"      Karsh J, Yang WH. An anaphylactic reaction to intra-articular triamcinolone: a case report and review of the literature. Ann Allergy Asthma Immunol 2003; 90:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/12\">",
"      Mace S, Vadas P, Pruzanski W. Anaphylactic shock induced by intraarticular injection of methylprednisolone acetate. J Rheumatol 1997; 24:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/13\">",
"      Pryse-Phillips WE, Chandra RK, Rose B. Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. Neurology 1984; 34:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/14\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/15\">",
"      Burgdorff T, Venemalm L, Vogt T, et al. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol 2002; 89:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/16\">",
"      Venturini M, Lobera T, del Pozo MD, et al. Immediate hypersensitivity to corticosteroids. J Investig Allergol Clin Immunol 2006; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/17\">",
"      Freedman MD, Schocket AL, Chapel N, Gerber JG. Anaphylaxis after intravenous methylprednisolone administration. JAMA 1981; 245:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/18\">",
"      Fulcher DA, Katelaris CH. Anaphylactoid reaction to intravenous hydrocortisone sodium succinate: a case report and literature review. Med J Aust 1991; 154:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/19\">",
"      Erdmann SM, Abuzahra F, Merk HF, et al. Anaphylaxis induced by glucocorticoids. J Am Board Fam Pract 2005; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/20\">",
"      Calogiuri GF, Muratore L, Nettis E, et al. Anaphylaxis to hydrocortisone hemisuccinate with cross-sensitivity to related compounds in a paediatric patient. Br J Dermatol 2004; 151:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/21\">",
"      Mendelson LM, Meltzer EO, Hamburger RN. Anaphylaxis-like reactions to corticosteroid therapy. J Allergy Clin Immunol 1974; 54:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/22\">",
"      Koutsostathis N, Vovolis V. Severe immunoglobulin E-mediated anaphylaxis to intravenous methylprednisolone succinate in a patient who tolerated oral methylprednisolone. J Investig Allergol Clin Immunol 2009; 19:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/23\">",
"      Ben Said B, Leray V, Nicolas JF, et al. Methylprednisolone-induced anaphylaxis: diagnosis by skin test and basophil activation test. Allergy 2010; 65:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/24\">",
"      Patterson DL, Yunginger JW, Dunn WF, et al. Anaphylaxis induced by the carboxymethylcellulose component of injectable triamcinolone acetonide suspension (Kenalog). Ann Allergy Asthma Immunol 1995; 74:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/25\">",
"      Preuss L. Allergic reactions to systemic glucocorticoids: a review. Ann Allergy 1985; 55:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/26\">",
"      Ventura MT, Calogiuri GF, Matino MG, et al. Alternative glucocorticoids for use in cases of adverse reaction to systemic glucocorticoids: a study on 10 patients. Br J Dermatol 2003; 148:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/27\">",
"      Padial A, Antunez C, Blanca-Lopez N, et al. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 2008; 38:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/28\">",
"      L&oacute;pez-Serrano MC, Moreno-Ancillo A, Contreras J, et al. Two cases of specific adverse reactions to systemic corticosteroids. J Investig Allergol Clin Immunol 1996; 6:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/29\">",
"      Ventura MT, Sanapo F, Calogiuri GF, Satriano F. Anaphylaxis induced by intramuscular betamethasone disodium phosphate: reflections on a clinical case. Int J Immunopathol Pharmacol 2007; 20:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/30\">",
"      Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989; 121:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/31\">",
"      Wilkinson SM. Corticosteroid cross-reactions: an alternative view. Contact Dermatitis 2000; 42:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/32\">",
"      Montoro J, Valero A, Elices A, et al. Anaphylactic shock after intra-articular injection of carboxymethylcellulose. Allergol Immunopathol (Madr) 2000; 28:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/33\">",
"      Murrieta-Aguttes M, Michelen V, Leynadier F, et al. Systemic allergic reactions to corticosteroids. J Asthma 1991; 28:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/34\">",
"      Laing ME, Fallis B, Murphy GM. Anaphylactic reaction to intralesional corticosteroid injection. Contact Dermatitis 2007; 57:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/35\">",
"      Bousquet PJ, Gaeta F, Bousquet-Rouanet L, et al. Provocation tests in diagnosing drug hypersensitivity. Curr Pharm Des 2008; 14:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30247/abstract/36\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16379 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30247=[""].join("\n");
var outline_f29_34_30247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10714237\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714189\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7948528\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7948535\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7948775\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714197\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19478802\">",
"      Immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19479067\">",
"      - Causative drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19478809\">",
"      Delayed reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1363067\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1362890\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714213\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19478944\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2815686\">",
"      - Suggested drug concentrations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19479317\">",
"      - Preservatives and excipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1364519\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19478951\">",
"      In vitro testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10714229\">",
"      Graded drug challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1362907\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1364784\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1364791\">",
"      - Safety issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1363326\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10714237\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30248="Chorioangiosis";
var content_f29_34_30248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Villous chorangiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Terminal villi show an increase in the number of capillaries per villous cross-section (more than capillaries in more than 10 contiguous villi in several areas of the placenta).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raymond W. Redline, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30248=[""].join("\n");
var outline_f29_34_30248=null;
var title_f29_34_30249="Symptomatic (secondary) myoclonus";
var content_f29_34_30249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Symptomatic (secondary) myoclonus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30249/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30249/contributors\">",
"     John N Caviness, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30249/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30249/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/34/30249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is a clinical sign that is characterized by brief, shock-like, involuntary movements caused by muscular contractions or inhibitions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/1\">",
"     1",
"    </a>",
"    ]. Muscular contractions produce positive myoclonus, whereas muscular inhibitions produce negative myoclonus (ie, asterixis). Patients will usually describe myoclonus as consisting of \"jerks,\" \"shakes,\" or \"spasms.\"",
"   </p>",
"   <p>",
"    Myoclonic movements have many possible etiologies, anatomic sources, and pathophysiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/2\">",
"     2",
"    </a>",
"    ]. Myoclonus may be classified by clinical presentation, examination findings, clinical neurophysiology testing, and etiology.",
"   </p>",
"   <p>",
"    This topic will discuss disorders associated with symptomatic (secondary) myoclonus. Other aspects of myoclonus are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link\">",
"     \"Classification and evaluation of myoclonus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link\">",
"     \"Treatment of myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification scheme of Marsden and colleagues uses four major categories to organize the numerous etiologies of myoclonus (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physiologic",
"     </li>",
"     <li>",
"      Essential",
"     </li>",
"     <li>",
"      Epileptic",
"     </li>",
"     <li>",
"      Symptomatic (secondary)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myoclonus that occurs secondary to a neurologic or systemic disorder has been traditionally termed symptomatic myoclonus. Symptomatic myoclonus can occur in association with conditions that span the entire spectrum of neurologic disease (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 1",
"    </a>",
"    ). Often there is clinical or pathologic evidence of diffuse nervous system involvement.",
"   </p>",
"   <p>",
"    Symptomatic myoclonus is the most common type of myoclonus, accounting for 72 percent of cases in one large epidemiologic study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/3\">",
"     3",
"    </a>",
"    ]. Posthypoxic state, neurodegenerative disease, and epilepsy syndromes are the most common causes. Toxic-metabolic and drug-induced etiologies are particularly common in the hospital setting.",
"   </p>",
"   <p>",
"    Most patients with symptomatic myoclonus have additional clinical manifestations, such as cognitive abnormalities, ataxia, or other movement disorders. These features can be more prominent than the myoclonus. While seizures may occur in many of these entities, encephalopathy (ie, a confusional state secondary to a diffuse brain disorder, sometimes called delirium) predominates, and the causative syndrome is not considered a primary epileptic disorder.",
"   </p>",
"   <p>",
"    Many conditions with symptomatic myoclonus are further characterized by chronic or subacute clinical progression. The cortex is the most common origin of the myoclonic jerks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGRESSIVE MYOCLONIC EPILEPSY AND PROGRESSIVE MYOCLONIC ATAXIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic myoclonus is a major feature of the rare, genetically heterogeneous syndromes known as progressive myoclonic epilepsy (PME) and progressive myoclonic ataxia (PMA). The latter is also known as dyssynergia cerebellaris myoclonica or the Ramsay-Hunt cerebellar syndrome (to be distinguished from the Ramsay-Hunt zoster syndrome of the facial nerve).",
"   </p>",
"   <p>",
"    PME and PMA share overlapping phenotypes and causes. The myoclonus physiology demonstrated in these disorders is cortical action",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortical reflex myoclonus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification and evaluation of myoclonus\", section on 'Anatomic and physiologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main features of PME are seizures, myoclonus, ataxia, and dementia, usually leading to severe mental impairment and death. PME can be differentiated from the more benign epileptic syndromes and from PMA by its progressive nature and the greater severity of the seizures and cognitive decline. The myoclonus associated with PME is typically multifocal and induced by action or by somatosensory stimulation, including touch, sound, or light [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of PME are Lafora disease, myoclonic epilepsy with ragged red fibers (MERRF), neuronal ceroid lipofuscinosis, dentatorubral pallidoluysian atrophy, and Gaucher disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare causes of PME include the action myoclonus-renal failure syndrome, juvenile Huntington disease, familial encephalopathy with neuroserpin inclusion bodies, noninfantile neuronopathic Gaucher disease, atypical inclusion body disease, neuroaxonal dystrophy, celiac disease, juvenile GM2 gangliosidosis, pantothenate kinase-associated neurodegeneration (formerly known as Hallervorden-Spatz disease), and early onset Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the syndrome of PMA, cerebellar ataxia and myoclonus are the more prominent or sole components [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinical progression is slower than in PME. The most frequent causes of PMA are Unverricht-Lundborg disease (ULD), sialidosis, celiac disease, mitochondrial disorders, certain spinocerebellar degenerations, and some late-onset metabolic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unverricht-Lundborg disease (ULD) is an autosomal recessive disorder. Symptoms usually begin between ages 6 and 15 years with stimulus-sensitive myoclonus. Affected patients develop dysarthria, ataxia, intention tremor, and mild intellectual decline. While progressive, the clinical course is variable. Some patients are bedridden within five years after onset of symptoms, while others are able to live independently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H36#H36\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Unverricht-Lundborg disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STORAGE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic metabolic disorders can be associated with symptomatic (secondary) myoclonus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lafora disease",
"     </li>",
"     <li>",
"      Gaucher disease (noninfantile neuronopathic form)",
"     </li>",
"     <li>",
"      GM2 gangliosidoses:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hexosaminidase A deficiency including infantile (Tay-Sachs disease), late infantile, and juvenile onset",
"     </li>",
"     <li>",
"      Hexosaminidase A and B deficiency (Sandhoff disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Krabbe leukodystrophy",
"     </li>",
"     <li>",
"      Neuronal ceroid lipofuscinosis",
"     </li>",
"     <li>",
"      Sialidosis types 1 and 2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conditions may manifest with features of the PME",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PMA syndromes. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Lafora disease, GM2 gangliosidoses, Gaucher disease, and Krabbe leukodystrophy almost always present as PME. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H37#H37\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Lafora body disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"     \"Krabbe disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuronal ceroid lipofuscinosis typically causes PME, but the late-onset subtype can cause PMA. Sialidosis can cause either type but is more often PMA. Unverricht-Lundborg disease almost always presents as PMA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the hereditary ataxias\", section on 'Sialidosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H36#H36\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Unverricht-Lundborg disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEURODEGENERATIVE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus can be a manifestation of many progressive neurodegenerative diseases, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinocerebellar degenerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Progressive myoclonus ataxia (Ramsay-Hunt syndrome)",
"     </li>",
"     <li>",
"      Friedreich ataxia",
"     </li>",
"     <li>",
"      Ataxia-telangiectasia",
"     </li>",
"     <li>",
"      Other spinocerebellar degenerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basal ganglia degenerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Torsion dystonia",
"     </li>",
"     <li>",
"      Pantothenate kinase associated neurodegeneration (formerly known as Hallervorden-Spatz disease)",
"     </li>",
"     <li>",
"      Progressive supranuclear palsy",
"     </li>",
"     <li>",
"      Huntington disease",
"     </li>",
"     <li>",
"      Parkinson disease",
"     </li>",
"     <li>",
"      Multiple system atrophy",
"     </li>",
"     <li>",
"      Corticobasal degeneration",
"     </li>",
"     <li>",
"      Dentatorubral pallidoluysian atrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dementias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Creutzfeldt-Jakob disease",
"     </li>",
"     <li>",
"      Alzheimer disease",
"     </li>",
"     <li>",
"      Dementia with Lewy bodies",
"     </li>",
"     <li>",
"      Frontotemporal dementia",
"     </li>",
"     <li>",
"      Rett syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these neurodegenerative disorders progress to involve multiple brain areas in the basal ganglia and cortex. Myoclonus may be absent or mild early in the course of these conditions, but eventually appears",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increases in significance during the middle and late stages of disease.",
"   </p>",
"   <p>",
"    Myoclonus has a variable expression in neurodegenerative disorders. It is usually multifocal, although it can be generalized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multifocal jerks occur in a widespread distribution as separate distinct nonsimultaneous jerks, such as a jerk in the right thigh, then the left shoulder, then the right forearm, and so on",
"     </li>",
"     <li>",
"      A generalized jerk occurs simultaneously in many muscles in a widespread distribution",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The myoclonus physiology demonstrated in these disorders is mostly cortical action",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortical reflex myoclonus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification and evaluation of myoclonus\", section on 'Anatomic and physiologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association of myoclonus with some of these neurodegenerative disorders is discussed in greater detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Creutzfeldt-Jakob disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creutzfeldt-Jakob disease (CJD) is a prion disorder characterized by a rapidly progressive dementia leading to death within weeks or months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/7\">",
"     7",
"    </a>",
"    ]. Myoclonus is a common, but not universal feature of CJD. It tends to be generalized and can be provoked by loud noise (startle). Periodic sharp waves on electroencephalography are a common finding with CJD, but are not specific for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alzheimer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus in Alzheimer disease (AD) is variable. It is usually multifocal, although it can be generalized. The appearance can be sporadic large myoclonic jerks or repetitive small ones. The jerks may occur at rest, with action, or with stimulation. It is common for all these various phenotypic characteristics to occur in a single patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of myoclonus increases steadily during disease progression, and up to 50 percent of patients with AD eventually develop myoclonus. An earlier age of AD onset, faster progression, or familial causes of AD are associated with myoclonus appearing earlier and more frequently.",
"   </p>",
"   <p>",
"    Some patients with rapidly progressive AD can have very prominent myoclonus with periodic sharp waves on electroencephalography and be misdiagnosed with Creutzfeldt-Jakob disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parkinson disease and dementia with Lewy bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus of cortical origin occurs across the spectrum of Lewy body disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small amplitude cortical myoclonus in Parkinson disease (PD) occurs during muscle activation and may appear repetitive and rhythmic enough to resemble action tremor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"       \"Clinical manifestations of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In dementia with Lewy bodies (DLB), cortical action myoclonus is more common (one-third of cases), has a larger amplitude, and is more likely to occur at rest compared with PD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"       \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cortical myoclonus has been found in one family with hereditary Lewy body disease due to an overexpression of alpha-synuclein [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The myoclonus in all of these Lewy body disorders shows identical physiologic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/11\">",
"     11",
"    </a>",
"    ]. Even though the parkinsonism in these conditions arises from a subcortical localization, the cortical action myoclonus physiology signifies that the sensorimotor cortex is not functioning properly. The fact that the dementia and myoclonus are more prominent in DLB than in PD suggests that cortical myoclonus is a marker for cortical dysfunction in Lewy body disorders and correlates with the presence or development of cognitive dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Corticobasal degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is an important feature of corticobasal degeneration and occurs in 50 percent of cases. The clinical presentation parallels that of the overall syndrome with a focal distribution in the arm, and less often in the leg. It is associated with other focal limb manifestations that can include apraxia, rigidity, dystonia, and alien limb phenomenon. A \"jerky tremor\" has been described as part of the syndrome, and the myoclonus is preceded by increased tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The myoclonus in corticobasal degeneration occurs in repetitive rhythmic fashion when an attempt is made to activate the arm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/13\">",
"     13",
"    </a>",
"    ]. Reflex myoclonus to somatosensory stimulation is also very common. This myoclonus is believed to have a cortical origin and may represent a distinct type of cortical reflex myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corticobasal degeneration is a sporadic disorder of the microtubular associated protein tau. The tau pathology has a strong presence in frontoparietal areas, and this could serve as a substrate for the generation of myoclonus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=see_link\">",
"     \"Corticobasal degeneration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Progressive supranuclear palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive supranuclear palsy (PSP) is another sporadic tau disorder, but in contrast to corticobasal degeneration, myoclonus has only been rarely observed in the context of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/15\">",
"     15",
"    </a>",
"    ]. In one case of autopsy-confirmed PSP and action myoclonus, pathology indicative of PSP was present in the cerebral cortex in addition to the more typical subcortical distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=see_link\">",
"     \"Progressive supranuclear palsy (PSP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Multiple system atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two series of patients with multiple system atrophy, an upper extremity small amplitude \"jerky postural tremor\" was reported in 20 and 55 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These reports focused on the action myoclonus of the parkinsonian type. Stimulus-sensitive myoclonus of the upper extremities and photic-induced myoclonus have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=see_link\">",
"     \"Multiple system atrophy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Frontotemporal dementia and parkinsonism linked to chromosome 17",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frontotemporal dementia is a heterogeneous entity that is characterized by focal atrophy of the frontal and temporal lobes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The syndromes of frontotemporal dementia and parkinsonism are associated with tau gene mutations linked to chromosome 17 (FTDP-17). Patients manifest cognitive, psychiatric, and parkinsonian symptoms. Although not initially thought to be a prominent feature, myoclonus was subsequently described in patients with N279K, P301S, and V337M tau mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FTDP-17 syndromes commonly have cortical and subcortical pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/21\">",
"     21",
"    </a>",
"    ]. The precise mechanism of myoclonus in FTDP-17 syndromes is unclear, but pathology in the frontoparietal area may be more predisposed to myoclonus than pathology in the frontotemporal area [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Huntington disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is unusual in Huntington disease, but can be clinically impressive when present. The myoclonus is usually restricted to individuals with a young age of onset and higher number of over expressed CAG trinucleotide repeats of the mutated HD gene on chromosome 4. Seizures may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=see_link\">",
"     \"Huntington disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapidly progressive young-onset cases of Huntington disease are presumed to have more pronounced cortical pathology than older patients with lower CAG repeat mutation values, thus enabling the cortical myoclonus to occur.",
"   </p>",
"   <p>",
"    The physiology is cortical action",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortical reflex myoclonus, although the cortical somatosensory evoked potential waves are rarely enlarged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dentatorubral pallidoluysian atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentatorubral pallidoluysian atrophy (DRPLA) is an autosomal dominant neurodegenerative disorder that is relatively common in Japan, but rare in other countries. It is associated with a CAG repeat expansion in a gene on chromosome 12. DRPLA has protean neurologic manifestations that include ataxia, chorea, dystonia, parkinsonism, epilepsy, psychosis, and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link&amp;anchor=H16#H16\">",
"     \"The spinocerebellar ataxias\", section on 'Dentatorubral pallidoluysian atrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myoclonus is an uncommon feature of DRPLA. When present, it is usually associated with a progressive myoclonic epilepsy or progressive myoclonic ataxia syndrome. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The physiology of the myoclonus with DRPLA is presumed to be cortical, but has received little study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFECTIOUS, POSTINFECTIOUS, AND AUTOIMMUNE INFLAMMATORY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus may be associated with numerous diffuse infectious, postinfectious, and autoimmune inflammatory disorders, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arbovirus encephalitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link\">",
"       \"Viral encephalitis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryptococcus",
"     </li>",
"     <li>",
"      Encephalitis lethargica",
"     </li>",
"     <li>",
"      Hashimoto's encephalopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=see_link\">",
"       \"Hashimoto's encephalopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herpes simplex encephalitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"       \"Herpes simplex virus type 1 encephalitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"       \"Approach to HIV-infected patients with central nervous system lesions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Human T-lymphotropic virus I (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=see_link\">",
"       \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lyme disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"       \"Clinical manifestations of Lyme disease in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malaria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"       \"Clinical manifestations of malaria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Miscellaneous bacteria (Streptococcus, Clostridium, other)",
"     </li>",
"     <li>",
"      Paraneoplastic syndromes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"       \"Overview of paraneoplastic syndromes of the nervous system\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Postinfectious encephalitis",
"     </li>",
"     <li>",
"      Progressive multifocal leukoencephalopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"       \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subacute sclerosing panencephalitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Syphilis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"       \"Neurosyphilis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, myoclonus is an early clue for diagnosis of these disorders. The acute or subacute onset of myoclonus in a previously healthy person should trigger the screening for these conditions, including specific infectious agents.",
"   </p>",
"   <p>",
"    The physiology of myoclonus in this group of disorders is heterogeneous and depends on localization of the pathology in the central nervous system. In infectious encephalitis, the myoclonus is commonly accompanied by seizures and altered mental status.",
"   </p>",
"   <p>",
"    Other notable causes of myoclonus under this category include opsoclonus-myoclonus syndrome and malabsorption disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Opsoclonus-myoclonus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opsoclonus is a disorder of ocular motility characterized by involuntary, repetitive, rapid and arrhythmic conjugate eye movements (ocular saccades) occurring in all directions of gaze without a saccadic interval.",
"   </p>",
"   <p>",
"    Opsoclonus-myoclonus syndrome (OMS), also known as \"saccadomania\", is a rare disorder, more common in children than adults. The pathogenesis is thought to be immune mediated, but the precise mechanism remains unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OMS can be a remote effect (paraneoplastic) of an underlying malignancy, usually a neuroblastoma in children, and lung or breast cancer in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"       \"Opsoclonus myoclonus ataxia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OMS can also occur in the context of infection, or without identifiable cause (idiopathic). Celiac disease has been rarely associated with OMS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Malabsorption disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The myoclonus in OMS is usually multifocal and action-related [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/25\">",
"     25",
"    </a>",
"    ]. There is often a prodrome of systemic complaints, including nausea, vomiting, vertigo, oscillopsia (jerks in vision), or gait difficulty. The onset of myoclonus can be abrupt or gradual. Onset over days to a few weeks is common, with ataxia, opsoclonus, myoclonus, and other movement disorders occurring together. Less often, the onset is gradual over weeks to months, and mild ataxia occurs before the onset of opsoclonus and myoclonus.",
"   </p>",
"   <p>",
"    The physiology of the myoclonus in both idiopathic and paraneoplastic OMS is subcortical-nonsegmental [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/26\">",
"     26",
"    </a>",
"    ]. In some patients, isolated myoclonus occurs as a remote effect of cancer without opsoclonus, and such cases have a different myoclonus physiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Malabsorption disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both celiac disease and Whipple's disease may cause myoclonus in the setting of malabsorption, but the myoclonus is generated from the disease process rather than the malabsorption per se.",
"   </p>",
"   <p>",
"    The myoclonus of celiac disease most commonly presents as a progressive myoclonus ataxia (PMA) with cortical action and cortical reflex physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/27\">",
"     27",
"    </a>",
"    ]. Celiac disease has been associated more rarely with the opsoclonus-myoclonus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Opsoclonus-myoclonus syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Whipple's disease can cause various types and distributions of myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The classic oculomasticatory myorhythmia resembles segmental myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     METABOLIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A long list of metabolic disorders is linked to myoclonus, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperthyroidism",
"     </li>",
"     <li>",
"      Hepatic failure",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Dialysis syndrome",
"     </li>",
"     <li>",
"      Hyponatremia",
"     </li>",
"     <li>",
"      Hypocalcemia",
"     </li>",
"     <li>",
"      Hypomagnesemia",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Nonketotic hyperglycemia",
"     </li>",
"     <li>",
"      Multiple carboxylase deficiency",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       Biotin",
"      </a>",
"      deficiency",
"     </li>",
"     <li>",
"      Hypoxia",
"     </li>",
"     <li>",
"      Metabolic alkalosis",
"     </li>",
"     <li>",
"      Vitamin E deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The onset of myoclonus secondary to acquired metabolic disorders, including organ and gland failure, is typically acute or subacute. The temporal relationship of the underlying metabolic disorder to the myoclonus may be offset by days, weeks, or longer. The distribution of myoclonus in these conditions is most often multifocal.",
"   </p>",
"   <p>",
"    In liver and kidney failure, tremors and altered mental status are common accompaniments to the myoclonus. Asterixis (negative myoclonus) is particularly common in patients with renal or hepatic failure. In addition, liver and kidney failure may produce myoclonus by inhibiting the metabolism or clearance of drugs or other chemical agents that cause myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DRUG-INDUCED AND TOXIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of medications and other agents that cross the blood-brain barrier may cause myoclonus, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Levodopa",
"     </li>",
"     <li>",
"      Psychiatric medications (eg, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antibiotics (eg, penicillins, cephalosporins, quinolones)",
"     </li>",
"     <li>",
"      Narcotics (particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Anesthetics",
"     </li>",
"     <li>",
"      Contrast media",
"     </li>",
"     <li>",
"      Cardiac medications (eg, calcium channel blockers, antiarrhythmic agents)",
"     </li>",
"     <li>",
"      Drug withdrawal from certain agents (eg, sedatives)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Toxins associated with myoclonus include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bismuth",
"     </li>",
"     <li>",
"      Heavy metals",
"     </li>",
"     <li>",
"      Methyl bromide",
"     </li>",
"     <li>",
"      Dichlorodiphenyltrichloroethane (DDT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As more drugs and toxins are introduced, the number of such agents has steadily increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms responsible for myoclonus induced by drugs or toxins are not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, it is not clear why myoclonus occurs in some exposed individuals but not others.",
"   </p>",
"   <p>",
"    The time profile of exposure to the drug or toxin may be acute, subacute, or chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Likewise, improvement in myoclonus after withdrawal may occur over an extended period. Polypharmacy can cause or worsen the drug-induced myoclonus of a single agent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Some agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , can cause a dose-dependent spectrum of motor cortex hyperexcitability disorders, ranging from isolated cortical action myoclonus to generalized tonic-clonic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myoclonus induced by drugs or toxins is potentially treatable, since the myoclonus typically resolves upon withdrawal of the offending agent(s). It is important to scrutinize all drugs, either in isolation or combination, when evaluating for a potential causative role in myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ENCEPHALOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus can be a feature of a number of conditions associated with diffuse or multifocal cerebral dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxia (acute and posthypoxic myoclonus)",
"     </li>",
"     <li>",
"      Head trauma",
"     </li>",
"     <li>",
"      Heat stroke",
"     </li>",
"     <li>",
"      Electric shock",
"     </li>",
"     <li>",
"      Decompression illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypoxia is the most common diffuse cerebral insult that causes myoclonus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Posthypoxic myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, posthypoxic myoclonus (also known as postanoxic myoclonus or Lance-Adams action myoclonus) occurs after severe acute hypoxic coma that lasts for several hours to days. Spontaneous myoclonus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures may or may not be present during the coma. With recovery from the severe hypoxic episode, posthypoxic myoclonus is present or subsequently develops quickly.",
"   </p>",
"   <p>",
"    Posthypoxic myoclonus can produce marked disability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/40\">",
"     40",
"    </a>",
"    ]. Action and reflex myoclonus, subsiding at rest, are characteristic features. In addition, ataxia and mental status changes are frequent parts of the syndrome, and cerebrospinal fluid serotonin metabolites are often decreased. This finding has led to the hypothesis that depression of serotonin system activity is important in this and other myoclonic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/41\">",
"     41",
"    </a>",
"    ]. The physiology of posthypoxic myoclonus is usually both cortical action and cortical reflex myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOCAL NERVOUS SYSTEM DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of pathology can cause a focal lesion of the central or peripheral nervous system that results in myoclonus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Post-stroke",
"     </li>",
"     <li>",
"      Post-thalamotomy",
"     </li>",
"     <li>",
"      Olivodentate lesions (palatal myoclonus)",
"     </li>",
"     <li>",
"      Spinal cord lesions",
"      <span class=\"nowrap\">",
"       (segmental/spinal",
"      </span>",
"      myoclonus)",
"     </li>",
"     <li>",
"      Tumor",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Inflammation (eg, multiple sclerosis)",
"     </li>",
"     <li>",
"      Moebius syndrome",
"     </li>",
"     <li>",
"      Developmental",
"     </li>",
"     <li>",
"      Idiopathic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral nervous system, including root and plexus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Hematoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Focal, multifocal, or generalized jerks may arise from damage to the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/42\">",
"     42",
"    </a>",
"    ]. Brainstem damage can produce generalized jerks in the form of exaggerated startle syndromes (eg, hyperekplexia) or reticular reflex myoclonus that are spontaneous and stimulus sensitive (reflex myoclonus) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/43\">",
"     43",
"    </a>",
"    ]. Rhythmic myoclonus in a brainstem or spinal segmental distribution raises the concern for a focal lesion at or near that segment of the",
"    <span class=\"nowrap\">",
"     brainstem/spinal",
"    </span>",
"    cord [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Propriospinal myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions in the spinal cord may cause propriospinal myoclonus, which is characterized by rostral and caudal spread of the hyperactivity from the damaged area [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/45\">",
"     45",
"    </a>",
"    ]. Propriospinal myoclonus takes the form of flexion or extension jerks of the trunk that can be spontaneous or stimulus sensitive (reflex myoclonus).",
"   </p>",
"   <p>",
"    In a report on propriospinal myoclonus confirmed by clinical neurophysiology in 10 adults (eight men, two women) ranging in age from 17 to 70 years, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All 10 patients had involuntary spontaneous repetitive jerks involving the abdominal wall muscles and legs. Lying down exacerbated the movements in eight patients, stimulus sensitivity occurred in four, and premonitory sensations (paresthesia, muscle tickling or tightening, cold sensation) were reported by six.",
"     </li>",
"     <li>",
"      The myoclonic generator was located at the thoracic level in eight patients.",
"     </li>",
"     <li>",
"      Magnetic resonance diffusion tensor imaging with fiber tracking revealed spinal tract disorganization in all 10 patients, and quantitative fiber thinning in nine. The abnormalities correlated with the level of the myoclonic generator in seven.",
"     </li>",
"     <li>",
"      A definite cause was identified for two patients, one with lymphocytic meningitis and another with a thoracic disc herniation. A possible cause was present for three others, including back trauma in two, and myelopathy associated with antithyroid antibodies in another.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Palatal myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palatal myoclonus is also known as palatal tremor because the movements are typically slow and rhythmic and thus resemble tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/47\">",
"     47",
"    </a>",
"    ]. A rare disorder, it is usually symptomatic (secondary) to a brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebellar lesion, such as a pontine infarct, within the triangle of Guillain and Mollaret [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/48\">",
"     48",
"    </a>",
"    ]. This triangle describes the neuronal circuit comprised of the following pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dentate nucleus in the cerebellum to the contralateral red nucleus in the midbrain via the superior cerebellar peduncle",
"     </li>",
"     <li>",
"      Red nucleus to the medullary inferior olivary nucleus via the central tegmental tract",
"     </li>",
"     <li>",
"      Inferior olivary nucleus to the contralateral dentate nucleus via the inferior cerebellar peduncle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic palatal myoclonus is usually characterized by contractions of the levator veli palatini, and middle ear myoclonus is characterized by contractions of the tensor tympani",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stapedius muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. However, some patients have no apparent structural lesion and are considered to have essential palatal myoclonus. In such cases, the myoclonus is characterized by contractions of the tensor veli palatini. These conditions may cause tinnitus or ear clicking [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With palatal myoclonus (mainly the symptomatic type), the myoclonic jerks can also involve the larynx, tongue, and face.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemifacial spasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nervous system lesions can cause myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/56\">",
"     56",
"    </a>",
"    ]. The best known example is hemifacial spasm, which is characterized by involuntary, irregular, tonic, and clonic movements of facial muscles innervated by the seventh cranial nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H22#H22\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Hemifacial spasm, blepharospasm, and Meige syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most often idiopathic, hemifacial spasm can be caused by extra-axial brainstem pathology, including tumors, and vascular compression of the facial nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DISORDERS AFFECTING MULTIPLE SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus can be a feature of several heterogeneous conditions that affect multiple organ systems, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Action myoclonus-renal failure syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mitochondrial disorders",
"     </li>",
"     <li>",
"      Triple A syndrome (achalasia, alacrima, and adrenal insufficiency) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DiGeorge syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Membranous lipodystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The action myoclonus-renal failure syndrome is a form of progressive myoclonic epilepsy associated with renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/57\">",
"     57",
"    </a>",
"    ]. It is inherited in an autosomal recessive manner. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Certain mitochondrial disorders can present with a progressive myoclonic epilepsy (eg, myoclonus epilepsy with ragged red fibers [MERRF]) or with progressive myoclonic ataxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SYNDROMES OVERLAPPING WITH MYOCLONUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syndromes that overlap with myoclonus include exaggerated startle syndromes and psychogenic jerks. Jerks associated with sleep or sleep transitions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification and evaluation of myoclonus\", section on 'Physiologic myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Exaggerated startle syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic and hereditary forms of hyperekplexia (exaggerated startle reflex) can produce generalized myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition to a nonfatigable startle reflex, the clinical syndrome may include hypertonia in infancy, hyperreflexia, falling attacks with retained consciousness, and tonic spasms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H38#H38\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Hyperekplexia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autosomal dominant inheritance exists in the hereditary form, and multiple genetic mutations have been found in the inhibitory neurotransmitter glycine receptor. A brainstem reticular formation source for the myoclonus is established and demonstrates subcortical-nonsegmental physiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Psychogenic jerks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jerks that occur in patients with a conversion disorder or malingering may appear quick enough to be confused with myoclonus. The characteristics of psychogenic jerks include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30249/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inconsistent character of the movements (amplitude, frequency, and distribution) and other features incongruous with typical \"organic\" myoclonus",
"     </li>",
"     <li>",
"      Associated psychogenic symptomatology",
"     </li>",
"     <li>",
"      Marked reduction of the myoclonus with distraction",
"     </li>",
"     <li>",
"      Exacerbation and relief with suggestion and placebo",
"     </li>",
"     <li>",
"      Spontaneous periods of remission",
"     </li>",
"     <li>",
"      Acute onset and sudden resolution",
"     </li>",
"     <li>",
"      Evidence of underlying psychopathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=see_link\">",
"       \"Patient information: Myoclonus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93830261\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myoclonus that occurs secondary to a neurologic or systemic disorder has been traditionally termed symptomatic myoclonus. Symptomatic myoclonus is the most common type of myoclonus and can occur in association with conditions that span the entire spectrum of neurologic disease (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 1",
"      </a>",
"      ). Posthypoxic state, neurodegenerative disease, and epilepsy syndromes are the most common causes. Toxic-metabolic and drug-induced etiologies are particularly common in the hospital setting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic myoclonus is associated with the following broad categories of disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Progressive myoclonic epilepsy and progressive myoclonic ataxia (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Storage diseases (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Storage diseases'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Neurodegenerative diseases (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Neurodegenerative diseases'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infectious, postinfectious, and autoimmune inflammatory disorders (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Infectious, postinfectious, and autoimmune inflammatory disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Metabolic disorders (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Metabolic disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Drug-induced and toxic syndromes (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Drug-induced and toxic syndromes'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Encephalopathies (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Encephalopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Focal nervous system damage (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Focal nervous system damage'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Disorders affecting multiple systems (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Disorders affecting multiple systems'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syndromes that overlap with myoclonus include exaggerated startle syndromes and psychogenic jerks. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Syndromes overlapping with myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Movement Disorders, Marsden CD, Fahn S (Eds), Butterworths, London 1982. p.196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/2\">",
"      Caviness JN. Myoclonus. Mayo Clin Proc 1996; 71:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/3\">",
"      Caviness JN, Alving LI, Maraganore DM, et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999; 74:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/4\">",
"      Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/5\">",
"      Marsden CD, Harding AE, Obeso JA, Lu CS. Progressive myoclonic ataxia (the Ramsay Hunt syndrome). Arch Neurol 1990; 47:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/6\">",
"      Borg M. Symptomatic myoclonus. Neurophysiol Clin 2006; 36:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/7\">",
"      Caviness JN. Myoclonus and neurodegenerative disease--what's in a name? Parkinsonism Relat Disord 2003; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/8\">",
"      Caviness JN, Adler CH, Beach TG, et al. Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations. Mov Disord 2002; 17:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/9\">",
"      Caviness JN, Adler CH, Caselli RJ, Hernandez JL. Electrophysiology of the myoclonus in dementia with Lewy bodies. Neurology 2003; 60:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/10\">",
"      Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysiological observations in hereditary parkinsonism-dementia with Lewy body pathology. Mov Disord 2000; 15:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/11\">",
"      Caviness JN, Adler CH, Beach TG, et al. Myoclonus in Lewy body disorders. Adv Neurol 2002; 89:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/12\">",
"      Brunt ER, van Weerden TW, Pruim J, Lakke JW. Unique myoclonic pattern in corticobasal degeneration. Mov Disord 1995; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/13\">",
"      Thompson PD, Shibasaki H. Myoclonus in corticobasal degeneration and other neurodegenerations. Adv Neurol 2000; 82:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/14\">",
"      Thompson PD, Day BL, Rothwell JC, et al. The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. Brain 1994; 117 ( Pt 5):1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/15\">",
"      Kurihara T, Landau WM, Torack RM. Progressive supranuclear palsy with action myoclonus, seizures. Neurology 1974; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/16\">",
"      Wenning GK, Ben Shlomo Y, Magalh&atilde;es M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 ( Pt 4):835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/17\">",
"      Gouider-Khouja N, Vidailhet M, Bonnet AM, et al. \"Pure\" striatonigral degeneration and Parkinson's disease: a comparative clinical study. Mov Disord 1995; 10:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/18\">",
"      Rodriguez ME, Artieda J, Zubieta JL, Obeso JA. Reflex myoclonus in olivopontocerebellar atrophy. J Neurol Neurosurg Psychiatry 1994; 57:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/19\">",
"      Artieda J, Obeso JA. The pathophysiology and pharmacology of photic cortical reflex myoclonus. Ann Neurol 1993; 34:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/20\">",
"      Caviness JN, Wszolek ZK. Myoclonus in pallido-ponto-nigral degeneration. Adv Neurol 2002; 89:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/21\">",
"      Bugiani O, Murrell JR, Giaccone G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999; 58:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/22\">",
"      Caviness JN, Kurth M. Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 1997; 12:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/23\">",
"      Warner TT, Williams LD, Walker RW, et al. A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol 1995; 37:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/24\">",
"      Deconinck N, Scaillon M, Segers V, et al. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol 2006; 34:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/25\">",
"      Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord 1995; 10:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/26\">",
"      Gwinn KA, Caviness JN. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord 1997; 12:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/27\">",
"      Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995; 118 ( Pt 5):1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/28\">",
"      Stoupel N, Monseu G, Pardoe A, et al. Encephalitis with myoclonus in Whipple's disease. J Neurol Neurosurg Psychiatry 1969; 32:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/29\">",
"      Henning S, Tings T, Schmidt H, et al. A case of cerebral Whipple's disease initially presenting with isolated focal myoclonus. Eur J Neurol 2006; 13:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/30\">",
"      Schwartz MA, Selhorst JB, Ochs AL, et al. Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple's disease. Ann Neurol 1986; 20:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/31\">",
"      Wierre L, Decaudin B, Barsumau J, et al. Dobutamine-induced myoclonia in severe renal failure. Nephrol Dial Transplant 2004; 19:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/32\">",
"      Zhang C, Glenn DG, Bell WL, O'Donovan CA. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia 2005; 46:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/33\">",
"      Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol 2002; 89:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/34\">",
"      Jim&eacute;nez-Jim&eacute;nez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 2004; 18:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/35\">",
"      Mirsattari SM, Hammond RR, Sharpe MD, et al. Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology 2004; 62:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/36\">",
"      Teepker M, Hamer HM, Knake S, et al. Myoclonic encephalopathy caused by chronic bismuth abuse. Epileptic Disord 2002; 4:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/37\">",
"      Reif A, Leonhard C, M&ouml;ssner R, et al. Encephalopathy and myoclonus triggered by valproic acid. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/38\">",
"      Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology 1999; 52:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/39\">",
"      Caviness JN, Evidente VG. Cortical myoclonus during lithium exposure. Arch Neurol 2003; 60:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/40\">",
"      Frucht SJ. The clinical challenge of posthypoxic myoclonus. Adv Neurol 2002; 89:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/41\">",
"      Chadwick D, Hallett M, Jenner P, Marsden CD. Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. Adv Neurol 1986; 43:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/42\">",
"      Kuzniecky R, Berkovic S, Andermann F, et al. Focal cortical myoclonus and rolandic cortical dysplasia: clarification by magnetic resonance imaging. Ann Neurol 1988; 23:317.",
"     </a>",
"    </li>",
"    <li>",
"     Brown P. Hyperekplexia. In: Handbook of Clinical Neurophysiology, Elsevier, Amsterdam 2003. p.479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/44\">",
"      Gregoire SM, Laloux P, Hanson P, et al. Segmental spinal myoclonus and syringomyelia: A case report. Acta Neurol Belg 2006; 106:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/45\">",
"      Brown P, Thompson PD, Rothwell JC, et al. Axial myoclonus of propriospinal origin. Brain 1991; 114 ( Pt 1A):197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/46\">",
"      Roze E, Bounolleau P, Ducreux D, et al. Propriospinal myoclonus revisited: Clinical, neurophysiologic, and neuroradiologic findings. Neurology 2009; 72:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/47\">",
"      Deuschl G, Mischke G, Schenck E, et al. Symptomatic and essential rhythmic palatal myoclonus. Brain 1990; 113 ( Pt 6):1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/48\">",
"      Deuschl G, Toro C, Valls-Sol&eacute; J, et al. Symptomatic and essential palatal tremor. 1. Clinical, physiological and MRI analysis. Brain 1994; 117 ( Pt 4):775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/49\">",
"      Wakata N, Sugimoto H, Iguchi H, et al. A case of voluntary palatal myoclonus with ear click: relationship between palatal myoclonus and click. Eur Neurol 2002; 48:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/50\">",
"      Fabiani G, Teive HA, S&aacute; D, et al. Palatal myoclonus: report of two cases. Arq Neuropsiquiatr 2000; 58:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/51\">",
"      Kutukcu Y, Imirzalioglu N, Odabasi Z, et al. Essential palatal myoclonus in monozygotic male twins. J Neurol 2003; 250:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/52\">",
"      Bento RF, Sanchez TG, Miniti A, Tedesco-Marchesi AJ. Continuous, high-frequency objective tinnitus caused by middle ear myoclonus. Ear Nose Throat J 1998; 77:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/53\">",
"      Golz A, Fradis M, Netzer A, et al. Bilateral tinnitus due to middle-ear myoclonus. Int Tinnitus J 2003; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/54\">",
"      Golz A, Fradis M, Martzu D, et al. Stapedius muscle myoclonus. Ann Otol Rhinol Laryngol 2003; 112:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/55\">",
"      Oliveira CA, Negreiros J&uacute;nior J, Cavalcante IC, et al. Palatal and middle-ear myoclonus: a cause for objective tinnitus. Int Tinnitus J 2003; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/56\">",
"      Camerota F, Celletti C, Paoloni M, et al. Myoclonus of the scapula after acute long thoracic nerve lesion: a case report. Mov Disord 2006; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/57\">",
"      Brown P. Action myoclonus-renal failure syndrome: the definitive clinico-pathological description. Brain 2004; 127:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/58\">",
"      Roubergue A, Apartis E, Vidailhet M, et al. Myoclonus and generalized digestive dysmotility in triple A syndrome with AAAS gene mutation. Mov Disord 2004; 19:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/59\">",
"      Sachdev P. Schizophrenia-like illness in velo-cardio-facial syndrome: a genetic subsyndrome of schizophrenia? J Psychosom Res 2002; 53:721.",
"     </a>",
"    </li>",
"    <li>",
"     Jarvi O, Hakola P, Sourander P, et al. Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLO-SL). In: Population Structure and Genetic Disorders, Eriksson A, Forsius H, Nevanlinna H, Workman P, Norio R (Eds), Academic Press, New York 1980. p.656.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30249/abstract/61\">",
"      Monday K, Jankovic J. Psychogenic myoclonus. Neurology 1993; 43:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4884 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30249=[""].join("\n");
var outline_f29_34_30249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H93830261\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGRESSIVE MYOCLONIC EPILEPSY AND PROGRESSIVE MYOCLONIC ATAXIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STORAGE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEURODEGENERATIVE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parkinson disease and dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Corticobasal degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Progressive supranuclear palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Multiple system atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Frontotemporal dementia and parkinsonism linked to chromosome 17",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Huntington disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dentatorubral pallidoluysian atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFECTIOUS, POSTINFECTIOUS, AND AUTOIMMUNE INFLAMMATORY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Opsoclonus-myoclonus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Malabsorption disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      METABOLIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DRUG-INDUCED AND TOXIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ENCEPHALOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Posthypoxic myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOCAL NERVOUS SYSTEM DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Propriospinal myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Palatal myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemifacial spasm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DISORDERS AFFECTING MULTIPLE SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SYNDROMES OVERLAPPING WITH MYOCLONUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Exaggerated startle syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Psychogenic jerks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93830261\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21455\" title=\"table 1\">",
"      Clinical etiologic classification myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=related_link\">",
"      Corticobasal degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=related_link\">",
"      Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=related_link\">",
"      Multiple system atrophy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=related_link\">",
"      Patient information: Myoclonus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=related_link\">",
"      Progressive supranuclear palsy (PSP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30250="Endovenous laser ablation for the treatment of lower extremity chronic venous disease";
var content_f29_34_30250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endovenous laser ablation for the treatment of lower extremity chronic venous disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Daniel M Ihnat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30250/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/34/30250/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/34/30250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H715136631\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovenous laser ablation (EVLA) is a percutaneous technique that uses laser energy to ablate incompetent superficial veins. The axial veins are the primary target for this therapy and include the great saphenous vein, small saphenous vein, and accessory saphenous veins. This topic will review the indications, perioperative care and outcomes of EVLA.",
"   </p>",
"   <p>",
"    Alternative approaches to the treatment of chronic venous disease using laser and light therapy, radiofrequency energy, liquid and foam sclerotherapy, and open surgical management are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"       \"Overview and management of lower extremity chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"       \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"       \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"       \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link\">",
"       \"Open surgical techniques for lower extremity vein ablation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136638\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for EVLA are the same as for other vein ablation therapies including radiofrequency ablation, sclerotherapy and open surgical stripping. Venous ablation is indicated in patients with symptoms and signs of venous disease that persist in spite of three months of medical management, and documented reflux in the target vein (ie, retrograde flow &gt;0.5 seconds). The patient&rsquo;s symptoms should directly relate to the incompetent veins being treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview and management of lower extremity chronic venous disease\", section on 'Management Approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136645\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVLA is contraindicated in patients with acute deep vein thrombosis and in pregnant patients, due to the risk of developing a new DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/1\">",
"     1",
"    </a>",
"    ]. We prefer to wait a minimum of six weeks after delivery in pregnant patients before performing EVLA.",
"   </p>",
"   <p>",
"    Patients with congenital venous abnormalities (eg, Klippel Trenaunay syndrome, Parkes Weber syndrome) should generally not undergo ablation of major superficial veins. Selected patients may, however, benefit from localized management of symptomatic segments (sclerotherapy, stab phlebectomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link&amp;anchor=H18#H18\">",
"     \"Open surgical techniques for lower extremity vein ablation\", section on 'Ambulatory phlebectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relative contraindications to EVLA for a given vein segment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic or recurrent phlebitis in the target vein, since formation of synechiae in the vein can prevent passage of the laser sheath.",
"     </li>",
"     <li>",
"      Severe tortuosity in which passage of the device may not be possible.",
"     </li>",
"     <li>",
"      Target veins that are not at least 1 cm deep to the skin dermis after tumescent anesthesia is administered. Ablation of veins closer to the skin may lead to skin burns.",
"     </li>",
"     <li>",
"      Target great saphenous vein segments that are aneurysmal (&gt;2.5 cm in diameter). These may have a greater risk of failure. (See",
"      <a class=\"local\" href=\"#H715136996\">",
"       'Anatomic failure'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with lower extremity ulceration should be assessed to ensure the adequacy of the arterial circulation, since patients with chronic venous disease complicated with ulceration can have coexistent peripheral artery disease. If the arterial circulation is found to be inadequate for wound healing, the arterial disease should be addressed prior to treating the venous disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136652\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136660\">",
"    <span class=\"h2\">",
"     Venous anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The veins of the lower extremity are divided into superficial, perforating, and deep veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ). The superficial veins lie superficial to the muscle fascia. The perforating veins cross the fascia and connect the superficial veins to the deep veins that are located beneath the fascia. The deep veins are",
"    <strong>",
"     never",
"    </strong>",
"    treated with endovenous therapies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Great saphenous vein &ndash; The great saphenous vein (GSV) is one of the two main superficial veins in the lower extremity (",
"      <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"       figure 1A-B",
"      </a>",
"      ). It is the longest vein in the body and originates on the medial aspect of the dorsal foot. It crosses anterior to the medial malleolus and ascends along the medial aspect of the leg and thigh. Just below the inguinal ligament, it enters the fossa ovalis and terminates in the common femoral vein at the saphenofemoral junction.",
"     </li>",
"     <li>",
"      Small saphenous vein &ndash; The small saphenous vein (SSV) originates laterally from the dorsal venous arch of the foot, crosses posterior to the lateral malleolus, and ascends in the posterior calf (",
"      <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"       figure 1A-B",
"      </a>",
"      ). In the upper calf, the SSV passes through the deep muscle fascia and terminates in the popliteal vein; however, the anatomy at the sapheno-popliteal junction is variable (",
"      <a class=\"graphic graphic_figure graphicRef82053 \" href=\"UTD.htm?0/19/310\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. The small saphenous vein can join a superficial cephalad extension in the posterior thigh (vein of Giacomini), connect to both the popliteal vein and the posterior thigh vein, or join the popliteal vein with no major tributaries near the junction (",
"      <a class=\"graphic graphic_figure graphicRef82053 \" href=\"UTD.htm?0/19/310\">",
"       figure 2",
"      </a>",
"      ). Anatomic variations in the SSV have implications for SSV ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H715136884\">",
"       'Small saphenous ablation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Accessory saphenous veins",
"      <strong>",
"      </strong>",
"      &ndash; The accessory saphenous veins (AASVs) are any of several venous segments that ascend parallel to the GSV. Anterior accessory saphenous veins are located anteriorly, and can be found in the thigh or leg (",
"      <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"       figure 1A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perforator veins &ndash; The normal flow in the perforating veins is from superficial to deep; however, many perforators demonstrate bidirectional flow. When the perforating veins are incompetent, flow is from deep to superficial. The most clinically significant perforating veins connect the posterior arch vein to the posterior tibial vein. These veins, termed posterior tibial perforators, were formerly known as Cockett&rsquo;s perforators.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136668\">",
"    <span class=\"h2\">",
"     Saphenous nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The saphenous nerve is the largest cutaneous branch of the femoral nerve. It lies near the superficial femoral artery in the thigh, exiting the adductor canal traveling deep to the sartorius muscle (",
"    <a class=\"graphic graphic_figure graphicRef66562 graphicRef52007 \" href=\"UTD.htm?10/17/10520\">",
"     figure 3A-B",
"    </a>",
"    ). It typically becomes superficial after it emerges medially between the tendons of the sartorius and gracilis muscles at the knee and then travels adjacent to the GSV. The saphenous nerve provides sensory innervation to the medial aspect of the leg. The saphenous nerve is adherent to the saphenous vein in the distal third of the calf [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136676\">",
"    <span class=\"h2\">",
"     Sural nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sural nerve is formed by the medial and lateral sural cutaneous nerves, which join at approximately the level of the distal one-third of the gastrocnemius muscles (",
"    <a class=\"graphic graphic_figure graphicRef62917 \" href=\"UTD.htm?0/17/272\">",
"     figure 4",
"    </a>",
"    ). It lies near the SSV and passes below the lateral malleolus. The sural nerve provides cutaneous innervation to the posterior leg and lateral foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136684\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION AND LASER DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers emit a single, coherent wavelength of light (",
"    <a class=\"graphic graphic_figure graphicRef69001 \" href=\"UTD.htm?5/29/5585\">",
"     figure 5",
"    </a>",
"    ). Laser therapy of venous structures is based upon the concept of selective photothermolysis (ie, selective thermal confinement of light-induced damage) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/8\">",
"     8",
"    </a>",
"    ]. The wavelength of light is chosen based upon the chromophore (the part of a molecule responsible for its color) of the target tissue. Vein wall injury is mediated directly by absorption of photon energy by the vein wall (thermal radiation) and indirectly by thermal convection from steam bubbles, and thermal conduction from heated blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commercially available devices for EVLA are manufactured by Angiodynamics (810 nm and 980 nm diode lasers), Dornier MedTech (940 nm diode laser), Sciton (1319 nm Nd:YAG laser), CoolTouch (1320 nm Nd:YAG laser), and Biolitec (1470 nm diode laser). The wavelength of laser may impact outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136692\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation is performed by taking a careful history, performing a physical exam, and obtaining noninvasive vascular laboratory studies. A venous duplex ultrasound of the affected lower extremity should evaluate the deep veins, GSV, accessory saphenous veins (if present) and SSV for patency as well as the presence of reflux. The clinical evaluation of lower extremity chronic venous insufficiency is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136700\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , antiplatelet agents, and nonsteroidal antiinflammatory drugs (NSAIDs) are sometimes discontinued to limit postoperative bruising. (See",
"    <a class=\"local\" href=\"#H715136948\">",
"     'Bruising/hematoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients who are therapeutically anticoagulated, cessation of anticoagulation is",
"    <strong>",
"     not",
"    </strong>",
"    necessary prior to EVLA. Perioperative anticoagulation with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    does not appear to affect the success of endovenous closure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cessation is selected,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may be temporarily discontinued or bridging anticoagulation initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Perioperative interruption and resumption of anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136708\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is generally not needed prior to EVLA. However, when EVLA is combined with vein excision, antibiotics are administered to decrease the risk of surgical site infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136716\">",
"    <span class=\"h2\">",
"     DVT prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVLA is a brief, outpatient procedure with an overall low risk of DVT. DVT prophylaxis is needed only for high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'High risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136724\">",
"    <span class=\"h2\">",
"     Planning supplemental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options to manage significant symptomatic varicose veins include micro-phlebectomy or sclerotherapy at the same time as EVLA, or deferred treatment. The main advantage of performing EVLA with concomitant treatment is a reduction in the overall treatment time. The advantage of waiting four to six weeks following EVLA is that the residual veins tend to be smaller and may be more amenable to injection sclerotherapy instead of phlebectomy, and in many cases, no further treatment is needed. This effect is due to reduced venous pressure in the tributaries of the EVLA-ablated saphenous vein. Large varicose veins and those located on the thigh are less likely to respond to elimination of reflux, and we prefer to manage these concurrently with the ablation procedure.",
"   </p>",
"   <p>",
"    One trial randomly assigned 50 patients to EVLA with concomitant phlebectomy or EVLA with sequential phlebectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/18\">",
"     18",
"    </a>",
"    ]. The concomitant treatment group required longer operative times, fewer subsequent procedures (1 of 25 verus 16 of 25), and a trend towards longer time to return to work (10 versus 3 days). The concomitant treatment group also had a lower HRQOL at six weeks and three months; however, no differences in HRQOL were seen at one year. It is important to note that in the sequential treatment group, a supplemental procedure was not needed in one-third of the patients.",
"   </p>",
"   <p>",
"    Similarly, a retrospective study of 80 patients treated with EVLA alone found that supplemental treatment was needed in only 42 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136732\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for the procedure, alternatives (eg, continued medical management, vein stripping), risks and benefits (relief of symptoms attributable to the venous insufficiency) should be discussed with the patient. The patient is informed that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unforeseen anatomic issues may result in failure (ie, the inability to perform an endovenous procedure) in which case the patient may need to be rescheduled for a repeat or alternative procedure. (See",
"      <a class=\"local\" href=\"#H715136996\">",
"       'Anatomic failure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In spite of successful technical application of the endovenous device, non-closure of the vein or late vein recanalization can occur and may be more common in larger diameter veins. In these cases, EVLA may be repeated or an alternative procedure performed. (See",
"      <a class=\"local\" href=\"#H715136996\">",
"       'Anatomic failure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Associated varicosities that have not been treated at the time of the EVLA should become less noticeable, but may not completely disappear. Supplemental procedures may be needed to achieve the desired cosmetic result [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Whether simultaneous versus delayed sclerotherapy or phlebectomy is being performed should be understood prior to the procedure. (See",
"      <a class=\"local\" href=\"#H715136724\">",
"       'Planning supplemental procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risks of the procedure can include bleeding, infection, phlebitis, deep vein thrombosis, and cutaneous nerve injury leading to numbness or paresthesias. (See",
"      <a class=\"local\" href=\"#H715136940\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Alternatives to endovenous laser ablation include no therapy, compression therapy, sclerotherapy, radiofrequency ablation, or surgical removal of refluxing superficial veins. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"       \"Medical management of lower extremity chronic venous disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"       \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"       \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link\">",
"       \"Open surgical techniques for lower extremity vein ablation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136740\">",
"    <span class=\"h2\">",
"     Compression stockings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are prescribed Class II or higher compression stockings (thigh-high or pantyhose), which they should obtain prior to the day of the scheduled procedure (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"UTD.htm?36/42/37547\">",
"     table 1",
"    </a>",
"    )",
"    <a class=\"external\" href=\"./../Graphics/Pages/Preview.aspx?graphicId=74574\">",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H7#H7\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Graduated compression stockings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136748\">",
"    <span class=\"h2\">",
"     Schedule duplex appointment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prescheduled appointment should be made for follow-up duplex examination two to three days after EVLA to assess for deep vein thrombosis. (See",
"    <a class=\"local\" href=\"#H715136924\">",
"     'Postoperative duplex ultrasound'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136756\">",
"    <span class=\"h2\">",
"     Vein mapping/marking",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the day of the procedure, the veins to be ablated are evaluated and mapped (ie, marked with indelible ink) with duplex ultrasound to reassess vein size and depth, confirm reflux, identify any large perforating veins or areas of superficial or deep vein thrombosis, and any significant anatomic variations (eg, duplication, early entrance of the vein into the deep venous system) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/22\">",
"     22",
"    </a>",
"    ]. Vein mapping also serves to confirm the correct surgical",
"    <span class=\"nowrap\">",
"     side/site",
"    </span>",
"    during preoperative time-out procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136764\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVLA can be performed in a clinic or office or other outpatient surgery setting with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and local anesthesia with or without supplemental venous procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/23\">",
"     23",
"    </a>",
"    ]. If moderate sedation is used, a nurse should be dedicated to monitoring the patient&rsquo;s level of consciousness, heart rate, blood pressure, and oxygen saturation. Local tumescent anesthesia is always required, even if the patient undergoes general anesthesia in an operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136772\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136780\">",
"    <span class=\"h3\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duplex ultrasound machine &ndash; The procedure can be performed with a portable ultrasound machine (gray scale imaging); however, color duplex imaging with a vascular probe is ideal.",
"     </li>",
"     <li>",
"      Laser generator &ndash; Check the machine for proper functioning; calibrate if necessary.",
"     </li>",
"     <li>",
"      Tilt table &ndash; The ability to adjust the patient&rsquo;s position between Trendelenburg and reverse Trendelenburg is highly desirable. Alternatively, a venous tourniquet can be used to assist engorgement of the vein during access, and an Esmarch bandage can be used to compress the vein.",
"     </li>",
"     <li>",
"      Pump for tumescent anesthesia (eg, Klein pump) &ndash; The pump is used to infuse tumescent anesthesia but is not essential. If a Klein pump is not available, the tumescent anesthesia can be injected by hand.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136788\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local anesthetic for puncture site: 1%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine. The addition of bicarbonate may help diminish the pain of injection.",
"     </li>",
"     <li>",
"      Tumescent anesthetic (a mixture of saline, epinephrine, bicarbonate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      for subcutaneous injection) should be ordered from the pharmacy in advance and mixed just prior to the procedure. Cold saline solution may be an alternative for patients with allergy to local anesthesia or at risk for toxicity (eg, impaired liver function) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136796\">",
"    <span class=\"h3\">",
"     Materials",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preparation materials: skin prep, sterile gloves",
"     </li>",
"     <li>",
"      Draping materials: sterile drape, bag for foot",
"     </li>",
"     <li>",
"      Tubing for tumescent",
"     </li>",
"     <li>",
"      Echogenic 21 gauge micropuncture needle",
"     </li>",
"     <li>",
"      10 mL syringe with 16 to 20 gauge needle to draw up anesthetic, 27 to 30 gauge needle to inject",
"     </li>",
"     <li>",
"      Micropuncture sheath kit: micropuncture wire (0.035\"), 4F device",
"      <span class=\"nowrap\">",
"       dilator/sheath",
"      </span>",
"     </li>",
"     <li>",
"      Additional guidewires: glidewire (0.018&rdquo;)",
"     </li>",
"     <li>",
"      Wound dressing: Gauze and elastic wrap or thigh-high elastic stocking with gauze pads, or adhesive strips or bandages",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136804\">",
"    <span class=\"h2\">",
"     General technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVLA is performed according to the manufacturer's recommendations. The general technique is described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136812\">",
"    <span class=\"h3\">",
"     Prepare and position the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned supine for treatment of the GSV or accessory saphenous veins. The prone position is preferred for treatment of the SSV but it can be successfully treated in the supine position. The leg should be prepped to include the saphenofemoral junction (for treatment of the GSV) or the sapheno-popliteal junction (for treatment of the SSV) since these areas must be imaged with ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136820\">",
"    <span class=\"h3\">",
"     Place the device sheath",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the patient is relaxed and well hydrated. The patient is placed in reverse Trendelenburg position to engorge the target vein, a position that facilitates venous access. Using ultrasound guidance, a micropuncture cannula is introduced into the vein near the knee for GSV ablation or near the ankle for SSV ablation and a long guidewire advanced toward the saphenofemoral junction (or sapheno-popliteal junction).",
"   </p>",
"   <p>",
"    On occasion, the vein may develop spasm during venipuncture. Carefully selecting an accessible portion of the vein and successfully obtaining access upon the first attempt greatly reduce the risk of vasospasm. Placement of a venous tourniquet just proximal to the vein or the application of 2%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    paste over the vein may break the spasm and prevent the need for a second venipuncture. Alternatively, a cutdown to access the vein can be performed.",
"   </p>",
"   <p>",
"    Difficulty advancing the wire or the sheath into the proximal vein may be encountered in the presence of a tortuous vein, venous aneurysms or vein segments that are sclerotic or occluded. Severely tortuous vein segments cannot be treated, though this should be recognized in advance on preoperative duplex ultrasound. (See",
"    <a class=\"local\" href=\"#H715136645\">",
"     'Contraindications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H715136756\">",
"     'Vein mapping/marking'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mildly tortuous venous segments, sclerotic segments and venous aneurysms can usually be crossed with manual manipulation of the overlying skin or by using a hydrophilic wire (eg, glidewire). Segmental occlusions can be managed with two treatments administered through two separate sheaths placed proximal and distal to the occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136828\">",
"    <span class=\"h3\">",
"     Position the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 4 French laser sheath is advanced over the wire and positioned in the proximal vein. Correct catheter position is critical to reduce the risk of deep vein thrombosis. The tip of the laser should be placed at least 2 cm below the saphenofemoral (or sapheno-popliteal) junction and the position confirmed with ultrasound. Ideally, the catheter tip should be just distal to at least one tributary vein to ensure continued flow in the more proximal vein. Patients with variant small saphenous vein anatomy with no tributaries to the proximal SSV may be at a higher risk for deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136660\">",
"     'Venous anatomy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H715136884\">",
"     'Small saphenous ablation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the sheath is in place, the patient should be placed in the Trendelenburg position. This serves to empty and allow better contact of the laser catheter to the wall of the vein, which may help reduce postprocedure pain.",
"   </p>",
"   <p>",
"    The laser sheath is backed out to expose the tip of the laser catheter. The position of the tip of the catheter should be rechecked with ultrasound and correct placement confirmed. This is a critical portion of the procedure. Sometimes air bubbles in the gel or hair around the groin can reduce visibility. Also, imaging the catheter in obese patients with deep veins can be a challenge. If technical issues obscure the catheter, and its position cannot be positively ascertained, the procedure should be aborted and an alternative procedure performed (eg, vein stripping, sclerotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136836\">",
"    <span class=\"h3\">",
"     Instill tumescent anesthetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;With ultrasound imaging, an echogenic micropuncture needle is used to inject tumescent anesthesia into the tissue surrounding the vein. Tumescent anesthesia has several important functions including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Providing anesthesia during EVLA",
"     </li>",
"     <li>",
"      Facilitating contact of the vein wall with the laser tip",
"     </li>",
"     <li>",
"      Deepening the vein relative to the skin to protect the skin from damage during laser treatment",
"     </li>",
"     <li>",
"      Acting as a heat sink to protect surrounding tissues from the thermal damage during laser treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After completion of the tumescent anesthesia, it is important to confirm with ultrasound that a halo of tumescent anesthetic surrounds the catheter, especially in the region of the saphenofemoral junction, and to ensure that the catheter and vein are at least 1 cm deep to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136844\">",
"    <span class=\"h3\">",
"     Ablate the vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;After adequate tumescent anesthesia has been delivered, the vein is ready for treatment. The catheter is slowly pulled back at an initial rate of 1 mm every second for the first 5 cm of treatment length. Thereafter, the catheter can be pulled back 2 to 3 mm every second. A slow, steady pullback provides even heating of the entire vein segment and minimizes the chance of vein perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136852\">",
"    <span class=\"h3\">",
"     Perform completion ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following completion of the procedure, ultrasound examination of the common femoral vein (or popliteal vein for treatment of the small saphenous vein) is performed to confirm patency and exclude thrombus. Closure of the treated vein is confirmed. The vein should appear thickened (ie, hyperechoic doughnut) with thrombus in its lumen with no identifiable venous flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136860\">",
"    <span class=\"h3\">",
"     Perform supplemental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful closure of the target veins, the extremity is evaluated for any significant residual varicose veins, which can be managed with phlebectomy or sclerotherapy depending upon their size or operator preference. (See",
"    <a class=\"local\" href=\"#H715136724\">",
"     'Planning supplemental procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When we identify large varicose tributaries to the ablated vein, we will selectively perform stab phlebectomy or sclerotherapy at the time of the EVLA to prevent superficial thrombophlebitis. (See",
"    <a class=\"local\" href=\"#H715136964\">",
"     'Superficial thrombophlebitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136868\">",
"    <span class=\"h2\">",
"     Specific anatomic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical aspects of the EVLA procedure vary with the anatomic site. Venous anatomy is described above. (See",
"    <a class=\"local\" href=\"#H715136660\">",
"     'Venous anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136876\">",
"    <span class=\"h3\">",
"     Great saphenous ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating the distal saphenous vein is not necessary because the majority of patients obtain adequate relief of their venous symptoms without extending the ablation below the mid-calf. Doing so may increase the risk of saphenous nerve injury. (See",
"    <a class=\"local\" href=\"#H715136980\">",
"     'Nerve injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 65 patients with above and below-knee GSV reflux into three groups: above knee GSV EVLA, mid-calf to groin (extended) GSV EVLA, or above knee EVLA plus below knee GSV foam sclerotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/26\">",
"       26",
"      </a>",
"      ]. All patients experienced significant improvements in symptoms; the extended EVLA group had the highest patient satisfaction and the lowest requirement for subsequent sclerotherapy, and the below-knee foam sclerotherapy group was a close second.",
"     </li>",
"     <li>",
"      The same group of investigators evaluated 69 below-knee GSV segments with duplex ultrasound six weeks following above-knee GSV EVLA, and found 59 percent had no or minimal reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/27\">",
"       27",
"      </a>",
"      ]. All patients experienced significant improvement in symptoms, but patients with persistent reflux in the below-knee GSV more often required sclerotherapy for residual symptomatic varicose veins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical failure following EVLA of the great saphenous vein can be due to large refluxing accessory saphenous tributaries (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ). As a result, we prefer to treat accessory saphenous veins that demonstrate significant reflux at the same time as great saphenous vein ablation. The second sheath needs to be placed in the accessory saphenous vein prior to instillation of tumescent anesthesia. We treat the great saphenous vein first, since it is usually the larger vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136884\">",
"    <span class=\"h3\">",
"     Small saphenous ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic variation in the sapheno-popliteal junction is common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/5\">",
"     5",
"    </a>",
"    ]. In about 30 percent of patients, the SSV does not communicate with the popliteal vein; rather, it drains cephalad continuing as the superficial posterior thigh vein (vein of Giacomini). In some individuals, the SSV drains into the popliteal vein directly with no significant tributaries. These patients have a higher risk of developing deep venous thrombosis with SSV endovenous ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136972\">",
"     'Deep vein thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Puncture of the SSV at the midcalf level was found in one trial of 60 patients to lead to less postoperative paresthesias without affecting the success of closure at six months follow up, compared with puncture at the ankle level [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136980\">",
"     'Nerve injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136892\">",
"    <span class=\"h2\">",
"     Perforator ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are special catheters designed to treat incompetent perforating veins (eg, Venacure&reg;), there are no studies showing that treatment of incompetent perforating veins leads to faster ulcer healing or a decreased incidence of ulcer recurrence. Studies that have evaluated patients undergoing treatment for incompetent perforating veins almost universally include patients with combined treatment of an incompetent GSV, making analysis of the clinical utility of adding the treatment of perforating veins difficult to determine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136900\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136908\">",
"    <span class=\"h2\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;EVLA is generally well tolerated and controlled with over-the-counter pain medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ). In one study, 85 percent of patients complained of no or minimal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/29\">",
"     29",
"    </a>",
"    ]. Moderate to severe pain is experienced in 4 to 9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Extensive concurrent vein excision may require stronger analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ). Pain gradually resolves with time and is improved by wearing compression stockings. (See",
"    <a class=\"local\" href=\"#H715136740\">",
"     'Compression stockings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs can be added in patients who develop a significant phlebitic reaction. An ice pack can also be applied to the affected areas for comfort. (See",
"    <a class=\"local\" href=\"#H715136964\">",
"     'Superficial thrombophlebitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229227692\">",
"    <span class=\"h2\">",
"     Patient instructions",
"    </span>",
"   </p>",
"   <p>",
"    Clinical symptoms that should prompt the patient to call their physician include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Swelling or excessive pain that is not relieved with the prescribed pain medications may be a symptom of deep vein thrombosis.",
"     </li>",
"     <li>",
"      Numbness, tingling, coolness or discoloration of the toes of the treated extremity. The compression",
"      <span class=\"nowrap\">",
"       bandages/stockings",
"      </span>",
"      may be too tight and need to be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine instructions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambulate normally and take short (20 minute) leisure walks three times daily.",
"     </li>",
"     <li>",
"      Avoid prolonged standing and sitting; when seated, elevate the treated extremity.",
"     </li>",
"     <li>",
"      Refrain from strenuous cardiovascular activities (eg, heavy lifting, exercise) for one to two weeks; thereafter, resume normal activities.",
"     </li>",
"     <li>",
"      Resume normal job duties within three to four days; however, jobs requiring prolonged standing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heavy lifting may require additional time off.",
"     </li>",
"     <li>",
"      Maintain the postoperative dressing and elastic",
"      <span class=\"nowrap\">",
"       bandages/stockings",
"      </span>",
"      until the postoperative duplex examination, which should occur within two to three days following the procedure.",
"     </li>",
"     <li>",
"      Reinforce any areas of bleeding that occur through the dressing, but patients should call their physician if excessive bleeding occurs. This is more commonly associated with vein excisions performed at the same time as the endovenous ablation.",
"     </li>",
"     <li>",
"      Wear thigh-high graded compression stockings day and night for one to two weeks following the procedure.",
"     </li>",
"     <li>",
"      Do not be alarmed if there is a pulling sensation or tightness over the treated vein. This is due to the scarring of the vein, which adheres to the surrounding tissues. Gentle stretching exercises in the area of the treated vein may be helpful. For great saphenous ablation, stretching the inner thigh muscle is accomplished by sitting on the floor with the feet pressed together and leaning forward. For the small saphenous vein, stretching the vein is accomplished by leaning forward against a wall with the affected leg placed behind the hips with the foot flat on the floor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136924\">",
"    <span class=\"h2\">",
"     Postoperative duplex ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should undergo duplex ultrasound within two to three days following the procedure to rule out deep vein thrombosis (DVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/30\">",
"     30",
"    </a>",
"    ]. The main purpose of the postoperative duplex study is to carefully evaluate the proximal extent of the ablated vein for thrombus and to determine whether any thrombus extends into the deep veins. Thrombus extending from the saphenous vein into the proximal deep vein cephalad to the level of the ablation can lead to DVT, although this is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/30\">",
"     30",
"    </a>",
"    ]. This process has been termed endovenous heat-induced thrombus (EHIT). (See",
"    <a class=\"local\" href=\"#H715136972\">",
"     'Deep vein thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A classification system has been proposed (based upon studies of endovenous radiofrequency ablation) to provide an accurate description of the level of proximal great saphenous thrombus due to EHIT for the purpose of guiding clinical therapy and further research [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/32\">",
"     32",
"    </a>",
"    ]. The classification scheme is as follows; levels I, II, and III represent superficial venous thrombosis (SVT) while levels IV, V, and VI represent deep venous thrombosis (DVT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Level I: Thrombus below the superficial epigastric vein",
"     </li>",
"     <li>",
"      Level II: Thrombus up to the origin of the superficial epigastric vein",
"     </li>",
"     <li>",
"      Level III: Thrombus up to but not into the common femoral vein",
"     </li>",
"     <li>",
"      Level IV: Thrombus bulging into the common femoral vein but not adherent to the wall of the common femoral vein",
"     </li>",
"     <li>",
"      Level V: Thrombus extending into the common femoral vein and adherent to the adjacent wall",
"     </li>",
"     <li>",
"      Level VI: Occlusive thrombus of the common femoral vein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the initial ultrasound demonstrates no thrombus in the deep vein, repeat ultrasound is not required unless the patient develops new symptoms.",
"   </p>",
"   <p>",
"    Patients with thrombus up to but not into the common femoral vein (level III) should have a repeat ultrasound in three to four days, since there are inadequate data at the present time to be certain the thrombus will not extend more cephalad [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/32\">",
"     32",
"    </a>",
"    ]. However, late propagation of thrombus into the deep vein has not been reported beyond two to three days. (See",
"    <a class=\"local\" href=\"#H715136964\">",
"     'Superficial thrombophlebitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thrombus within the deep vein is treated accordingly. (See",
"    <a class=\"local\" href=\"#H715136972\">",
"     'Deep vein thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136932\">",
"    <span class=\"h2\">",
"     Physician follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of symptoms, the patient should be seen in the office within six weeks of the procedure to re-evaluate the clinical",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of venous disease and determine the need and timing for any possible supplemental procedures. (See",
"    <a class=\"local\" href=\"#H715136724\">",
"     'Planning supplemental procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136940\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although EVLA is generally well tolerated, a variety of complications can occur. The most important are nerve injury and deep vein thrombosis (DVT). (See",
"    <a class=\"local\" href=\"#H715136980\">",
"     'Nerve injury'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H715136972\">",
"     'Deep vein thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136948\">",
"    <span class=\"h2\">",
"     Bruising/hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of patients treated with EVLA have ecchymosis to some extent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33\">",
"     33",
"    </a>",
"    ]. The median time to resolution is about two weeks. The incidence of bruising has been reported to be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/29,33\">",
"     29,33",
"    </a>",
"    ], as well as higher [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/34\">",
"     34",
"    </a>",
"    ], compared with vein stripping. More severe bruising is probably related to perforation of the treated vein, which may be due to contact of the laser tip with the vein wall.",
"   </p>",
"   <p>",
"    Hematoma occurs in 1 to 5 percent of patients undergoing EVLA of the GSV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/23,30,34\">",
"     23,30,34",
"    </a>",
"    ]. One trial that randomly assigned 200 patients to EVLA or GSV ligation and stripping found significantly more hematomas in patients who underwent GSV ligation and stripping (12 versus 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/34\">",
"     34",
"    </a>",
"    ]. Another trial found that the size of hematomas that occurred was significantly smaller at one week for EVLA compared with surgical stripping [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136956\">",
"    <span class=\"h2\">",
"     Skin burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin burns are a preventable complication and should be a rare occurrence following EVLA. The infusion of adequate amounts of tumescent anesthesia should be performed to ensure that the treated vein is more than 1 cm below the skin surface. Investigators performing EVLA without tumescent anesthesia have reported an incidence of skin burns of about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136836\">",
"     'Instill tumescent anesthetic'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136964\">",
"    <span class=\"h2\">",
"     Superficial thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild superficial thrombophlebitis is anticipated along the course of the ablated vein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, varicose veins that are in direct communication with the treated vein may thrombose, or collapse and scar down. The reported incidence of symptomatic phlebitis following EVLA ranges from 0 to 5.2 percent and does not appear to be related to whether or not concomitant phlebectomy was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/13,29-31,33\">",
"     13,29-31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial thrombophlebitis is managed conservatively. Thrombosed veins that are painful and tender can be treated with cold compresses and nonsteroidal antiinflammatory drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link&amp;anchor=H20#H20\">",
"     \"Superficial thrombophlebitis of the lower extremity\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More significant signs or symptoms of pain or edema warrant ultrasound examination to evaluate for thrombus extending from the saphenous vein into the common femoral vein. Superficial venous thrombosis with thrombus up to but not into the common femoral vein due to endovenous heat-induced thrombosis (EHIT) is thought to be more benign than spontaneous thrombus in this location. A repeat ultrasound should be performed within a week. Patients with thrombus in the proximal saphenous vein due to EHIT may or may not be anticoagulated while awaiting repeat ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136924\">",
"     'Postoperative duplex ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136972\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic complications following EVLA are uncommon. The incidence varies in the literature depending upon whether routine duplex ultrasound is performed within two to three days following EVLA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Some large series of EVLA with duplex ultrasound follow-up have noted 0 percent incidence of DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/29,31,33,37\">",
"     29,31,33,37",
"    </a>",
"    ], while others report an incidence of 0.9 to 2.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/30,32,36,38\">",
"     30,32,36,38",
"    </a>",
"    ]. The author&rsquo;s experience is consistent with the latter reports. Pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/39\">",
"     39",
"    </a>",
"    ], and stroke in a patient with a patent foramen ovale [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/40\">",
"     40",
"    </a>",
"    ], have also been reported following EVLA.",
"   </p>",
"   <p>",
"    Some of the variation in the incidence of DVT may also be related to how well the saphenofemoral junction is examined with duplex ultrasound following EVLA. An experienced technician should perform the examination. (See",
"    <a class=\"local\" href=\"#H715136924\">",
"     'Postoperative duplex ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of DVT following EVLA appears to be related to extension of clot from thrombus induced in the ablated vein and is more commonly partially occlusive (level IV or V). Direct thermal injury to the deep veins due to catheter tip malposition can also occur. Patients diagnosed with DVT are anticoagulated and a follow-up duplex ultrasound should be obtained in four to five days.",
"   </p>",
"   <p>",
"    In many cases, thrombus contraction occurs with the thrombus no longer apparent within the common femoral vein, at which point anticoagulation may be discontinued. DVT due to endovenous therapies usually resolves within two weeks following initiation of anticoagulation, which is faster than with spontaneous DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. In our experience, most resolve within a week. Patients whose thrombus extension into the deep vein persists are treated with anticoagulation using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and a repeat ultrasound in two to three weeks. If thrombus contraction has occurred, the patient can discontinue anticoagulation.",
"   </p>",
"   <p>",
"    Patients with persistent thrombus extension and those with occlusive deep venous thrombosis are managed according to standard protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H45#H45\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'VTE and a reversible or time-limited risk factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136980\">",
"    <span class=\"h2\">",
"     Nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory abnormalities due to nerve injury following EVLA occur with a reported incidence ranging between &lt;1 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/31,37,39\">",
"     31,37,39",
"    </a>",
"    ]. Symptoms of saphenous nerve injury include pain or numbness along the medial aspect of the calf or lateral foot and occasionally a feeling of pressure or tightness around the knee or ankle. These symptoms typically resolve four to six weeks after EVLA.",
"   </p>",
"   <p>",
"    Because of the close proximity of the saphenous nerve and vein in the distal calf, saphenous nerve injury may be more likely when the endovenous sheath is placed below the level of the mid-calf, due to the adherence of the saphenous nerve to the saphenous vein in the distal third of the calf [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H715136668\">",
"     'Saphenous nerve'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adequate tumescent anesthesia is probably the most important factor in preventing nerve injuries. In an observational study of patients undergoing EVLA without tumescent anesthesia, the rate of paresthesia was much higher at 36 percent compared with other studies in which tumescent anesthesia was used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the risk for saphenous nerve injury, surgical stripping of the saphenous vein in the mid- to distal calf is no longer recommended. For similar reasons, we prefer not to extend ablation of the GSV below the mid- to upper-calf. (See",
"    <a class=\"local\" href=\"#H715136876\">",
"     'Great saphenous ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136988\">",
"    <span class=\"h2\">",
"     Technical complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715136996\">",
"    <span class=\"h3\">",
"     Anatomic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following saphenous ablation, duplex ultrasound can show procedural failure, but some of these patients have clinical improvement that is maintained long-term. Anatomic failure is a useful term to distinguish these patients from those with clinical failure (ie, recurrent clinical symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    varicose veins). Anatomic failure has been classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonocclusion &ndash; Type I anatomic failure refers to veins that failed to occlude initially and never occlude during follow-up.",
"     </li>",
"     <li>",
"      Recanalization &ndash; Type II anatomic failure refers to veins that were initially confirmed to be occluded but later recanalized, either partially or completely.",
"     </li>",
"     <li>",
"      Groin reflux &ndash; Type III anatomic failure refers to the situation in which the vein trunk was occluded but reflux persisted in the groin region. This type of failure often involves an accessory saphenous vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137004\">",
"    <span class=\"h3\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other technical complications have been described in case reports. The development of arteriovenous fistula in the popliteal fossa following small saphenous vein ablation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This complication may be related to errant placement of the tumescent needle. The popliteal fossa is felt to be at increased risk for this complication due to the proximity of the sural arteries to the vein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although uncommon, a retained foreign body from a broken laser catheter tip has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/39\">",
"     39",
"    </a>",
"    ]. Care in placement of the tumescent needle minimizes the potential of this complication. Device components should be examined carefully after they are removed from the patient to ensure their integrity. If there is any question about the possible loss of a device, radiographs should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137012\">",
"    <span class=\"h1\">",
"     VEIN CLOSURE RATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137020\">",
"    <span class=\"h2\">",
"     Great saphenous vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial technical and short-term success for treatment of the GSV ranges from 90 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33,44-48\">",
"     33,44-48",
"    </a>",
"    ]. A systematic review and meta-analysis of the various modalities for the treatment of lower extremity chronic venous disease including endovenous therapies found that the pooled success rate for EVLA at three years was significantly higher compared with radiofrequency ablation, vein excision, or sclerotherapy (94 versus 84, 77, and 78 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure of endovenous laser ablation for the great saphenous vein appears to depend upon the diameter of the vein:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 500 patients treated with EVLA, 98 percent of GSV were successfully closed on the initial postprocedure duplex ultrasound. After four years, the closure rate had decreased to 97 percent. All failures occurred in patients with a saphenofemoral junction &gt;11 mm, or a GSV diameter &gt;8 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, initial success for EVLA of the GSV was found to be 95 percent. In the successfully treated veins, the average maximum vein diameter was 11 mm, whereas, for the failures, the mean maximum vein diameter was 21 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found no significant differences in the failure rates of EVLA in 732 patients with large diameter veins &gt;10 mm (4.5 versus 3.4 percent) compared with smaller diameter veins [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/50\">",
"       50",
"      </a>",
"      ]. Large veins constituted 12 percent of the total veins treated and 1 percent of the veins had a diameter &gt;20 mm. The vein obliteration rate in the largest veins (20 to 24 mm) was 100 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137028\">",
"    <span class=\"h2\">",
"     Accessory and small saphenous veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term results of EVLA of the accessory saphenous veins and small saphenous vein have shown closure rates equivalent to great saphenous vein EVLA with minimal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. The primary success rates are 87 to 98 percent for the anterior accessory saphenous vein, and 91 to 93 percent for the small saphenous vein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/50,53\">",
"     50,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137036\">",
"    <span class=\"h2\">",
"     Perforating veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies are not available looking at long-term success or clinical outcomes (eg, ulcer healing) of laser perforator ablation. Feasibility studies have shown that EVLA is technically possible and appears safe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/38,57\">",
"     38,57",
"    </a>",
"    ]. The largest study treated 67 incompetent perforator veins; all but one vein was occluded by day one following treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137044\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although vein stripping has been the standard for the management of lower extremity varicose veins and venous reflux, randomized trials have found that minimally-invasive therapies, including radiofrequency ablation (RFA), EVLA, and sclerotherapy, provide similar or improved clinical outcomes compared with GSV ligation and stripping [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/44,58,59\">",
"     44,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measures of venous symptom severity (eg, Venous Clinical Severity Score, Aberdeen Varicose Vein Symptom Score), and quality of life scores (eg, Medical Outcomes Study Short Form-36) have been used to compare outcomes of EVLA and great saphenous vein ligation and stripping in several clinical trials. No significant differences in these scores have been found at short-term (one to three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33,45,60\">",
"     33,45,60",
"    </a>",
"    ], or long-term (one year, two year) follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/34,46\">",
"     34,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single trial has compared EVLA with radiofrequency ablation. Patients diagnosed with saphenous vein reflux were randomly assigned to EVLA using 980 nm wavelength laser (64 patients) or radiofrequency ablation using VNUS ClosureFAST&reg; (67 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/61\">",
"     61",
"    </a>",
"    ]. No significant differences were found in the outcomes measures listed above at six weeks follow-up.",
"   </p>",
"   <p>",
"    One small trial that randomly assigned 20 patients with bilateral symptomatic GSV reflux to EVLA for one leg and vein stripping for the other leg found that 70 percent of the patients preferred EVLA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137052\">",
"    <span class=\"h2\">",
"     Return to normal activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time to return to normal activities or return to work is variable among the available clinical trials. One trial of 99 patients found a decreased time to return to normal activity (2 versus 7 days) and return to work (4 versus 17 days) for EVLA compared with great saphenous vein ligation and stripping [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, two trials involving 200 and 121 patients found no significant differences in return to normal activity or work (average, 7 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/34,60\">",
"     34,60",
"    </a>",
"    ]. Yet another trial found a longer time until return to work for EVLA compared with great saphenous vein ligation and stripping (20 versus 14 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137060\">",
"    <span class=\"h2\">",
"     Postoperative pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with return to normal activities, EVLA is associated with variable levels of pain compared with great saphenous vein ligation and stripping. Trials have found more pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/62\">",
"     62",
"    </a>",
"    ], less pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/33\">",
"     33",
"    </a>",
"    ], or no difference in pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/29,34,60\">",
"     29,34,60",
"    </a>",
"    ], experienced by patients undergoing EVLA.",
"   </p>",
"   <p>",
"    A trial that compared EVLA with radiofrequency ablation found more postoperative pain following EVLA (mean pain score 34 versus 22) and more analgesic use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/61\">",
"     61",
"    </a>",
"    ]. The average numbers of analgesic tablets for EVLA versus radiofrequency ablation were 14 versus 9 tablets by postoperative day 3, and 36 versus 20 tablets by postoperative day 10.",
"   </p>",
"   <p>",
"    Compared with open surgery, EVLA appears to be better tolerated. A trial that randomly assigned 280 patients to open surgery or EVLA found significant improvements in Venous Clinical Severity Score (VCSS) and Aberdeen Varicose Vein Questionnaire for both groups after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/63\">",
"     63",
"    </a>",
"    ]. Periprocedural quality of life measures were maintained following EVLA, but surgical patients experienced more pain and disability with a significant decline in five of eight Short Form 36 (SF-36",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) domains leading to a significant difference between the two treatments in pain scores. As a result, surgical patients took longer to return to work and normal activity compared with patients undergoing EVLA (14 versus 4 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137068\">",
"    <span class=\"h2\">",
"     Vein recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicose vein recurrence is reported with long-term follow-up at rates that are similar to radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/47\">",
"     47",
"    </a>",
"    ]. In large retrospective studies, varicose vein recurrence has been reported to occur in 7 to 14 percent of patients long-term (two to seven years) following EVLA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/53,64\">",
"     53,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have found a varying incidence of recurrent varicose veins following EVLA when compared with great saphenous vein ligation and stripping.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 121 patients involving 137 legs, varicose veins recurred in 26 percent in the EVLA group compared with 37 percent of the great saphenous vein ligation and stripping group [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study involving 121 patients reported recurrent varicose veins in 9 percent of EVLA patients and 10 percent of patients who underwent GSV ligation and stripping [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial involving 280 patients found a significantly lower incidence of varicose vein recurrence in patients treated with EVLA (4 versus 20.4 percent) compared with those treated with surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/65\">",
"       65",
"      </a>",
"      ]. The authors noted that over half of the recurrences in the GSV stripping group were due to reflux in the below-knee GSV that was not treated. The second most common cause for recurrence was neovascularization at the saphenofemoral junction, a process that was much less common after EVLA.",
"     </li>",
"     <li>",
"      Recurrences in another trial were 26 percent and 37 percent in the EVLA and surgery groups, respectively, a difference that was not significant [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/46\">",
"       46",
"      </a>",
"      ]. The source of reflux was not significantly different between the groups.",
"     </li>",
"     <li>",
"      In another trial that randomly assigned 400 patients to high ligation and stripping or endovenous laser ablation, recurrent varicose veins were observed in both groups but the difference was not significant (16.2 percent [EVLA] versus 23.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/66\">",
"       66",
"      </a>",
"      ]. However, duplex-detected saphenofemoral reflux was significantly more frequent after EVLT (17.8 versus 1.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137084\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;One trial evaluated differences in cost between EVLA and great saphenous vein ligation and stripping and found no significant differences between these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/34/30250/abstract/60\">",
"     60",
"    </a>",
"    ]. Total costs of each procedure, including lost wages and equipment, were calculated for 121 patients. The total cost for EVLA was $4347 (&euro; 3396) and for great saphenous vein ligation and stripping, $3948 (&euro; 3084).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=see_link\">",
"       \"Patient information: Vein ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715137092\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endovenous laser ablation (EVLA) is a minimally-invasive percutaneous technique using laser energy to ablate incompetent superficial veins. EVLA is used primarily to treat venous insufficiency of the axial veins (ie, great, small, or accessory saphenous veins). (See",
"      <a class=\"local\" href=\"#H715136631\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview and management of lower extremity chronic venous disease\", section on 'Ablation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candidates for endovenous laser ablation are patients with persistent",
"      <span class=\"nowrap\">",
"       symptoms/signs",
"      </span>",
"      of venous disease after three months of medical therapy plus documented reflux (ie, retrograde flow &gt;0.5 second duration) as a source of their symptoms. (See",
"      <a class=\"local\" href=\"#H715136638\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovenous laser ablation is typically performed in an office or ambulatory surgery setting with local anesthesia and anxiolytics. If concurrent vein excision is performed, moderate sedation is preferred. (See",
"      <a class=\"local\" href=\"#H715136764\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For great saphenous vein ablation, we suggest not extending EVLA below the mid-calf to minimize the risk of saphenous nerve injury (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Symptoms of saphenous nerve injury may include pain or numbness along the medial aspect of the calf or lateral foot. These symptoms typically resolve within four to six weeks of the procedure. (See",
"      <a class=\"local\" href=\"#H715136820\">",
"       'Place the device sheath'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H715136980\">",
"       'Nerve injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some degree of pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bruising is common following EVLA and a mild superficial phlebitis is expected. Pain associated with EVLA is usually controlled with over-the-counter pain medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ). Pain gradually resolves over time and is improved by wearing compression stockings. Extensive concurrent vein excision may require stronger analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H715136908\">",
"       'Pain management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1229227692\">",
"       'Patient instructions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H715136740\">",
"       'Compression stockings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duplex ultrasound should be performed within two to three days of the procedure to evaluate for deep vein thrombosis. The presence of thrombus up to but not into the common femoral vein indicates the need for repeat duplex to look for thrombus extension. Patients found to have thrombus within the common femoral vein are treated for deep venous thrombosis. (See",
"      <a class=\"local\" href=\"#H715136924\">",
"       'Postoperative duplex ultrasound'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H715136964\">",
"       'Superficial thrombophlebitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H715136972\">",
"       'Deep vein thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/1\">",
"      Schoonover JP, King JT, Gray C, et al. 3 alternatives to standard varicose vein treatment. J Fam Pract 2009; 58:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/2\">",
"      Kumari J, Nishanth Reddy N, Kalyani Rao P, et al. A review of literature along with a cadaveric study of the prevalence of the Giacomini vein (the thigh extension of the small saphenous vein) in the Indian population. Rom J Morphol Embryol 2008; 49:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/3\">",
"      Gibson KD, Ferris BL, Polissar N, et al. Endovenous laser treatment of the small [corrected] saphenous vein: efficacy and complications. J Vasc Surg 2007; 45:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/4\">",
"      Delis KT, Knaggs AL, Khodabakhsh P. Prevalence, anatomic patterns, valvular competence, and clinical significance of the Giacomini vein. J Vasc Surg 2004; 40:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/5\">",
"      Schweighofer G, M&uuml;hlberger D, Brenner E. The anatomy of the small saphenous vein: fascial and neural relations, saphenofemoral junction, and valves. J Vasc Surg 2010; 51:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/6\">",
"      Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002; 36:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/7\">",
"      Dayan V, Cura L, Cubas S, Carriquiry G. Surgical anatomy of the saphenous nerve. Ann Thorac Surg 2008; 85:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/8\">",
"      Schmedt CG, Sroka R, Steckmeier S, et al. Investigation on radiofrequency and laser (980 nm) effects after endoluminal treatment of saphenous vein insufficiency in an ex-vivo model. Eur J Vasc Endovasc Surg 2006; 32:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/9\">",
"      Proebstle TM, Sandhofer M, Kargl A, et al. Thermal damage of the inner vein wall during endovenous laser treatment: key role of energy absorption by intravascular blood. Dermatol Surg 2002; 28:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/10\">",
"      Mordon SR, Wassmer B, Zemmouri J. Mathematical modeling of endovenous laser treatment (ELT). Biomed Eng Online 2006; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/11\">",
"      Disselhoff BC, Rem AI, Verdaasdonk RM, et al. Endovenous laser ablation: an experimental study on the mechanism of action. Phlebology 2008; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/12\">",
"      Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. J Vasc Surg 2006; 43:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/13\">",
"      Chang CJ, Chua JJ. Endovenous laser photocoagulation (EVLP) for varicose veins. Lasers Surg Med 2002; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/14\">",
"      Doganci S, Demirkilic U. Comparison of 980 nm laser and bare-tip fibre with 1470 nm laser and radial fibre in the treatment of great saphenous vein varicosities: a prospective randomised clinical trial. Eur J Vasc Endovasc Surg 2010; 40:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/15\">",
"      Theivacumar NS, Gough MJ. Influence of warfarin on the success of endovenous laser ablation (EVLA) of the great saphenous vein (GSV). Eur J Vasc Endovasc Surg 2009; 38:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/16\">",
"      Riesenman PJ, de Fritas DJ, Konigsberg SG, Kasirajan K. Noninterruption of warfarin therapy is safe and does not compromise outcome in patients undergoing endovenous laser therapy (EVLT). Vasc Endovascular Surg 2011; 45:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/17\">",
"      Sharifi M, Mehdipour M, Bay C, et al. Effect of anticoagulation on endothermal ablation of the great saphenous vein. J Vasc Surg 2011; 53:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/18\">",
"      Carradice D, Mekako AI, Hatfield J, Chetter IC. Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. Br J Surg 2009; 96:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/19\">",
"      Schanzer H. Endovenous ablation plus microphlebectomy/sclerotherapy for the treatment of varicose veins: single or two-stage procedure? Vasc Endovascular Surg 2010; 44:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/20\">",
"      Monahan DL. Can phlebectomy be deferred in the treatment of varicose veins? J Vasc Surg 2005; 42:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/21\">",
"      Welch HJ. Endovenous ablation of the great saphenous vein may avert phlebectomy for branch varicose veins. J Vasc Surg 2006; 44:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/22\">",
"      Pichot O, Sessa C, Chandler JG, et al. Role of duplex imaging in endovenous obliteration for primary venous insufficiency. J Endovasc Ther 2000; 7:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/23\">",
"      Hamel-Desnos C, G&eacute;rard JL, Desnos P. Endovenous laser procedure in a clinic room: feasibility and side effects study of 1,700 cases. Phlebology 2009; 24:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/24\">",
"      Chong PFS, Kumar R, Kushwaha R, et, al. Technical tip: cold saline infiltration instead of local anaesthetic in endovenous laser treatment. Phlebology  2006; 21:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/25\">",
"      Pannier F, Rabe E, Maurins U. 1470 nm diode laser for endovenous ablation (EVLA) of incompetent saphenous veins - a prospective randomized pilot study comparing warm and cold tumescence anaesthesia. Vasa 2010; 39:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/26\">",
"      Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above- and below-knee reflux? A randomized controlled trial. J Vasc Surg 2008; 48:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/27\">",
"      Theivacumar NS, Darwood RJ, Dellegrammaticas D, et al. The clinical significance of below-knee great saphenous vein reflux following endovenous laser ablation of above-knee great saphenous vein. Phlebology 2009; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/28\">",
"      Doganci S, Yildirim V, Demirkilic U. Does puncture site affect the rate of nerve injuries following endovenous laser ablation of the small saphenous veins? Eur J Vasc Endovasc Surg 2011; 41:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/29\">",
"      de Medeiros CA, Luccas GC. Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins. Dermatol Surg 2005; 31:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/30\">",
"      Puggioni A, Kalra M, Carmo M, et al. Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications. J Vasc Surg 2005; 42:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/31\">",
"      Desmytt&egrave;re J, Grard C, Wassmer B, Mordon S. Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients. J Vasc Surg 2007; 46:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/32\">",
"      Lawrence PF, Chandra A, Wu M, et al. Classification of proximal endovenous closure levels and treatment algorithm. J Vasc Surg 2010; 52:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/33\">",
"      Kalteis M, Berger I, Messie-Werndl S, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study. J Vasc Surg 2008; 47:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/34\">",
"      Christenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surg 2010; 52:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/35\">",
"      Dunst KM, Huemer GM, Wayand W, Shamiyeh A. Diffuse phlegmonous phlebitis after endovenous laser treatment of the greater saphenous vein. J Vasc Surg 2006; 43:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/36\">",
"      Marsh P, Price BA, Holdstock J, et al. Deep vein thrombosis (DVT) after venous thermoablation techniques: rates of endovenous heat-induced thrombosis (EHIT) and classical DVT after radiofrequency and endovenous laser ablation in a single centre. Eur J Vasc Endovasc Surg 2010; 40:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/37\">",
"      Nwaejike N, Srodon PD, Kyriakides C. 5-years of endovenous laser ablation (EVLA) for the treatment of varicose veins--a prospective study. Int J Surg 2009; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/38\">",
"      Proebstle TM, Herdemann S. Early results and feasibility of incompetent perforator vein ablation by endovenous laser treatment. Dermatol Surg 2007; 33:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/39\">",
"      Van Den Bos RR, Neumann M, De Roos KP, Nijsten T. Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg 2009; 35:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/40\">",
"      Caggiati A, Franceschini M. Stroke following endovenous laser treatment of varicose veins. J Vasc Surg 2010; 51:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/41\">",
"      Khilnani NM, Grassi CJ, Kundu S, et al. Multi-society consensus quality improvement guidelines for the treatment of lower-extremity superficial venous insufficiency with endovenous thermal ablation from the Society of Interventional Radiology, Cardiovascular Interventional Radiological Society of Europe, American College of Phlebology and Canadian Interventional Radiology Association. J Vasc Interv Radiol 2010; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/42\">",
"      Vaz C, Matos A, Oliveira J, et al. Iatrogenic arteriovenous fistula following endovenous laser therapy of the short saphenous vein. Ann Vasc Surg 2009; 23:412.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/43\">",
"      Timperman PE. Arteriovenous fistula after endovenous laser treatment of the short saphenous vein. J Vasc Interv Radiol 2004; 15:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/44\">",
"      van den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/45\">",
"      Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg 2008; 95:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/46\">",
"      Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years. Eur J Vasc Endovasc Surg 2010; 39:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/47\">",
"      Ravi R, Rodriguez-Lopez JA, Trayler EA, et al. Endovenous ablation of incompetent saphenous veins: a large single-center experience. J Endovasc Ther 2006; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/48\">",
"      Agus GB, Mancini S, Magi G, IEWG. The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period. Int Angiol 2006; 25:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/49\">",
"      Kim HS, Paxton BE. Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments. J Vasc Interv Radiol 2006; 17:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/50\">",
"      Chaar CI, Hirsch SA, Cwenar MT, et al. Expanding the role of endovenous laser therapy: results in large diameter saphenous, small saphenous, and anterior accessory veins. Ann Vasc Surg 2011; 25:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/51\">",
"      Bush RG, Hammond K. Treatment of incompetent vein of Giacomini (thigh extension branch). Ann Vasc Surg 2007; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/52\">",
"      Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation (EVLA) of great saphenous vein to abolish \"paradoxical reflux\" in the Giacomini vein: a short report. Eur J Vasc Endovasc Surg 2007; 34:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/53\">",
"      Ravi R, Trayler EA, Barrett DA, Diethrich EB. Endovenous thermal ablation of superficial venous insufficiency of the lower extremity: single-center experience with 3000 limbs treated in a 7-year period. J Endovasc Ther 2009; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/54\">",
"      Nwaejike N, Srodon PD, Kyriakides C. Endovenous laser ablation for short saphenous vein incompetence. Ann Vasc Surg 2009; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/55\">",
"      Trip-Hoving M, Verheul JC, van Sterkenburg SM, et al. Endovenous laser therapy of the small saphenous vein: patient satisfaction and short-term results. Photomed Laser Surg 2009; 27:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/56\">",
"      Theivacumar NS, Darwood RJ, Gough MJ. Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein. Eur J Vasc Endovasc Surg 2009; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/57\">",
"      Ozkan U. Endovenous laser ablation of incompetent perforator veins: a new technique in treatment of chronic venous disease. Cardiovasc Intervent Radiol 2009; 32:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/58\">",
"      Hoggan BL, Cameron AL, Maddern GJ. Systematic review of endovenous laser therapy versus surgery for the treatment of saphenous varicose veins. Ann Vasc Surg 2009; 23:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/59\">",
"      Darwood RJ, Gough MJ. Endovenous laser treatment for uncomplicated varicose veins. Phlebology 2009; 24 Suppl 1:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/60\">",
"      Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg 2007; 46:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/61\">",
"      Shepherd AC, Gohel MS, Brown LC, et al. Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins. Br J Surg 2010; 97:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/62\">",
"      Pronk P, Gauw SA, Mooij MC, et al. Randomised controlled trial comparing sapheno-femoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anaesthesia: one year results. Eur J Vasc Endovasc Surg 2010; 40:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/63\">",
"      Carradice D, Mekako AI, Mazari FA, et al. Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg 2011; 98:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/64\">",
"      Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003; 14:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/65\">",
"      Carradice D, Mekako AI, Mazari FA, et al. Clinical and technical outcomes from a randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg 2011; 98:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/34/30250/abstract/66\">",
"      Rass K, Frings N, Glowacki P, et al. Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study). Arch Dermatol 2012; 148:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15198 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30250=[""].join("\n");
var outline_f29_34_30250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H715137092\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136631\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136638\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136645\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136652\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136660\">",
"      Venous anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136668\">",
"      Saphenous nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136676\">",
"      Sural nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136684\">",
"      MECHANISM OF ACTION AND LASER DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136692\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136700\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136708\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136716\">",
"      DVT prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136724\">",
"      Planning supplemental procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136732\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136740\">",
"      Compression stockings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136748\">",
"      Schedule duplex appointment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136756\">",
"      Vein mapping/marking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136764\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136772\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136780\">",
"      - Equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136788\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136796\">",
"      - Materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136804\">",
"      General technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136812\">",
"      - Prepare and position the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136820\">",
"      - Place the device sheath",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136828\">",
"      - Position the catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136836\">",
"      - Instill tumescent anesthetic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136844\">",
"      - Ablate the vein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136852\">",
"      - Perform completion ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136860\">",
"      - Perform supplemental procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136868\">",
"      Specific anatomic considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136876\">",
"      - Great saphenous ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136884\">",
"      - Small saphenous ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136892\">",
"      Perforator ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136900\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136908\">",
"      Pain management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229227692\">",
"      Patient instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136924\">",
"      Postoperative duplex ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136932\">",
"      Physician follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715136940\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136948\">",
"      Bruising/hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136956\">",
"      Skin burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136964\">",
"      Superficial thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136972\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136980\">",
"      Nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715136988\">",
"      Technical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715136996\">",
"      - Anatomic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715137004\">",
"      - Other issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715137012\">",
"      VEIN CLOSURE RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137020\">",
"      Great saphenous vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137028\">",
"      Accessory and small saphenous veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137036\">",
"      Perforating veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715137044\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137052\">",
"      Return to normal activities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137060\">",
"      Postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137068\">",
"      Vein recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715137084\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715137092\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15198|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/46/36579\" title=\"figure 1A\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42671\" title=\"figure 1B\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/19/310\" title=\"figure 2\">",
"      Variation small saphenous vein anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/11/42164\" title=\"figure 3A\">",
"      Femoral nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/22/7521\" title=\"figure 3B\">",
"      Saphenous nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/17/272\" title=\"figure 4\">",
"      Sural nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/29/5585\" title=\"figure 5\">",
"      Wavelengths of light used for venous laser therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/42/37547\" title=\"table 1\">",
"      Compression stockings in chronic venous disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=related_link\">",
"      Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=related_link\">",
"      Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=related_link\">",
"      Open surgical techniques for lower extremity vein ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=related_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=related_link\">",
"      Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_34_30251="Causes portal vein thrombosis";
var content_f29_34_30251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of portal vein thrombosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Abdominal sepsis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Behcet's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Collagen vascular diseases (eg, lupus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compression or invasion of the portal vein by tumor (eg, pancreatic cancer)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endoscopic sclerotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Factor V Leiden",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatocellular carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperhomocysteinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory bowel disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myeloproliferative syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omphalitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral contraceptives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paroxysmal nocturnal hemoglobinuria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Protein C deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombin gene mutation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Retroperitoneal fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transjugular intrahepatic portosystemic shunt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30251=[""].join("\n");
var outline_f29_34_30251=null;
var title_f29_34_30252="Rare serious side effects AEDs";
var content_f29_34_30252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rare but serious side effects of AEDs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, lupus syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        Aplastic anemia, liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacosamide",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, hypersensitivity, aseptic meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, toxic epidermal necrolysis, multiorgan hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, adenopathy, pseudolymphoma, neuropathy, ataxia, lupus-syndrome, hirsuitism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primidone, phenobarbital",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, hepatic failure, dermatitis/rash, serum sickness, connective tissue contractures (eg, Duputrens)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, dermatitis/rash, shortened QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiagabine",
"       </td>",
"       <td>",
"        Unknown, nonconvulsive status epilepticus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        Acute myopia and glaucoma; kidney stones; oligohydrosis and hyperthermia which primarily occur in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigabatrin",
"       </td>",
"       <td>",
"        MRI abnormalities, depression, weight gain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide",
"       </td>",
"       <td>",
"        Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, nephrolithiasis; in children, fever and hyperhidrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30252=[""].join("\n");
var outline_f29_34_30252=null;
var title_f29_34_30253="Tiotropium bromide";
var content_f29_34_30253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tiotropium bromide",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kaiser HB, Findlay SR, Georgitis JW, et al. J Allergy Clin Immunol 1995; 95(5 Pt 2):1117.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30253=[""].join("\n");
var outline_f29_34_30253=null;
var title_f29_34_30254="Filamentous fungi MICs";
var content_f29_34_30254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro susceptibility of filamentous fungi to systemically active antifungal agents determined by CLSI M38-A2 broth microdilution methods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Antifungal agent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        No. tested",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        MIC, &micro;g/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        50 percent*",
"       </td>",
"       <td class=\"subtitle2\">",
"        90 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <em>",
"         Aspergillus fumigatus",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        1119",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        1119",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        1119",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        1119",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        256",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         A. flavus",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         A. niger",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         A. versicolor",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         A. terreus",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         Fusarium",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         Scedosporium apiospermum",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        &gt;16",
"       </td>",
"       <td>",
"        &gt;16",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <em>",
"         S. prolificans",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        &gt;32",
"       </td>",
"       <td>",
"        &gt;32",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Mucorales",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        128",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CLSI: Clinical and Laboratory Standards Institute.",
"     <br>",
"      * 50 percent and 90 percent; MIC encompassing 50 percent and 90 percent of isolates tested, respectively.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Amphotericin B MICs determined by Etest.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Sabatelli, F, Patel, R, Mann, PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.",
"       </li>",
"       <li>",
"        Diekema, DJ, Messer, SA, Hollis, RJ, Jones, RN, Pfaller, MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623.",
"       </li>",
"       <li>",
"        Pfaller, MA, Messer, SA, Boyken, L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568.",
"       </li>",
"       <li>",
"        Cortez, KJ, Roilides, E, Quiroz-Telles, F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30254=[""].join("\n");
var outline_f29_34_30254=null;
var title_f29_34_30255="ECG subarachnoid hemorrhage";
var content_f29_34_30255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    T wave abnormalities following stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inverted, symmetric T waves are seen on the EKG of a patient with subarachnoid hemorrhage. Normal serume cardiac enzymes concentrations as well as subsequent normalization of the T waves attest to the neurogenic origin of the EKG pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_34_30255=[""].join("\n");
var outline_f29_34_30255=null;
